Index	Sentence	Entity	Entity_Startindex	Entity_Stopindex	Entity_Info
PMC6443786_OgerInput.txtOger_out.csv:234	The cytochrome P450 enzymes might be the most significant class of enzyme to study the metabolic behavior of lead compounds. 	cytochrome P450	37871	37886	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:7	Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. 	cytochrome P450	820	835	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:7	Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. 	cytochrome P450	820	835	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:7	Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. 	cytochrome P450	855	870	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:7	Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. 	cytochrome P450	855	870	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:36	Consequently, search terms used included names of individual drugs AND overdose, toxicokinetics, pharmacokinetics, cytochrome P450 (CYP) enzyme, metabolism, or active metabolites. 	cytochrome P450	5193	5208	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:36	Consequently, search terms used included names of individual drugs AND overdose, toxicokinetics, pharmacokinetics, cytochrome P450 (CYP) enzyme, metabolism, or active metabolites. 	cytochrome P450	5193	5208	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:1	 Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?. 	cytochrome P450	43	58	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:1	 Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?. 	cytochrome P450	43	58	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:2	This review covers the current knowledge of the cytochrome P450 enzymes (CYPs) of the human pathogen Mycobacterium tuberculosis (Mtb) and their endogenous redox partners, focusing on their biological function, expression, regulation, involvement in antibiotic resistance, and suitability for exploitation as antitubercular targets. 	cytochrome P450	203	218	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:2	This review covers the current knowledge of the cytochrome P450 enzymes (CYPs) of the human pathogen Mycobacterium tuberculosis (Mtb) and their endogenous redox partners, focusing on their biological function, expression, regulation, involvement in antibiotic resistance, and suitability for exploitation as antitubercular targets. 	cytochrome P450	203	218	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:14	Genome mapping revealed that Mtb encodes a high number of cytochrome P450 enzymes (CYPs or P450s). 	cytochrome P450	3232	3247	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:14	Genome mapping revealed that Mtb encodes a high number of cytochrome P450 enzymes (CYPs or P450s). 	cytochrome P450	3232	3247	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:9	Moreover, seventy-eight cytochrome P450s and multiple transcription factors (five MYB, two bHLH, and three WD40 family genes) may be associated with the regulation of the flavonoid biosynthesis process. 	cytochrome P450	1417	1432	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:9	Moreover, seventy-eight cytochrome P450s and multiple transcription factors (five MYB, two bHLH, and three WD40 family genes) may be associated with the regulation of the flavonoid biosynthesis process. 	cytochrome P450	1417	1432	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:24	In addition, glycosyltransferases and cytochrome P450s also contribute to flavonoid regulation in plants. 	cytochrome P450	4192	4207	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:24	In addition, glycosyltransferases and cytochrome P450s also contribute to flavonoid regulation in plants. 	cytochrome P450	4192	4207	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:59	These enzymes belong to three pathways, namely (a) the COX pathway (COX1, COX2) resulting in production of prostaglandins, (b) the Lipoxygenases pathway (5-LOX, 1LOX, 15LOX) resulting in production of leukotrienes and lipoxins, and (c) the cytochrome P450 pathway which forms the hydroxyeicosotetranoic acids and the epoxyeicosotrienoic acids (Hanna and Hafez,. 	cytochrome P450	11358	11373	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:59	These enzymes belong to three pathways, namely (a) the COX pathway (COX1, COX2) resulting in production of prostaglandins, (b) the Lipoxygenases pathway (5-LOX, 1LOX, 15LOX) resulting in production of leukotrienes and lipoxins, and (c) the cytochrome P450 pathway which forms the hydroxyeicosotetranoic acids and the epoxyeicosotrienoic acids (Hanna and Hafez,. 	cytochrome P450	11358	11373	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6508646_OgerInput.txtOger_out.csv:18	The MPB genome contains 86 different cytochrome P450 genes, and three of these P450s have previously been shown to function in terpenoid metabolism or terpenoid pheromone biosynthesis in the MPB. 	cytochrome P450	2648	2663	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6508646_OgerInput.txtOger_out.csv:18	The MPB genome contains 86 different cytochrome P450 genes, and three of these P450s have previously been shown to function in terpenoid metabolism or terpenoid pheromone biosynthesis in the MPB. 	cytochrome P450	2648	2663	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:17	Second, an oxidative cyclisation cascade consisting typically of three to four cytochrome P450 (Oxy) enzymes (one enzyme per ring formed, see Fig ) is then recruited to the NRPS-bound heptapeptide in order to perform the stepwise cyclisation of the peptide into a rigid, active antibiotic^,. 	cytochrome P450	2981	2996	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:17	Second, an oxidative cyclisation cascade consisting typically of three to four cytochrome P450 (Oxy) enzymes (one enzyme per ring formed, see Fig ) is then recruited to the NRPS-bound heptapeptide in order to perform the stepwise cyclisation of the peptide into a rigid, active antibiotic^,. 	cytochrome P450	2981	2996	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:40	Strikingly, the biosynthetic gene cluster of this GPA encodes only two cytochrome P450 enzymes (KisN and KisO) implicated in the crosslinking of the aromatic side chains of the peptide, despite there being three crosslinks in kistamicin. 	cytochrome P450	8216	8231	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:40	Strikingly, the biosynthetic gene cluster of this GPA encodes only two cytochrome P450 enzymes (KisN and KisO) implicated in the crosslinking of the aromatic side chains of the peptide, despite there being three crosslinks in kistamicin. 	cytochrome P450	8216	8231	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:178	For isoflavones, the gut microbiome and phase I cytochrome P450 enzymes in human liver microsome were responsible for O-demethylation at 4 carbon; hence formononetin is converted to daidzein and biochanin A to genistein Anthocyanidins, or their monoglucosides of anthocyanins, remained unchanged when incubated with rat liver microsomes in the presence of NADPH, which suggests that anthocyanidins are not affected by phase I enzymes. 	cytochrome P450	31143	31158	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:178	For isoflavones, the gut microbiome and phase I cytochrome P450 enzymes in human liver microsome were responsible for O-demethylation at 4 carbon; hence formononetin is converted to daidzein and biochanin A to genistein Anthocyanidins, or their monoglucosides of anthocyanins, remained unchanged when incubated with rat liver microsomes in the presence of NADPH, which suggests that anthocyanidins are not affected by phase I enzymes. 	cytochrome P450	31143	31158	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:95	Markers of pharmacokinetics/toxicity: (1) Sofarenib metabolism: The metabolism of sorafenib is well-established and occurs mainly in the liver through two pathways: Phase I oxidation mediated by cytochrome P450 3A4, and phase II conjugation mediated by UDP glucuronosyltransferase 1A9. 	cytochrome P450	17863	17878	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:95	Markers of pharmacokinetics/toxicity: (1) Sofarenib metabolism: The metabolism of sorafenib is well-established and occurs mainly in the liver through two pathways: Phase I oxidation mediated by cytochrome P450 3A4, and phase II conjugation mediated by UDP glucuronosyltransferase 1A9. 	cytochrome P450	17863	17878	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:18	Insects have employed cytochrome P450 monooxygenases (P450s) that promote more a rapid metabolism to defer the cost of a counter-defence against toxic plant compounds. 	cytochrome P450	2700	2715	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:18	Insects have employed cytochrome P450 monooxygenases (P450s) that promote more a rapid metabolism to defer the cost of a counter-defence against toxic plant compounds. 	cytochrome P450	2700	2715	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:102	The AhR/ARNT heterodimer binds the xenobiotic responsive elements in the promoter, leading to the transcription of genes that encode xenobiotic metabolism enzymes, such as cytochrome P450 genes, which in mammals include CYP1A1, CYP1A2, and CYP1B1. 	cytochrome P450	17929	17944	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:102	The AhR/ARNT heterodimer binds the xenobiotic responsive elements in the promoter, leading to the transcription of genes that encode xenobiotic metabolism enzymes, such as cytochrome P450 genes, which in mammals include CYP1A1, CYP1A2, and CYP1B1. 	cytochrome P450	17929	17944	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:3	The expression of cytochrome P450, sodA (encoding Fe/Mn superoxide dismutase), recA, and superoxide anion radical generation rate increased after the addition of all studied hydrocarbons. 	cytochrome P450	366	381	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:3	The expression of cytochrome P450, sodA (encoding Fe/Mn superoxide dismutase), recA, and superoxide anion radical generation rate increased after the addition of all studied hydrocarbons. 	cytochrome P450	366	381	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:27	The aim of this study was to evaluate the expression of genes, cytochrome P450, superoxide dismutases A and C, recA, as well as generation of superoxide anion radical and hydrogen peroxide under the influence of hydrocarbons on Rhodococcus. 	cytochrome P450	3411	3426	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:27	The aim of this study was to evaluate the expression of genes, cytochrome P450, superoxide dismutases A and C, recA, as well as generation of superoxide anion radical and hydrogen peroxide under the influence of hydrocarbons on Rhodococcus. 	cytochrome P450	3411	3426	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:134	It is well known that in the course of enzymatic reactions of cytochrome P450 the socalled disjunction of the cycle may occur when the flow of electrons derived from NAD(P)H to P450 molecules leads to the generation of superoxide anion radical and/or hydrogen peroxide instead of the products of monooxygenase reaction (Guengerich, ; Goeptar, Scheerens, & Vermeulen,. 	cytochrome P450	18072	18087	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:134	It is well known that in the course of enzymatic reactions of cytochrome P450 the socalled disjunction of the cycle may occur when the flow of electrons derived from NAD(P)H to P450 molecules leads to the generation of superoxide anion radical and/or hydrogen peroxide instead of the products of monooxygenase reaction (Guengerich, ; Goeptar, Scheerens, & Vermeulen,. 	cytochrome P450	18072	18087	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:162	The ROS produced by cytochrome P450 are likely to cause DNA damage. 	cytochrome P450	22635	22650	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6816061_OgerInput.txtOger_out.csv:162	The ROS produced by cytochrome P450 are likely to cause DNA damage. 	cytochrome P450	22635	22650	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:3	A growing amount of data have demonstrated the biosynthesis of flavonoids through multienzyme complexes of which the membrane-bounded cytochrome P450 supergene family shares a crucial part. 	cytochrome P450	377	392	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:3	A growing amount of data have demonstrated the biosynthesis of flavonoids through multienzyme complexes of which the membrane-bounded cytochrome P450 supergene family shares a crucial part. 	cytochrome P450	377	392	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:15	The ER-bound enzyme complex belongs to the cytochrome P450 superfamily. 	cytochrome P450	2279	2294	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:15	The ER-bound enzyme complex belongs to the cytochrome P450 superfamily. 	cytochrome P450	2279	2294	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:16	In most of the plant species, cytochrome P450 is found abundantly and produces multiple groups of secondary metabolites through hydroxylation and monooxygenation reactions. 	cytochrome P450	2338	2353	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:16	In most of the plant species, cytochrome P450 is found abundantly and produces multiple groups of secondary metabolites through hydroxylation and monooxygenation reactions. 	cytochrome P450	2338	2353	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:17	CYP701, a member of cytochrome P450 encoding ent-kaurene oxidase, is essential for the biosynthesis of gibberellins. 	cytochrome P450	2501	2516	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:17	CYP701, a member of cytochrome P450 encoding ent-kaurene oxidase, is essential for the biosynthesis of gibberellins. 	cytochrome P450	2501	2516	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:19	Furthermore, several other studies have discovered the pharmacological importance of the cytochrome P450 supergene family by stimulating plant immunity against various pathogens. 	cytochrome P450	3035	3050	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:19	Furthermore, several other studies have discovered the pharmacological importance of the cytochrome P450 supergene family by stimulating plant immunity against various pathogens. 	cytochrome P450	3035	3050	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:26	Though the diversity of flavonoid biosynthesis has been reported in Arabidopsis thaliana seeds, the mechanism of stress-responsive cytochrome P450 genes encoding a single or group of enzymes promoting the flavonoid biosynthesis pathway in Arabidopsis remains unexplained. 	cytochrome P450	4247	4262	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:26	Though the diversity of flavonoid biosynthesis has been reported in Arabidopsis thaliana seeds, the mechanism of stress-responsive cytochrome P450 genes encoding a single or group of enzymes promoting the flavonoid biosynthesis pathway in Arabidopsis remains unexplained. 	cytochrome P450	4247	4262	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:27	As a point of paramount significance, it is important to focus on studies related to identification and characterization of putative cytochrome P450 genes promoting the flavonoid biosynthetic pathway in plants. 	cytochrome P450	4521	4536	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:27	As a point of paramount significance, it is important to focus on studies related to identification and characterization of putative cytochrome P450 genes promoting the flavonoid biosynthetic pathway in plants. 	cytochrome P450	4521	4536	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:134	Based on predicted open-reading frames, the unigenes were further subjected to cytochrome P450 database (http://drnelson.uthsc.edu/CytochromeP450.html). 	cytochrome P450	22343	22358	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:134	Based on predicted open-reading frames, the unigenes were further subjected to cytochrome P450 database (http://drnelson.uthsc.edu/CytochromeP450.html). 	cytochrome P450	22343	22358	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:244	In the present study, we also predicted the computational structure of rutin against a comprehensive metabolite prediction tool (GLORY) that contained the cytochrome P450 prediction module according to the instructions of. 	cytochrome P450	40431	40446	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:244	In the present study, we also predicted the computational structure of rutin against a comprehensive metabolite prediction tool (GLORY) that contained the cytochrome P450 prediction module according to the instructions of. 	cytochrome P450	40431	40446	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:265	These findings provide a theoretical and practical basis for identifying the intrinsic relation of a stress-responsive cytochrome P450 gene during flavonoid biosynthesis in plants.	cytochrome P450	44748	44763	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:265	These findings provide a theoretical and practical basis for identifying the intrinsic relation of a stress-responsive cytochrome P450 gene during flavonoid biosynthesis in plants.	cytochrome P450	44748	44763	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6830213_OgerInput.txtOger_out.csv:18	Heme enzymes, such as the cytochrome P450s, are involved in the metabolism/breakdown of approximately 90% of small-molecule drugs, and are more generally themselves drug targets in yeast, fungi and tuberculosis infections (McLean & Munro, 2017; Guengerich et al., 2016; Rendic & Guengerich, 2015). 	cytochrome P450	3031	3046	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6830213_OgerInput.txtOger_out.csv:18	Heme enzymes, such as the cytochrome P450s, are involved in the metabolism/breakdown of approximately 90% of small-molecule drugs, and are more generally themselves drug targets in yeast, fungi and tuberculosis infections (McLean & Munro, 2017; Guengerich et al., 2016; Rendic & Guengerich, 2015). 	cytochrome P450	3031	3046	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:30	Two major functional classes of enzymes are involved in the biosynthesis of all steroid hormones, namely the cytochrome P450 and hydroxysteroid dehydrogenase enzymes. 	cytochrome P450	5069	5084	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:30	Two major functional classes of enzymes are involved in the biosynthesis of all steroid hormones, namely the cytochrome P450 and hydroxysteroid dehydrogenase enzymes. 	cytochrome P450	5069	5084	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:38	Cytochrome P450 type II enzymes are found in the Endoplasmic Reticulum and are dependent on the electron donor enzyme cytochrome P450 oxidoreductase for electron delivery. 	cytochrome P450	6332	6347	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:38	Cytochrome P450 type II enzymes are found in the Endoplasmic Reticulum and are dependent on the electron donor enzyme cytochrome P450 oxidoreductase for electron delivery. 	cytochrome P450	6332	6347	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:12	Phenobarbital metabolism is highly dependent upon the cytochrome P450 and genetic polymorphisms can lead to variability in active drug levels. 	cytochrome P450	1572	1587	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:12	Phenobarbital metabolism is highly dependent upon the cytochrome P450 and genetic polymorphisms can lead to variability in active drug levels. 	cytochrome P450	1572	1587	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:155	The sequences for all promoters in CYP2C19 gene are as follows: CYP2C19-201 identified in chromosome position at 94762681 (ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG), CYP2C19-202 chromosome position 94842926 (ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA), and CYP2C19-203 chromosome position 94775489 (ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG) In addition, we identified the following Kyoto Encyclopedia Of Genes And Genomes pathways of CYP2C19 which include arachidonic acid metabolism, organism-specific biosystem, chemical carcinogenesis, organism-specific biosystem, drug metabolism (cytochrome P450), organism-specific biosystem, linoleic acid metabolism, organism-specific biosystem, metabolic pathways, organism-specific biosystem, and serotonergic synapse. 	cytochrome P450	29282	29297	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:14	Genome mapping revealed that Mtb encodes a high number of cytochrome P450 enzymes (CYPs or P450s). 	cytochrome P450 enzymes	3232	3255	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:40	Strikingly, the biosynthetic gene cluster of this GPA encodes only two cytochrome P450 enzymes (KisN and KisO) implicated in the crosslinking of the aromatic side chains of the peptide, despite there being three crosslinks in kistamicin. 	cytochrome P450 enzymes	8216	8239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6680729_OgerInput.txtOger_out.csv:178	For isoflavones, the gut microbiome and phase I cytochrome P450 enzymes in human liver microsome were responsible for O-demethylation at 4 carbon; hence formononetin is converted to daidzein and biochanin A to genistein Anthocyanidins, or their monoglucosides of anthocyanins, remained unchanged when incubated with rat liver microsomes in the presence of NADPH, which suggests that anthocyanidins are not affected by phase I enzymes. 	cytochrome P450 enzymes	31143	31166	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:35	Celastrol biosynthesis likely adheres to the common triterpenoid scheme that starts with cycloisomerization of 2,3-oxidosqualene by an oxidosqualene cyclase (OSC) and continues with oxidative decoration(s) of the 30-carbon triterpenoid core structure by cytochrome P450 enzymes [,. 	cytochrome P450 enzymes	5969	5992	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:3	The current study aimed to investigate the impact of co-administration of pomegranate peel and guava leaves extracts, including their quality markers namely; ellagic acid and quercetin, respectively, on warfarins in vivo dynamic activity and pharmacokinetic actions, in addition to potential in vitro cytochrome P450 enzymes inhibition. 	P450 enzymes	658	670	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:116	This study includes the quantitative measurement of drug-like properties such as, lipophilicity, solubility, pKa (negative logarithmic measure of acid dissociation constant), permeability, absorption, bioavailability, blood-brain barrier penetration, transporters, dermal and ocular penetration, plasma-protein binding, metabolism and drug-drug interaction, volume of distribution (V_d), clearance, half-life, p-glycoprotein efflux and inhibition as well as inhibition of the hepatic organic anion transporting polypeptide (OATP-1B1) transporter, cytochromes P450 enzymes, and UDP-glucuronosyltransferases. 	P450 enzymes	17749	17761	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:116	This study includes the quantitative measurement of drug-like properties such as, lipophilicity, solubility, pKa (negative logarithmic measure of acid dissociation constant), permeability, absorption, bioavailability, blood-brain barrier penetration, transporters, dermal and ocular penetration, plasma-protein binding, metabolism and drug-drug interaction, volume of distribution (V_d), clearance, half-life, p-glycoprotein efflux and inhibition as well as inhibition of the hepatic organic anion transporting polypeptide (OATP-1B1) transporter, cytochromes P450 enzymes, and UDP-glucuronosyltransferases. 	P450 enzymes	17749	17761	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:234	The cytochrome P450 enzymes might be the most significant class of enzyme to study the metabolic behavior of lead compounds. 	P450 enzymes	37882	37894	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:234	The cytochrome P450 enzymes might be the most significant class of enzyme to study the metabolic behavior of lead compounds. 	P450 enzymes	37882	37894	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:240	In identifying the affinity of studies compound with CYP-P450 enzymes in quantitative terms, the Michaelis-Menten constant (K_m), maximum metabolic rate (V_max) and intrinsic clearance (C_Lint) calculated, which provide the knowledge of the rate of metabolism. 	P450 enzymes	38682	38694	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:240	In identifying the affinity of studies compound with CYP-P450 enzymes in quantitative terms, the Michaelis-Menten constant (K_m), maximum metabolic rate (V_max) and intrinsic clearance (C_Lint) calculated, which provide the knowledge of the rate of metabolism. 	P450 enzymes	38682	38694	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:7	Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. 	P450 enzymes	831	843	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:7	Most antidepressant and antipsychotic drugs are metabolized by cytochrome P450 enzymes and, where cytochrome P450 inhibitors are co-ingested, serial plasma concentrations should optimally be obtained in order to assess a suitable time for reintroduction of the psychoactive drugs. 	P450 enzymes	831	843	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:1	 Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?. 	P450 enzymes	54	66	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:1	 Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?. 	P450 enzymes	54	66	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:2	This review covers the current knowledge of the cytochrome P450 enzymes (CYPs) of the human pathogen Mycobacterium tuberculosis (Mtb) and their endogenous redox partners, focusing on their biological function, expression, regulation, involvement in antibiotic resistance, and suitability for exploitation as antitubercular targets. 	P450 enzymes	214	226	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:2	This review covers the current knowledge of the cytochrome P450 enzymes (CYPs) of the human pathogen Mycobacterium tuberculosis (Mtb) and their endogenous redox partners, focusing on their biological function, expression, regulation, involvement in antibiotic resistance, and suitability for exploitation as antitubercular targets. 	P450 enzymes	214	226	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:14	Genome mapping revealed that Mtb encodes a high number of cytochrome P450 enzymes (CYPs or P450s). 	P450 enzymes	3243	3255	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6469627_OgerInput.txtOger_out.csv:14	Genome mapping revealed that Mtb encodes a high number of cytochrome P450 enzymes (CYPs or P450s). 	P450 enzymes	3243	3255	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:106	The lipophilic sterol metabolites produced by IFN signaling including oxysterols are substrates for Cytochrome P450 enzymes and they profoundly influence cellular metabolism (Newmark et al., ) which in turn has been shown to influence Mycobacterium Tuberculosis replication inside cells (Huang et al.,. 	P450 enzymes	22650	22662	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:106	The lipophilic sterol metabolites produced by IFN signaling including oxysterols are substrates for Cytochrome P450 enzymes and they profoundly influence cellular metabolism (Newmark et al., ) which in turn has been shown to influence Mycobacterium Tuberculosis replication inside cells (Huang et al.,. 	P450 enzymes	22650	22662	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:161	The Cytochrome P450 enzymes are heme containing monooxygenases involved in the pathways associated with the metabolism of fatty acids, steroids and other lipophilic molecules (Pikuleva,. 	P450 enzymes	34777	34789	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:161	The Cytochrome P450 enzymes are heme containing monooxygenases involved in the pathways associated with the metabolism of fatty acids, steroids and other lipophilic molecules (Pikuleva,. 	P450 enzymes	34777	34789	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:162	The loss of Cytochrome P450 enzymes prevents Apolipoprotein (Apo) A1 synthesis thus affecting the removal of cholesterol from the cells to the liver for biliary excretion (Rubin et al., ; Nebert and Russell, ; Guan et al.,. 	P450 enzymes	34972	34984	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:162	The loss of Cytochrome P450 enzymes prevents Apolipoprotein (Apo) A1 synthesis thus affecting the removal of cholesterol from the cells to the liver for biliary excretion (Rubin et al., ; Nebert and Russell, ; Guan et al.,. 	P450 enzymes	34972	34984	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:164	Since the activity of the Cytochrome P450 enzymes can be modulated post-translationally, they are targets to manipulate cholesterol homeostasis (Luoma,. 	P450 enzymes	35384	35396	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:164	Since the activity of the Cytochrome P450 enzymes can be modulated post-translationally, they are targets to manipulate cholesterol homeostasis (Luoma,. 	P450 enzymes	35384	35396	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:166	For example, Mycobacterium Tuberculosis has about 20 different Cytochrome P450 enzymes, and several Cytochrome P450 genes have been associated with mycobacterial viability (Mclean et al.,. 	P450 enzymes	35634	35646	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:166	For example, Mycobacterium Tuberculosis has about 20 different Cytochrome P450 enzymes, and several Cytochrome P450 genes have been associated with mycobacterial viability (Mclean et al.,. 	P450 enzymes	35634	35646	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:168	have reported that the Mycobacterium Tuberculosis genome sequence has a very high number of Cytochrome P450 enzymes, with Cyp128 contributing to synthesis of cell wall sulpholipid and being necessary for in-vitro growth of the bacterium (Cole et al., ; Holsclaw et al., ; Sogi et al.,. 	P450 enzymes	35864	35876	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:168	have reported that the Mycobacterium Tuberculosis genome sequence has a very high number of Cytochrome P450 enzymes, with Cyp128 contributing to synthesis of cell wall sulpholipid and being necessary for in-vitro growth of the bacterium (Cole et al., ; Holsclaw et al., ; Sogi et al.,. 	P450 enzymes	35864	35876	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6508646_OgerInput.txtOger_out.csv:5	Cytochrome P450 enzymes (P450s) of the MPB are thought to be involved in the metabolism of at least some of these defense compounds. 	P450 enzymes	556	568	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6508646_OgerInput.txtOger_out.csv:5	Cytochrome P450 enzymes (P450s) of the MPB are thought to be involved in the metabolism of at least some of these defense compounds. 	P450 enzymes	556	568	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:40	Strikingly, the biosynthetic gene cluster of this GPA encodes only two cytochrome P450 enzymes (KisN and KisO) implicated in the crosslinking of the aromatic side chains of the peptide, despite there being three crosslinks in kistamicin. 	P450 enzymes	8227	8239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:40	Strikingly, the biosynthetic gene cluster of this GPA encodes only two cytochrome P450 enzymes (KisN and KisO) implicated in the crosslinking of the aromatic side chains of the peptide, despite there being three crosslinks in kistamicin. 	P450 enzymes	8227	8239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:86	The active site heme iron is coordinated by the thiolate of the conserved, proximal Cys332 residue, whilst the I-helix that runs across the top of the heme contains the Glu/Gln pair of residues (Glu228, Gln229) that are required in P450 enzymes to maintain an effective protonation cascade during oxygen activation. 	P450 enzymes	17338	17350	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:86	The active site heme iron is coordinated by the thiolate of the conserved, proximal Cys332 residue, whilst the I-helix that runs across the top of the heme contains the Glu/Gln pair of residues (Glu228, Gln229) that are required in P450 enzymes to maintain an effective protonation cascade during oxygen activation. 	P450 enzymes	17338	17350	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:19	Cytochrome P450 enzymes, responsible for the biotransformation of more than 85% of existing drugs, may contain genetic variants that result in poor, intermediate, extensive or ultra-rapid metabolic rates^,. 	P450 enzymes	2814	2826	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:19	Cytochrome P450 enzymes, responsible for the biotransformation of more than 85% of existing drugs, may contain genetic variants that result in poor, intermediate, extensive or ultra-rapid metabolic rates^,. 	P450 enzymes	2814	2826	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:145	Inhibition of CYP2C8, CYP2C9, and CYP3A4 BACULOSOMES^ was quantified, as described in. 	CYP2C8	21579	21585	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:145	Inhibition of CYP2C8, CYP2C9, and CYP3A4 BACULOSOMES^ was quantified, as described in. 	CYP2C8	21579	21585	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:146	The data generated were exported to an Excel (Microsoft Headquarters, One Microsoft Way, Redmond, WA, USA) worksheet and the amount of metabolite formed at various concentrations relative to the control was calculated using the following equation: The relative percentage activity was plotted against the log transformed concentrations of the extracts, compounds and positive controls, ie quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor). 	CYP2C8	22061	22067	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:146	The data generated were exported to an Excel (Microsoft Headquarters, One Microsoft Way, Redmond, WA, USA) worksheet and the amount of metabolite formed at various concentrations relative to the control was calculated using the following equation: The relative percentage activity was plotted against the log transformed concentrations of the extracts, compounds and positive controls, ie quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor). 	CYP2C8	22061	22067	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:152	This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs. 	CYP2C8	22946	22952	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:152	This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs. 	CYP2C8	22946	22952	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:45	456255), CYP2C8 (Lot No. 	CYP2C8	8308	8314	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:45	456255), CYP2C8 (Lot No. 	CYP2C8	8308	8314	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2C8	12868	12874	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2C8	12868	12874	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2C8	14147	14153	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2C8	14147	14153	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2C8	19945	19951	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2C8	19945	19951	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP2C8	24531	24537	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP2C8	24531	24537	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:11	Significant reduction in CYP2C8, 2C9, and 3A4 was seen upon concomitant use of warfarin with ellagic acid, guava leaves and quercetin, unlike pomegranate that insignificantly affected Cytochrome P450 Enzymes activities. 	CYP2C8	1970	1976	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:11	Significant reduction in CYP2C8, 2C9, and 3A4 was seen upon concomitant use of warfarin with ellagic acid, guava leaves and quercetin, unlike pomegranate that insignificantly affected Cytochrome P450 Enzymes activities. 	CYP2C8	1970	1976	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:119	Combination of ellagic acid with warfarin significantly inhibited activities of CYP2C8, 2C9 and 3A4 (p < 0.05), however treatment of cells with ellagic acid alone presented significant inhibition on CYP2C9 activity despite other CYPs (p < 0.05). 	CYP2C8	18753	18759	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:119	Combination of ellagic acid with warfarin significantly inhibited activities of CYP2C8, 2C9 and 3A4 (p < 0.05), however treatment of cells with ellagic acid alone presented significant inhibition on CYP2C9 activity despite other CYPs (p < 0.05). 	CYP2C8	18753	18759	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:120	Although guava leaves extract showed an insignificant effect on CYP2C8 when used alone, it significantly reduced its activity when combined with warfarin (p < 0.01) and however, inhibited the activities of CYP2C9 and 3A4 when used alone and concomitantly with warfarin (p-values are marked in Figs. 	CYP2C8	18983	18989	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_508', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:120	Although guava leaves extract showed an insignificant effect on CYP2C8 when used alone, it significantly reduced its activity when combined with warfarin (p < 0.01) and however, inhibited the activities of CYP2C9 and 3A4 when used alone and concomitantly with warfarin (p-values are marked in Figs. 	CYP2C8	18983	18989	('Cytochromes', 'Cytochrome P-450 CYP2C8', 'NCCS', 'NCCS_398', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:123	A mixture containing 0.1% of organic solvent, reaction buffer (200 mM potassium phosphate (reaction buffer I) or 100 mM potassium phosphate (reaction buffer II)) and regeneration system (333 mM glucose-6-phosphate and 30 U/mL glucose-6-phosphate dehydrogenase in 100 mM potassium phosphate, pH 8.0) solution with the addition of each enzyme (CYP2C8, CYP2C9, or CYP3A4) was prepared. 	CYP2C9	17937	17943	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:128	Compounds, PPAG and ASP, and the rooibos extracts, GRT and FRE, were screened for their inhibitory effects on CYP2C8, CYP2C9, and CYP3A4 using one-point screening kinetics. 	CYP2C9	18706	18712	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:130	Briefly, inhibitors, extracts, and compounds were pre-incubated with either CYP2C8 or CYP2C9 at a concentration of 100 g/mL, or CYP3A4 at a concentration of 200 g/mL. 	CYP2C9	18947	18953	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:132	As per the manufacturers instruction, 50 L of Vivid^ Master Pre-Mix (BACULOSOMES^ enzymes (CYP2C8, CYP2C9 or CYP3A4), regeneration system, reaction buffer (I/II), and NADP^+) was added to each well. 	CYP2C9	19239	19245	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:134	After incubation, 10 L reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II were added to each well and incubated for 30 min at 37 C. Fluorescence was measured on a SpectraMax i3 plate reader at 5 min intervals to determine reaction kinetics. 	CYP2C9	19449	19455	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:136	Enzyme activity was measured by formation of the metabolites at excitation and emission wavelengths of 485/530 nm (CYP2C8) and 406/460 nm (CYP2C9 and CYP3A4), respectively. 	CYP2C9	19884	19890	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:137	A three-fold serial dilution of PPAG, ASP, GRT, and FRE was added to CYP2C8 and CYP2C9 (concentration range 100-0.41 g/mL) and CYP3A4 (concentration range 200-0.82 g/mL) to determine their respective IC_50 concentrations. 	CYP2C9	19998	20004	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP2C9	20148	20154	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP2C9	20485	20491	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:139	Time-dependent inhibition (TDI) using the respective serial dilutions employed for IC_50 determination (CYP2C8 and CYP2C9; 100-0.41 g/mL and for CYP3A4; 200-0.82 g/mL) was performed. 	CYP2C9	20848	20854	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:140	The extracts and compounds were pre-incubated with CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ and NADPH for 30 min. 	CYP2C9	20975	20981	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:145	Inhibition of CYP2C8, CYP2C9, and CYP3A4 BACULOSOMES^ was quantified, as described in. 	CYP2C9	21587	21593	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:146	The data generated were exported to an Excel (Microsoft Headquarters, One Microsoft Way, Redmond, WA, USA) worksheet and the amount of metabolite formed at various concentrations relative to the control was calculated using the following equation: The relative percentage activity was plotted against the log transformed concentrations of the extracts, compounds and positive controls, ie quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor). 	CYP2C9	22105	22111	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6316878_OgerInput.txtOger_out.csv:265	Queried databases included, eg, PharmGKB, PharmVar (available only for CYP2C9, 2C19, 2D6 genes), ADReCS-Target an Adverse Drug Reaction Classification System-Target Profile (http://bioinf.xmu.edu.cn/ADReCS-Target), which provides comprehensive information about ADRs caused by drug interaction with protein, gene and genetic variation, PheWas Resources (phenome-wide association studies with antineoplastic drugs), Clinvar and dbSNP. 	CYP2C9	41810	41816	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:4	Recombinant CYPs showing the highest specific activity were CYP3A4, CYP3A7 and to lower extent CYP2C9 and CTP2C8. 	CYP2C9	738	744	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:5	Michaelis-Menten enzyme kinetics were determined for pooled human liver microsomes, recombinant CYP3A4, CYP3A7 and CYP2C9. 	CYP2C9	872	878	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:7	The combined results show that the 5hydroxylation of flucloxacillin is primarily catalysed by CYP3A4, CYP3A7 and CYP2C9. 	CYP2C9	1131	1137	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:12	Quantification of specific activities and enzyme kinetics of flucloxacillin hydroxylation by HLM and 14 recombinant human CYPs.Next to CYP3A4, CYP3A7 and CYP2C9 may contribute significantly to flucloxacillin hydroxylation.Sulfaphenazole, considered as a selective CYP2C9 inhibitor, strongly inhibits CYP3Amediated flucloxacillin hydroxylation. 	CYP2C9	2173	2179	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:12	Quantification of specific activities and enzyme kinetics of flucloxacillin hydroxylation by HLM and 14 recombinant human CYPs.Next to CYP3A4, CYP3A7 and CYP2C9 may contribute significantly to flucloxacillin hydroxylation.Sulfaphenazole, considered as a selective CYP2C9 inhibitor, strongly inhibits CYP3Amediated flucloxacillin hydroxylation. 	CYP2C9	2283	2289	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:13	Interindividual variability and drugdrug interactions at the level of CYP3A4, CYP3A7 and CYP2C9 may be important factors determining the risk of flucloxacillininduced liver injury. 	CYP2C9	2452	2458	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:46	456252), CYP2C9*1(Arg144) (Lot No. 	CYP2C9	8333	8339	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:78	Because these incubations were only performed to identify the most active enzymes, duplicate experiments were deemed sufficient since reproducibility of incubations with recombinant enzymes from the same source was always within 5%, For the most active Gentest Supersomes and pooled HLM, the enzyme kinetics of the formation of 5HMFLX were determined by incubating with 11 concentrations of flucloxacillin, ranging from 0 to 500 M. Each flucloxacillin concentration was incubated in duplicate for 10 min with 0.5 mgmL^1 pooled HLM, 100 nM CYP3A4, CYP3A7 and CYP2C9 Supersomes in 100 mM potassium phosphate buffer, pH 7.4 supplemented with 5 mM MgCl_2 and 2 mM EDTA. 	CYP2C9	12242	12248	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2C9	12898	12904	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2C9	12925	12931	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2C9	13088	13094	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:85	Because the CYP2C9specific inhibitor sulfaphenazole appeared to almost completely block formation of 5HMFLX by pooled HLM, it was also added at different concentrations to incubations of CYP3A4 and CYP3A7 Supersomes with flucloxacillin (10 M) and testosterone (50 M). 	CYP2C9	13558	13564	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2C9	14183	14189	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:118	At a flucloxacillin concentration of 10 M, recombinant CYP3A4, CYP3A7 and to a lesser extent CYP2C9 showed the highest activity, in terms of the formation of 5HMFLX. 	CYP2C9	19689	19695	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2C9	19929	19935	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:121	As CYP3A4, CYP3A7 and CYP2C9 Supersomes showed highest activity at both concentrations, the enzyme kinetics of 5HMFLX formation was also determined for these recombinant CYPs. 	CYP2C9	20018	20024	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:123	Using the Michaelis-Menten model, the following enzyme kinetic parameters were determined: CYP3A4, K _M 124  15 M, V_max 197  9 pmolmin^1nmol^1 P450; CYP3A7: K _M 65  8 M, V_max 193  7 pmolmin^1nmol^1 P450; and CYP2C9: K _M of 508  82 M, V_max 67  7 pmolmin^1nmol^1 P450. 	CYP2C9	20468	20474	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:128	Although recombinant CYP2C9 showed much lower activity when compared to CYP3A4, an almost 90% inhibition of 5HMFLX formation was observed in the presence of sulfaphenazole, which is considered to be a selective CYP2C9 inhibitor. 	CYP2C9	21097	21103	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:128	Although recombinant CYP2C9 showed much lower activity when compared to CYP3A4, an almost 90% inhibition of 5HMFLX formation was observed in the presence of sulfaphenazole, which is considered to be a selective CYP2C9 inhibitor. 	CYP2C9	21287	21293	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:129	However, fluvoxamine, the other CYP2C9 inhibitor used, did not show significant inhibition of 5HMFLX formation. 	CYP2C9	21337	21343	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:138	At both concentrations of flucloxacillin, the highest correlation coefficients were found with CYP2C9catalysed diclofenac 4hydroxylation, with Pearson correlation coefficients of 0.78 and 0.58, respectively, and CYP3Acatalysed 6BETAhydroxylation, with correlation coefficients of 0.69 and 0.58 respectively. 	CYP2C9	22900	22906	('Cytochromes', 'Cytochrome P-450 CYP2C9', 'NCCS', 'NCCS_536', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:161	The localization images of CYP1A1 and 3A4 showed no preferential localization of these isoforms for either mitochondria or Endoplasmic Reticulum, as also shown by other groups in several models. 	CYP1A1	24397	24403	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:161	The localization images of CYP1A1 and 3A4 showed no preferential localization of these isoforms for either mitochondria or Endoplasmic Reticulum, as also shown by other groups in several models. 	CYP1A1	24397	24403	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:184	The quantification of relative mRNA levels for the isoforms CYP1A1, 2D6 and 2E1 was carried out after incubation of SH-SY5Y cells for 48 h with BETA-NF (4 M), dissolved in dimethyl sulfoxide (DMSO; 0.1% maximum final concentration used, v/v), and EtOH (100 mM), dissolved in water. 	CYP1A1	27774	27780	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:184	The quantification of relative mRNA levels for the isoforms CYP1A1, 2D6 and 2E1 was carried out after incubation of SH-SY5Y cells for 48 h with BETA-NF (4 M), dissolved in dimethyl sulfoxide (DMSO; 0.1% maximum final concentration used, v/v), and EtOH (100 mM), dissolved in water. 	CYP1A1	27774	27780	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	CYP1A1	28716	28722	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	CYP1A1	28716	28722	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:196	The analysis of protein levels was performed for isoforms CYP1A1, 2D6, 2E1, and 3A4 in both undifferentiated and differentiated SH-SY5Y cells. 	CYP1A1	29795	29801	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:196	The analysis of protein levels was performed for isoforms CYP1A1, 2D6, 2E1, and 3A4 in both undifferentiated and differentiated SH-SY5Y cells. 	CYP1A1	29795	29801	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP1A1	30711	30717	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP1A1	30711	30717	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:26	To determine the effect of B[ALPHA]P on the gene signature in human T lymphocytes, primary cultures of T lymphocytes purified from healthy blood donors and activated with anti-CD3 and anti-CD28 antibodies for 72 h, were used and co-exposed to 2 M B[ALPHA]P for the last 48 h. We previously reported an early and functional up-regulation of the Aryl Hydrocarbon by such human T lymphocyte activation during 24 h, followed by a maximal response of target genes such as CYP1A1 and CYP1B1 after exposure to 2 M B[ALPHA]P. Such a 2 M concentration is in the range of B[ALPHA]P concentrations known to lead to maximal response of target genes in cultured human cells. 	CYP1A1	5440	5446	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:26	To determine the effect of B[ALPHA]P on the gene signature in human T lymphocytes, primary cultures of T lymphocytes purified from healthy blood donors and activated with anti-CD3 and anti-CD28 antibodies for 72 h, were used and co-exposed to 2 M B[ALPHA]P for the last 48 h. We previously reported an early and functional up-regulation of the Aryl Hydrocarbon by such human T lymphocyte activation during 24 h, followed by a maximal response of target genes such as CYP1A1 and CYP1B1 after exposure to 2 M B[ALPHA]P. Such a 2 M concentration is in the range of B[ALPHA]P concentrations known to lead to maximal response of target genes in cultured human cells. 	CYP1A1	5440	5446	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:31	Among these genes, as expected, CYP1A1 and CYP1B1, well-known targets of Aryl Hydrocarbon, appear as the top genes over-expressed after exposure to B[ALPHA]P, thus validating our experimental conditions. 	CYP1A1	6372	6378	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:31	Among these genes, as expected, CYP1A1 and CYP1B1, well-known targets of Aryl Hydrocarbon, appear as the top genes over-expressed after exposure to B[ALPHA]P, thus validating our experimental conditions. 	CYP1A1	6372	6378	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:33	We thus selected the most significantly affected genes: CYP1A1 and 1B1, gap junction beta-2 and beta-6 (GJB6) proteins, TCDD-inducible poly(ADP-ribose) polymerase (TIPARP), transmembrane protein 167A, oligodendrocyte transcription factor 3, cyclin-dependent kinase-binding protein (CABLES1), proto-oncogene c-KIT and E3 ubiquitin ligase specificity subunit (ASB2) for the 10 most up-regulated genes; IFN-induced proteins 44L, 44 (IFI44), p78 (MX1) with tetratricopeptide repeats 2 (IFIT2), collagen (COL6A3), microcephalin MCPH1, lysosomal trafficking regulator, enzyme oligoadenylate synthetase like, proteoglycan (PRG4), and cell surface antigen (THY1) for the 10 most down-regulated ones. 	CYP1A1	6823	6829	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:33	We thus selected the most significantly affected genes: CYP1A1 and 1B1, gap junction beta-2 and beta-6 (GJB6) proteins, TCDD-inducible poly(ADP-ribose) polymerase (TIPARP), transmembrane protein 167A, oligodendrocyte transcription factor 3, cyclin-dependent kinase-binding protein (CABLES1), proto-oncogene c-KIT and E3 ubiquitin ligase specificity subunit (ASB2) for the 10 most up-regulated genes; IFN-induced proteins 44L, 44 (IFI44), p78 (MX1) with tetratricopeptide repeats 2 (IFIT2), collagen (COL6A3), microcephalin MCPH1, lysosomal trafficking regulator, enzyme oligoadenylate synthetase like, proteoglycan (PRG4), and cell surface antigen (THY1) for the 10 most down-regulated ones. 	CYP1A1	6823	6829	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:35	Thus, CYP1A1, CYP1B1, Gap Junction Beta-2, GJB6, TIPARP, Oligodendrocyte Transcription Factor 3, CABLES1, KIT and ASB2 transcriptional levels were confirmed to be up-regulated after B[ALPHA]P exposure; with inductions reaching a significant level for all these genes except for Oligodendrocyte Transcription Factor 3 and TIPARP (A). 	CYP1A1	7680	7686	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:35	Thus, CYP1A1, CYP1B1, Gap Junction Beta-2, GJB6, TIPARP, Oligodendrocyte Transcription Factor 3, CABLES1, KIT and ASB2 transcriptional levels were confirmed to be up-regulated after B[ALPHA]P exposure; with inductions reaching a significant level for all these genes except for Oligodendrocyte Transcription Factor 3 and TIPARP (A). 	CYP1A1	7680	7686	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:40	Among genes belonging to Aryl Hydrocarbon signaling, we recently reported the regulation of CYP1A1, CYP1B1 and the cyclin-dependent kinase inhibitor 1A in human T lymphocytes upon exposure to B[ALPHA]P. The Aryl Hydrocarbon repressor, the cyclin E2 and the NAD(P)H dehydrogenase (NQO1) have already been reported to be robust targets of B[ALPHA]P but, in different cell types, but not in primary T lymphocytes. 	CYP1A1	9162	9168	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:40	Among genes belonging to Aryl Hydrocarbon signaling, we recently reported the regulation of CYP1A1, CYP1B1 and the cyclin-dependent kinase inhibitor 1A in human T lymphocytes upon exposure to B[ALPHA]P. The Aryl Hydrocarbon repressor, the cyclin E2 and the NAD(P)H dehydrogenase (NQO1) have already been reported to be robust targets of B[ALPHA]P but, in different cell types, but not in primary T lymphocytes. 	CYP1A1	9162	9168	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:41	We then validated by RT-qPCR assays these changes in Ahr Repressor, Cyclin E2, Cyclin-Dependent Kinase Inhibitor 1a, CYP1A1, CYP1B1, and NQO1 gene expression changes using the 16 individual RNA samples isolated from Concentration Of Dmso and B[ALPHA]P-treated T lymphocyte cultures (A). 	CYP1A1	9598	9604	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:41	We then validated by RT-qPCR assays these changes in Ahr Repressor, Cyclin E2, Cyclin-Dependent Kinase Inhibitor 1a, CYP1A1, CYP1B1, and NQO1 gene expression changes using the 16 individual RNA samples isolated from Concentration Of Dmso and B[ALPHA]P-treated T lymphocyte cultures (A). 	CYP1A1	9598	9604	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:67	Additionally, except for the Aryl Hydrocarbon target genes, CYP1A1 and CYP1B1, few of the 158 differentially expressed transcripts displayed strong amplitude in the changes observed. 	CYP1A1	16998	17004	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:67	Additionally, except for the Aryl Hydrocarbon target genes, CYP1A1 and CYP1B1, few of the 158 differentially expressed transcripts displayed strong amplitude in the changes observed. 	CYP1A1	16998	17004	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:70	Among genes identified by our study, some have already been described to be targeted by B[ALPHA]P. This is notably true for CYP1A1, CYP1B1, the ferredoxin reductase, NQO1, Cyclin-Dependent Kinase Inhibitor 1a, Ahr Repressor, ASB2 or TIPARP up-regulated genes and MX1 or the solute carrier SLC25A37, regarding the down-regulated ones. 	CYP1A1	17692	17698	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:70	Among genes identified by our study, some have already been described to be targeted by B[ALPHA]P. This is notably true for CYP1A1, CYP1B1, the ferredoxin reductase, NQO1, Cyclin-Dependent Kinase Inhibitor 1a, Ahr Repressor, ASB2 or TIPARP up-regulated genes and MX1 or the solute carrier SLC25A37, regarding the down-regulated ones. 	CYP1A1	17692	17698	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:76	Nevertheless, AhR- and p53-target genes such as CYP1A1, CYP1B1, Ahr Repressor, ASB2 or Cyclin-Dependent Kinase Inhibitor 1a and the ribonucleotide reductase RRM2B were shown to be modulated in both type of cells, all encoding enzymes important in the detoxication and the DNA damage response induced after B[ALPHA]P exposure. 	CYP1A1	18881	18887	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6274903_OgerInput.txtOger_out.csv:76	Nevertheless, AhR- and p53-target genes such as CYP1A1, CYP1B1, Ahr Repressor, ASB2 or Cyclin-Dependent Kinase Inhibitor 1a and the ribonucleotide reductase RRM2B were shown to be modulated in both type of cells, all encoding enzymes important in the detoxication and the DNA damage response induced after B[ALPHA]P exposure. 	CYP1A1	18881	18887	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:38	Hitoshi et al reported that SWCNT also downregulated genes coding other CYP isoenzymes, namely, CYP1A1 and CYP1B1. 	CYP1A1	5793	5799	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:38	Hitoshi et al reported that SWCNT also downregulated genes coding other CYP isoenzymes, namely, CYP1A1 and CYP1B1. 	CYP1A1	5793	5799	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:191	In other studies by Hitoshi et al, multi-walled carbon nanotubes downregulated CYP1A1 and in HepG2 cells by repression of AhR binding to the enhancer region. 	CYP1A1	31770	31776	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:191	In other studies by Hitoshi et al, multi-walled carbon nanotubes downregulated CYP1A1 and in HepG2 cells by repression of AhR binding to the enhancer region. 	CYP1A1	31770	31776	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:41	The enzymes used were CYP1A1 (Lot No. 	CYP1A1	8208	8214	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:41	The enzymes used were CYP1A1 (Lot No. 	CYP1A1	8208	8214	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP1A1	19969	19975	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP1A1	19969	19975	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP1A1	24515	24521	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP1A1	24515	24521	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:102	The AhR/ARNT heterodimer binds the xenobiotic responsive elements in the promoter, leading to the transcription of genes that encode xenobiotic metabolism enzymes, such as cytochrome P450 genes, which in mammals include CYP1A1, CYP1A2, and CYP1B1. 	CYP1A1	17977	17983	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:102	The AhR/ARNT heterodimer binds the xenobiotic responsive elements in the promoter, leading to the transcription of genes that encode xenobiotic metabolism enzymes, such as cytochrome P450 genes, which in mammals include CYP1A1, CYP1A2, and CYP1B1. 	CYP1A1	17977	17983	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:425	CYP3A4 is the major enzyme responsible for the 16ALPHA-hydroxylation of estrone in adults, though CYP1A1, CYP2C19 and CYP3A5 can also catalyze the reaction. 	CYP1A1	70351	70357	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:425	CYP3A4 is the major enzyme responsible for the 16ALPHA-hydroxylation of estrone in adults, though CYP1A1, CYP2C19 and CYP3A5 can also catalyze the reaction. 	CYP1A1	70351	70357	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:426	Conversely, CYP1A2 is the dominant enzyme catalyzing the 16ALPHA-hydroxylation of 17BETA-estradiol, with CYP3A4, CYP1A1 and CYP1B1 also demonstrating this activity. 	CYP1A1	70523	70529	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:426	Conversely, CYP1A2 is the dominant enzyme catalyzing the 16ALPHA-hydroxylation of 17BETA-estradiol, with CYP3A4, CYP1A1 and CYP1B1 also demonstrating this activity. 	CYP1A1	70523	70529	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:429	These reactions are catalyzed by a variety of CYPs, including CYP3A4 and CYP1A2 in the liver, or CYP1A1 and CYP3A4 in peripheral tissues. 	CYP1A1	70856	70862	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:429	These reactions are catalyzed by a variety of CYPs, including CYP3A4 and CYP1A2 in the liver, or CYP1A1 and CYP3A4 in peripheral tissues. 	CYP1A1	70856	70862	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:14	CYP1A subfamily contains only two functional genes, CYP1A1 and CYP1A2, which are highly conserved among species. 	CYP1A1	2010	2016	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:14	CYP1A subfamily contains only two functional genes, CYP1A1 and CYP1A2, which are highly conserved among species. 	CYP1A1	2010	2016	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A1	2244	2250	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A1	2244	2250	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A1	2358	2364	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A1	2358	2364	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:17	Although the transcriptional regulation of CYP1A1 and 1A2 may be simultaneously controlled by bidirectional gene elements, their expression patterns are different. 	CYP1A1	2422	2428	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:17	Although the transcriptional regulation of CYP1A1 and 1A2 may be simultaneously controlled by bidirectional gene elements, their expression patterns are different. 	CYP1A1	2422	2428	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:18	For example, CYP1A2 is constitutively and specifically expressed in the liver, while CYP1A1 is mainly expressed outside the liver^,. 	CYP1A1	2628	2634	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:18	For example, CYP1A2 is constitutively and specifically expressed in the liver, while CYP1A1 is mainly expressed outside the liver^,. 	CYP1A1	2628	2634	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:192	Interestingly, we observed induction of CYP1A2 upon treatment with GN. 	CYP1A2	31889	31895	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:192	Interestingly, we observed induction of CYP1A2 upon treatment with GN. 	CYP1A2	31889	31895	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:193	A known inducer of CYP1A2 is cigarette smoke containing a significant amount of nanoparticulated carbon black and PAH., Thus, it might be related to GN structure, more similar to compounds found in the cigarette smoke, when compared to the DN or GO used in this study, as PAH structure also consists of sp^2-hybridized carbon atoms with delocalized  electrons, which is a reason for naming PAH nanographenes or cutouts of graphene. 	CYP1A2	31939	31945	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:193	A known inducer of CYP1A2 is cigarette smoke containing a significant amount of nanoparticulated carbon black and PAH., Thus, it might be related to GN structure, more similar to compounds found in the cigarette smoke, when compared to the DN or GO used in this study, as PAH structure also consists of sp^2-hybridized carbon atoms with delocalized  electrons, which is a reason for naming PAH nanographenes or cutouts of graphene. 	CYP1A2	31939	31945	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:42	456211), CYP1A2 (Lot No. 	CYP1A2	8233	8239	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:42	456211), CYP1A2 (Lot No. 	CYP1A2	8233	8239	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP1A2	12817	12823	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP1A2	12817	12823	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP1A2	12932	12938	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP1A2	12932	12938	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP1A2	14044	14050	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP1A2	14044	14050	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP1A2	19988	19994	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP1A2	19988	19994	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP1A2	24523	24529	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP1A2	24523	24529	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:149	did not detect 5HMFLX in incubations with recombinant CYP1A2, CYP2C9 and CYP3A5 might be attributed to the less sensitive analytical method used (HPLC-UV detection versus LC-MS) and/or the use of yeastexpressed CYPs with lower specific activity than the Supersomes used in the present study. 	CYP1A2	24649	24655	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:149	did not detect 5HMFLX in incubations with recombinant CYP1A2, CYP2C9 and CYP3A5 might be attributed to the less sensitive analytical method used (HPLC-UV detection versus LC-MS) and/or the use of yeastexpressed CYPs with lower specific activity than the Supersomes used in the present study. 	CYP1A2	24649	24655	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:237	Mostly all the compounds were found to be a substrate of CYP1A2, except F25, whereas, for CYP2C8, only compound F2 was found to be the substrate. 	CYP1A2	38313	38319	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:237	Mostly all the compounds were found to be a substrate of CYP1A2, except F25, whereas, for CYP2C8, only compound F2 was found to be the substrate. 	CYP1A2	38313	38319	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:241	Results revealed that for predicting the site of enzyme CYP1A2, the K_m value was 28.53, 33.79, 18.55, 16.59, 7.42, 158.31 and 49.91 M, whereas the V_max constant was 1.76, 4.22, 5.34, 1.18, 1.99, 5.19 and 8.04 nM/min/nM and the C_Lint was 3.21, 6.49, 14.96, 3.69, 13.92, 1.70, and 8.37 L/min/mg for compounds F2, F3, F8, F11, F13, F20, and F21, respectively. 	CYP1A2	38942	38948	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:241	Results revealed that for predicting the site of enzyme CYP1A2, the K_m value was 28.53, 33.79, 18.55, 16.59, 7.42, 158.31 and 49.91 M, whereas the V_max constant was 1.76, 4.22, 5.34, 1.18, 1.99, 5.19 and 8.04 nM/min/nM and the C_Lint was 3.21, 6.49, 14.96, 3.69, 13.92, 1.70, and 8.37 L/min/mg for compounds F2, F3, F8, F11, F13, F20, and F21, respectively. 	CYP1A2	38942	38948	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP1A2	40379	40385	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP1A2	40379	40385	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:70	^, Chronic tobacco smokers have induced hepatic CYP enzymes, particularly CYP1A2. 	CYP1A2	9559	9565	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:70	^, Chronic tobacco smokers have induced hepatic CYP enzymes, particularly CYP1A2. 	CYP1A2	9559	9565	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:73	CYP1A2 is a relevant enzyme in the metabolism of commonly prescribed psychoactive medications, including clozapine, duloxetine, olanzapine and imipramine are not metabolized by CYP1A2. 	CYP1A2	9775	9781	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:73	CYP1A2 is a relevant enzyme in the metabolism of commonly prescribed psychoactive medications, including clozapine, duloxetine, olanzapine and imipramine are not metabolized by CYP1A2. 	CYP1A2	9775	9781	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:73	CYP1A2 is a relevant enzyme in the metabolism of commonly prescribed psychoactive medications, including clozapine, duloxetine, olanzapine and imipramine are not metabolized by CYP1A2. 	CYP1A2	9952	9958	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:73	CYP1A2 is a relevant enzyme in the metabolism of commonly prescribed psychoactive medications, including clozapine, duloxetine, olanzapine and imipramine are not metabolized by CYP1A2. 	CYP1A2	9952	9958	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:9	PharmG+ clozapine treated patients with CYP1A2 or CYP2C19 UM and PMs variants also showed higher reductions in UKU scores than PharmG clozapine patients in general. 	CYP1A2	1469	1475	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:9	PharmG+ clozapine treated patients with CYP1A2 or CYP2C19 UM and PMs variants also showed higher reductions in UKU scores than PharmG clozapine patients in general. 	CYP1A2	1469	1475	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP1A2	3323	3329	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP1A2	3323	3329	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP1A2	3356	3362	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP1A2	3356	3362	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP1A2	8069	8075	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP1A2	8069	8075	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP1A2	9556	9562	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP1A2	9556	9562	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP1A2	9620	9626	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP1A2	9620	9626	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:81	When analysing patients with functional variants in CYP1A2, CYP2D6 and/or CYP2C19 (N = 155), no differences were observed between PharmG+ and PharmG patients in PANSS improvement, nor was it observed in the subgroups of patients treated with clozapine (p > 0.05 for all comparisons, see Table. 	CYP1A2	12931	12937	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:81	When analysing patients with functional variants in CYP1A2, CYP2D6 and/or CYP2C19 (N = 155), no differences were observed between PharmG+ and PharmG patients in PANSS improvement, nor was it observed in the subgroups of patients treated with clozapine (p > 0.05 for all comparisons, see Table. 	CYP1A2	12931	12937	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:85	Analyses of patients with functional variants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer improvements in the profile of side effects in the PharmG+ patients in comparison to PharmG patients. 	CYP1A2	13857	13863	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:85	Analyses of patients with functional variants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer improvements in the profile of side effects in the PharmG+ patients in comparison to PharmG patients. 	CYP1A2	13857	13863	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:111	However, those differences were not statistically significant, even when considering patients with CYP1A2 or CYP2C19 UM and PMs variants (p > 0.05 in all comparisons). 	CYP1A2	18287	18293	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:111	However, those differences were not statistically significant, even when considering patients with CYP1A2 or CYP2C19 UM and PMs variants (p > 0.05 in all comparisons). 	CYP1A2	18287	18293	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:114	Several studies have proven the clinical value of a commercial array combining genetic information in metabolic enzymes (CYP1A2, CYP2D6 and CYP2C19) and antidepressant targets (serotonin transporter, SLC6A4 and serotonin receptor 2A, HTR2A). 	CYP1A2	18815	18821	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:114	Several studies have proven the clinical value of a commercial array combining genetic information in metabolic enzymes (CYP1A2, CYP2D6 and CYP2C19) and antidepressant targets (serotonin transporter, SLC6A4 and serotonin receptor 2A, HTR2A). 	CYP1A2	18815	18821	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP1A2	39916	39922	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	CYP1A2	39916	39922	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:102	The AhR/ARNT heterodimer binds the xenobiotic responsive elements in the promoter, leading to the transcription of genes that encode xenobiotic metabolism enzymes, such as cytochrome P450 genes, which in mammals include CYP1A1, CYP1A2, and CYP1B1. 	CYP1A2	17985	17991	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6770377_OgerInput.txtOger_out.csv:102	The AhR/ARNT heterodimer binds the xenobiotic responsive elements in the promoter, leading to the transcription of genes that encode xenobiotic metabolism enzymes, such as cytochrome P450 genes, which in mammals include CYP1A1, CYP1A2, and CYP1B1. 	CYP1A2	17985	17991	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:426	Conversely, CYP1A2 is the dominant enzyme catalyzing the 16ALPHA-hydroxylation of 17BETA-estradiol, with CYP3A4, CYP1A1 and CYP1B1 also demonstrating this activity. 	CYP1A2	70422	70428	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:426	Conversely, CYP1A2 is the dominant enzyme catalyzing the 16ALPHA-hydroxylation of 17BETA-estradiol, with CYP3A4, CYP1A1 and CYP1B1 also demonstrating this activity. 	CYP1A2	70422	70428	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:429	These reactions are catalyzed by a variety of CYPs, including CYP3A4 and CYP1A2 in the liver, or CYP1A1 and CYP3A4 in peripheral tissues. 	CYP1A2	70832	70838	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:429	These reactions are catalyzed by a variety of CYPs, including CYP3A4 and CYP1A2 in the liver, or CYP1A1 and CYP3A4 in peripheral tissues. 	CYP1A2	70832	70838	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP1A2	24750	24756	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP1A2	24750	24756	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:140	Similar serum antibodies to drug-modified and/or unmodified P450s and other native cellular proteins have also been detected in idiosyncratic liver injury upon halothane-exposure (anti-trifluoroacetyl-CYP2E1), aromatic anti-convulsant (anti-CYP3A), dihydralazine (anti-CYP1A2), tienilic acid (anti-tienilic acid-CYP2C9) and/or chronic alcohol intake (anti-acetaldehyde-CYP2E1 and anti-hydroxyethyl-CYP2E1),. 	CYP1A2	32120	32126	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:140	Similar serum antibodies to drug-modified and/or unmodified P450s and other native cellular proteins have also been detected in idiosyncratic liver injury upon halothane-exposure (anti-trifluoroacetyl-CYP2E1), aromatic anti-convulsant (anti-CYP3A), dihydralazine (anti-CYP1A2), tienilic acid (anti-tienilic acid-CYP2C9) and/or chronic alcohol intake (anti-acetaldehyde-CYP2E1 and anti-hydroxyethyl-CYP2E1),. 	CYP1A2	32120	32126	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:14	CYP1A subfamily contains only two functional genes, CYP1A1 and CYP1A2, which are highly conserved among species. 	CYP1A2	2021	2027	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:14	CYP1A subfamily contains only two functional genes, CYP1A1 and CYP1A2, which are highly conserved among species. 	CYP1A2	2021	2027	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A2	2218	2224	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A2	2218	2224	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A2	2369	2375	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:16	Phylogenetic analysis of CYP1A gene shows that the CYP1A2 gene may rise from CYP1A1 and they have a common 5-anking region, which has been proved to contain bidirectional regulators both for CYP1A1 and CYP1A2^,. 	CYP1A2	2369	2375	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:18	For example, CYP1A2 is constitutively and specifically expressed in the liver, while CYP1A1 is mainly expressed outside the liver^,. 	CYP1A2	2556	2562	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:18	For example, CYP1A2 is constitutively and specifically expressed in the liver, while CYP1A1 is mainly expressed outside the liver^,. 	CYP1A2	2556	2562	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:19	CYP1A-catalyzed reactions include hydroxylation and oxidation of aromatic compounds, in which CYP1A1 is mainly involved in the metabolism of aromatic hydrocarbon, while CYP1A2 prefers aromatic amines and heterocyclic compounds. 	CYP1A2	2845	2851	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:19	CYP1A-catalyzed reactions include hydroxylation and oxidation of aromatic compounds, in which CYP1A1 is mainly involved in the metabolism of aromatic hydrocarbon, while CYP1A2 prefers aromatic amines and heterocyclic compounds. 	CYP1A2	2845	2851	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:33	Compared with CYP1A2, CYP1A1 is the main isoform mediating the biotransformation of pregnenolone. 	CYP1A2	4942	4948	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:33	Compared with CYP1A2, CYP1A1 is the main isoform mediating the biotransformation of pregnenolone. 	CYP1A2	4942	4948	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:13	The highly polymorphic CYP2C19 isozymes are responsible for metabolizing a large portion of routinely prescribed drugs and variants contribute significantly to adverse drug reactions and therapeutic failures. 	CYP2C19	1684	1691	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:14	A limited number of CYP2C19 single nucleotide polymorphisms are involved in drug metabolism. 	CYP2C19	1890	1897	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:19	The aim of this study is to better understand and provide further knowledge about the metabolism and interactions between phenobarbital and CYP2C19 polymorphisms in children with epilepsy, interplay between sleep, and Eversus Understanding this interplay between epilepsy and sleep is helpful in the optimal treatment of all patients with epileptic seizures. 	CYP2C19	2620	2627	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	CYP2C19	24766	24773	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:137	In the report we will only discuss the CYP2C19 gene as outlined in. 	CYP2C19	25683	25690	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:138	The Cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19 gene) is located within a cluster of Cytochrome P450 genes (CYP2C19) on chromosome 10q23.33 with reference sequence number (NM_000769) and ensemble accession number ENST00000371321.8. 	CYP2C19	25772	25779	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:138	The Cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19 gene) is located within a cluster of Cytochrome P450 genes (CYP2C19) on chromosome 10q23.33 with reference sequence number (NM_000769) and ensemble accession number ENST00000371321.8. 	CYP2C19	25840	25847	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:139	CYP2C19 is expressed in the liver and to a lesser extent in the small intestine, contributing to the metabolism of a large number of clinically relevant drugs and drug classes including phenytoin and phenobarbital. 	CYP2C19	25964	25971	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:140	The CYP2C19 gene is part of the CYP2C cluster comprising four genes (CYP2C8, CYP2C9, CYP2C18 and CYP2C19). 	CYP2C19	26183	26190	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:140	The CYP2C19 gene is part of the CYP2C cluster comprising four genes (CYP2C8, CYP2C9, CYP2C18 and CYP2C19). 	CYP2C19	26276	26283	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:141	This CYP2C19 gene encompasses 90,637 bases and is composed of nine exons encoding 490 amino acids. 	CYP2C19	26291	26298	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:143	We checked nucleotide human sequence homology of CYP2C19 (NP_000760.1) with National Institute of Health databases (https://www.ncbi.nlm.nih.gov/), and we found that 84% of CYPC29 (NP_000760.1), 81% of CYP2C18 isoform 2 precursor (NP_000762.2), 81% of Cytochrome P450 2C8 isoform c (NP_000763.1), 79% of Cytochrome P450 2C8 isoform b (NP_001185783.1), 78% Cytochrome P450 2C8 isoform a precursor (NP_000761.3), 58% Cytochrome P450 2E1 precursor (NP_000764.1), 56% Cytochrome P450 2F1 isoform X7 (XP_016881875.1), and 48% CYPP450 2F1 isoform X4 (XP_011524855.1). 	CYP2C19	26494	26501	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:144	Understanding the biological function of CYP2C19 gene can provide a good foundation for subsequently interpreting the potential influence of genetic associations on a disease phenotype and so can greatly support any identified genetic association. 	CYP2C19	27048	27055	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:151	Potential binding sites for the transcription factors such as GATA proteins, progesterone receptor, TATA box elements and nuclear factors in CYP2C19 promoter region has been described. 	CYP2C19	28169	28176	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:153	This CYP2C19 gene (RefSeq accession number NM_000769.4) has three promoter regions. 	CYP2C19	28374	28381	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:154	As shown in, CYP2C19-201 has nine exons and eight introns and consists of 490 amino acids, while CYP2C10-202 has 162 amino acids, however, CYP2C19-203 does not produce protein products. 	CYP2C19	28466	28473	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:154	As shown in, CYP2C19-201 has nine exons and eight introns and consists of 490 amino acids, while CYP2C10-202 has 162 amino acids, however, CYP2C19-203 does not produce protein products. 	CYP2C19	28592	28599	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:155	The sequences for all promoters in CYP2C19 gene are as follows: CYP2C19-201 identified in chromosome position at 94762681 (ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG), CYP2C19-202 chromosome position 94842926 (ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA), and CYP2C19-203 chromosome position 94775489 (ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG) In addition, we identified the following Kyoto Encyclopedia Of Genes And Genomes pathways of CYP2C19 which include arachidonic acid metabolism, organism-specific biosystem, chemical carcinogenesis, organism-specific biosystem, drug metabolism (cytochrome P450), organism-specific biosystem, linoleic acid metabolism, organism-specific biosystem, metabolic pathways, organism-specific biosystem, and serotonergic synapse. 	CYP2C19	28674	28681	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:155	The sequences for all promoters in CYP2C19 gene are as follows: CYP2C19-201 identified in chromosome position at 94762681 (ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG), CYP2C19-202 chromosome position 94842926 (ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA), and CYP2C19-203 chromosome position 94775489 (ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG) In addition, we identified the following Kyoto Encyclopedia Of Genes And Genomes pathways of CYP2C19 which include arachidonic acid metabolism, organism-specific biosystem, chemical carcinogenesis, organism-specific biosystem, drug metabolism (cytochrome P450), organism-specific biosystem, linoleic acid metabolism, organism-specific biosystem, metabolic pathways, organism-specific biosystem, and serotonergic synapse. 	CYP2C19	28703	28710	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:155	The sequences for all promoters in CYP2C19 gene are as follows: CYP2C19-201 identified in chromosome position at 94762681 (ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG), CYP2C19-202 chromosome position 94842926 (ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA), and CYP2C19-203 chromosome position 94775489 (ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG) In addition, we identified the following Kyoto Encyclopedia Of Genes And Genomes pathways of CYP2C19 which include arachidonic acid metabolism, organism-specific biosystem, chemical carcinogenesis, organism-specific biosystem, drug metabolism (cytochrome P450), organism-specific biosystem, linoleic acid metabolism, organism-specific biosystem, metabolic pathways, organism-specific biosystem, and serotonergic synapse. 	CYP2C19	28825	28832	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:155	The sequences for all promoters in CYP2C19 gene are as follows: CYP2C19-201 identified in chromosome position at 94762681 (ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG), CYP2C19-202 chromosome position 94842926 (ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA), and CYP2C19-203 chromosome position 94775489 (ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG) In addition, we identified the following Kyoto Encyclopedia Of Genes And Genomes pathways of CYP2C19 which include arachidonic acid metabolism, organism-specific biosystem, chemical carcinogenesis, organism-specific biosystem, drug metabolism (cytochrome P450), organism-specific biosystem, linoleic acid metabolism, organism-specific biosystem, metabolic pathways, organism-specific biosystem, and serotonergic synapse. 	CYP2C19	28934	28941	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:155	The sequences for all promoters in CYP2C19 gene are as follows: CYP2C19-201 identified in chromosome position at 94762681 (ttaattagcatggagtgttataaaaagcttggagtgcaagctcacggttGTCTTAACAAG), CYP2C19-202 chromosome position 94842926 (ccggagcccctgcatgcaggacaggggccacatgccctacacagatgctGTGGTGCACGA), and CYP2C19-203 chromosome position 94775489 (ctcatgacgctgcggaattttgggatggggaagaggagcattgaggaccGTGTTCAAGAG) In addition, we identified the following Kyoto Encyclopedia Of Genes And Genomes pathways of CYP2C19 which include arachidonic acid metabolism, organism-specific biosystem, chemical carcinogenesis, organism-specific biosystem, drug metabolism (cytochrome P450), organism-specific biosystem, linoleic acid metabolism, organism-specific biosystem, metabolic pathways, organism-specific biosystem, and serotonergic synapse. 	CYP2C19	29131	29138	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:157	For the cellular component, the CYP2C19 gene is found in different part of the cells: cytoplasm (GO:0005737), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020), and organelle membrane (GO:0031090). 	CYP2C19	29691	29698	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:160	Next, we used STRING software to build a gene network of the CYP2C19 gene and other neighbor genes using https://string-db.org/ as shown in. 	CYP2C19	30454	30461	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:161	This network shows high interaction between CYP2C19 and other genes such as glutathione S-transferase mu 1, glutathione S-transferase mu 2 (muscle), glutathione S-transferase mu 3 (brain), glutathione S-transferase theta 1. 	CYP2C19	30578	30585	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:165	Next, we used genome at USSC to find out the CYP2C19 tagged Single Nucleotide Polymorphisms (https://genome.ucsc.edu/cgi-bin/hgGateway). 	CYP2C19	31410	31417	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:166	The tagged Single Nucleotide Polymorphisms associated with the CYP2C19 gene are shown in. 	CYP2C19	31565	31572	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:168	In this report, we will focus only on CYP2C19 Single Nucleotide Polymorphisms that has been reported to be associated with drug metabolism as shown in. 	CYP2C19	31805	31812	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:169	We identified the position of each amino acid for each Single Nucleotide Polymorphisms and the upstream Single Nucleotide Polymorphisms and downstream Single Nucleotide Polymorphisms including Single Nucleotide Polymorphisms (rs28399504 (CYP2C19*4) located on amino acid number 1 (valine), rs17878459 (CYP2C19*17), located on amino acid 92, (aspartic, D), rs4986893 CYP2C19*3 located on amino acid number 212 (NA), rs4244285 (CYP2C19*2) located on amino acid 227 (proline), and rs56337013 (CYP2C19*5) located on amino acid number 433 (tryptophan, W).  	CYP2C19	32157	32164	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:169	We identified the position of each amino acid for each Single Nucleotide Polymorphisms and the upstream Single Nucleotide Polymorphisms and downstream Single Nucleotide Polymorphisms including Single Nucleotide Polymorphisms (rs28399504 (CYP2C19*4) located on amino acid number 1 (valine), rs17878459 (CYP2C19*17), located on amino acid 92, (aspartic, D), rs4986893 CYP2C19*3 located on amino acid number 212 (NA), rs4244285 (CYP2C19*2) located on amino acid 227 (proline), and rs56337013 (CYP2C19*5) located on amino acid number 433 (tryptophan, W).  	CYP2C19	32221	32228	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:169	We identified the position of each amino acid for each Single Nucleotide Polymorphisms and the upstream Single Nucleotide Polymorphisms and downstream Single Nucleotide Polymorphisms including Single Nucleotide Polymorphisms (rs28399504 (CYP2C19*4) located on amino acid number 1 (valine), rs17878459 (CYP2C19*17), located on amino acid 92, (aspartic, D), rs4986893 CYP2C19*3 located on amino acid number 212 (NA), rs4244285 (CYP2C19*2) located on amino acid 227 (proline), and rs56337013 (CYP2C19*5) located on amino acid number 433 (tryptophan, W).  	CYP2C19	32285	32292	('Cytochromes', 'Cytochrome P-450 CYP2C19', 'NCCS', 'NCCS_541', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:83	Then, 50 L of Master Pre-Mix consisting of Baculosomes (containing either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and NADPH reductase) in working buffer and the regeneration system (consisting of glucose-6-phosphate and glucose-6- phosphate dehydrogenase) were added to each well. 	CYP2D6	12450	12456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:83	Then, 50 L of Master Pre-Mix consisting of Baculosomes (containing either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and NADPH reductase) in working buffer and the regeneration system (consisting of glucose-6-phosphate and glucose-6- phosphate dehydrogenase) were added to each well. 	CYP2D6	12450	12456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:83	Then, 50 L of Master Pre-Mix consisting of Baculosomes (containing either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and NADPH reductase) in working buffer and the regeneration system (consisting of glucose-6-phosphate and glucose-6- phosphate dehydrogenase) were added to each well. 	CYP2D6	12450	12456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:83	Then, 50 L of Master Pre-Mix consisting of Baculosomes (containing either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and NADPH reductase) in working buffer and the regeneration system (consisting of glucose-6-phosphate and glucose-6- phosphate dehydrogenase) were added to each well. 	CYP2D6	12450	12456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2D6	18366	18372	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2D6	18366	18372	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2D6	18366	18372	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2D6	18366	18372	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP2D6	20646	20652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP2D6	20646	20652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP2D6	20646	20652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP2D6	20646	20652	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	20971	20977	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	20971	20977	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	20971	20977	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	20971	20977	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	21061	21067	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	21061	21067	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	21061	21067	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP2D6	21061	21067	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:140	However, additional measurements performed with the control Baculosomes, which did not express any recombinant CYP isoenzyme, revealed that the binding might not be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, since a similar decrease in the protein level was observed. 	CYP2D6	22067	22073	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:140	However, additional measurements performed with the control Baculosomes, which did not express any recombinant CYP isoenzyme, revealed that the binding might not be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, since a similar decrease in the protein level was observed. 	CYP2D6	22067	22073	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:140	However, additional measurements performed with the control Baculosomes, which did not express any recombinant CYP isoenzyme, revealed that the binding might not be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, since a similar decrease in the protein level was observed. 	CYP2D6	22067	22073	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:140	However, additional measurements performed with the control Baculosomes, which did not express any recombinant CYP isoenzyme, revealed that the binding might not be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, since a similar decrease in the protein level was observed. 	CYP2D6	22067	22073	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:141	In the enzymatic test based on Baculosomes, all three types of nanostructures inhibited reactions by CYP1A2, CYP2D6 and CYP3A4 isoenzymes. 	CYP2D6	22263	22269	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:141	In the enzymatic test based on Baculosomes, all three types of nanostructures inhibited reactions by CYP1A2, CYP2D6 and CYP3A4 isoenzymes. 	CYP2D6	22263	22269	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:141	In the enzymatic test based on Baculosomes, all three types of nanostructures inhibited reactions by CYP1A2, CYP2D6 and CYP3A4 isoenzymes. 	CYP2D6	22263	22269	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:141	In the enzymatic test based on Baculosomes, all three types of nanostructures inhibited reactions by CYP1A2, CYP2D6 and CYP3A4 isoenzymes. 	CYP2D6	22263	22269	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:142	Inhibition rate was compared to inhibition in positive control samples with the known specific inhibitors miconazole, quinidine and ketoconazole for CYP1A2, CYP2D6 and CYP3A4, respectively. 	CYP2D6	22450	22456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:142	Inhibition rate was compared to inhibition in positive control samples with the known specific inhibitors miconazole, quinidine and ketoconazole for CYP1A2, CYP2D6 and CYP3A4, respectively. 	CYP2D6	22450	22456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:142	Inhibition rate was compared to inhibition in positive control samples with the known specific inhibitors miconazole, quinidine and ketoconazole for CYP1A2, CYP2D6 and CYP3A4, respectively. 	CYP2D6	22450	22456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:142	Inhibition rate was compared to inhibition in positive control samples with the known specific inhibitors miconazole, quinidine and ketoconazole for CYP1A2, CYP2D6 and CYP3A4, respectively. 	CYP2D6	22450	22456	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:158	No significant changes were observed for CYP2D6; however, in other studied members of the CYP2 subfamily (2B6 and 2E1), we observed lower expression of both genes in HepaRG cells, while in HepG2 cells, the 2B6 level was increased. 	CYP2D6	24933	24939	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:158	No significant changes were observed for CYP2D6; however, in other studied members of the CYP2 subfamily (2B6 and 2E1), we observed lower expression of both genes in HepaRG cells, while in HepG2 cells, the 2B6 level was increased. 	CYP2D6	24933	24939	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:158	No significant changes were observed for CYP2D6; however, in other studied members of the CYP2 subfamily (2B6 and 2E1), we observed lower expression of both genes in HepaRG cells, while in HepG2 cells, the 2B6 level was increased. 	CYP2D6	24933	24939	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:158	No significant changes were observed for CYP2D6; however, in other studied members of the CYP2 subfamily (2B6 and 2E1), we observed lower expression of both genes in HepaRG cells, while in HepG2 cells, the 2B6 level was increased. 	CYP2D6	24933	24939	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:162	In this study, we presented interactions among three nanostructures of different carbon allotropes, namely, DN, GO and GN, and isoenzymes of CYP450, namely, CYP1A2, CYP2D6 and CYP3A4, in the model of Baculosomes. 	CYP2D6	25836	25842	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:162	In this study, we presented interactions among three nanostructures of different carbon allotropes, namely, DN, GO and GN, and isoenzymes of CYP450, namely, CYP1A2, CYP2D6 and CYP3A4, in the model of Baculosomes. 	CYP2D6	25836	25842	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:162	In this study, we presented interactions among three nanostructures of different carbon allotropes, namely, DN, GO and GN, and isoenzymes of CYP450, namely, CYP1A2, CYP2D6 and CYP3A4, in the model of Baculosomes. 	CYP2D6	25836	25842	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:162	In this study, we presented interactions among three nanostructures of different carbon allotropes, namely, DN, GO and GN, and isoenzymes of CYP450, namely, CYP1A2, CYP2D6 and CYP3A4, in the model of Baculosomes. 	CYP2D6	25836	25842	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:174	The most important evidence for the direct interaction between CYP-expressing microsomes and DN, GO and GN is inhibition of the catalytic activity of CYP1A2, CYP2D6 and CYP3A4 measured separately for all three isoforms and revealing subtle differences among the isoenzymes. 	CYP2D6	28392	28398	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:174	The most important evidence for the direct interaction between CYP-expressing microsomes and DN, GO and GN is inhibition of the catalytic activity of CYP1A2, CYP2D6 and CYP3A4 measured separately for all three isoforms and revealing subtle differences among the isoenzymes. 	CYP2D6	28392	28398	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:174	The most important evidence for the direct interaction between CYP-expressing microsomes and DN, GO and GN is inhibition of the catalytic activity of CYP1A2, CYP2D6 and CYP3A4 measured separately for all three isoforms and revealing subtle differences among the isoenzymes. 	CYP2D6	28392	28398	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:174	The most important evidence for the direct interaction between CYP-expressing microsomes and DN, GO and GN is inhibition of the catalytic activity of CYP1A2, CYP2D6 and CYP3A4 measured separately for all three isoforms and revealing subtle differences among the isoenzymes. 	CYP2D6	28392	28398	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:175	Product formation on CYP1A2 was highly inhibited by DN and GN, while on CYP2D6 and CYP3A4, all nanostructures inhibited the reaction at similar levels. 	CYP2D6	28580	28586	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:175	Product formation on CYP1A2 was highly inhibited by DN and GN, while on CYP2D6 and CYP3A4, all nanostructures inhibited the reaction at similar levels. 	CYP2D6	28580	28586	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:175	Product formation on CYP1A2 was highly inhibited by DN and GN, while on CYP2D6 and CYP3A4, all nanostructures inhibited the reaction at similar levels. 	CYP2D6	28580	28586	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:175	Product formation on CYP1A2 was highly inhibited by DN and GN, while on CYP2D6 and CYP3A4, all nanostructures inhibited the reaction at similar levels. 	CYP2D6	28580	28586	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:49	456259), CYP2D6*1 (Lot No. 	CYP2D6	8420	8426	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:49	456259), CYP2D6*1 (Lot No. 	CYP2D6	8420	8426	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:49	456259), CYP2D6*1 (Lot No. 	CYP2D6	8420	8426	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:49	456259), CYP2D6*1 (Lot No. 	CYP2D6	8420	8426	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2D6	12991	12997	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2D6	12991	12997	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2D6	12991	12997	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2D6	12991	12997	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2D6	14257	14263	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2D6	14257	14263	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2D6	14257	14263	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2D6	14257	14263	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2D6	19977	19983	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2D6	19977	19983	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2D6	19977	19983	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2D6	19977	19983	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40399	40405	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40399	40405	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40399	40405	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40399	40405	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40452	40458	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40452	40458	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40452	40458	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:246	However, results of inhibition studies showed that all the compound might inhibit CYP1A2, CYP2C9, and CYP2D6, except compound F2 which did not inhibit the CYP2D6. 	CYP2D6	40452	40458	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:54	Most antidepressant and antipsychotic drugs have moderately long half-lives in the range of 12-36 h; poor (with either inactive or low-activity CYP2D6); or ultrarapid metabolizers owing to genetic polymorphisms. 	CYP2D6	7790	7796	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:54	Most antidepressant and antipsychotic drugs have moderately long half-lives in the range of 12-36 h; poor (with either inactive or low-activity CYP2D6); or ultrarapid metabolizers owing to genetic polymorphisms. 	CYP2D6	7790	7796	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:54	Most antidepressant and antipsychotic drugs have moderately long half-lives in the range of 12-36 h; poor (with either inactive or low-activity CYP2D6); or ultrarapid metabolizers owing to genetic polymorphisms. 	CYP2D6	7790	7796	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:54	Most antidepressant and antipsychotic drugs have moderately long half-lives in the range of 12-36 h; poor (with either inactive or low-activity CYP2D6); or ultrarapid metabolizers owing to genetic polymorphisms. 	CYP2D6	7790	7796	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:56	Thus, relatively slow recovery is anticipated from overdoses if the patient carries the low-activity or absent CYP2D6, with more rapid recovery in extensive or ultrarapid metabolizers. 	CYP2D6	8102	8108	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:56	Thus, relatively slow recovery is anticipated from overdoses if the patient carries the low-activity or absent CYP2D6, with more rapid recovery in extensive or ultrarapid metabolizers. 	CYP2D6	8102	8108	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:56	Thus, relatively slow recovery is anticipated from overdoses if the patient carries the low-activity or absent CYP2D6, with more rapid recovery in extensive or ultrarapid metabolizers. 	CYP2D6	8102	8108	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:56	Thus, relatively slow recovery is anticipated from overdoses if the patient carries the low-activity or absent CYP2D6, with more rapid recovery in extensive or ultrarapid metabolizers. 	CYP2D6	8102	8108	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:57	Between 5% and 10% of Europeans and approximately 1% of Asians are poor metabolizers via CYP2D6. 	CYP2D6	8265	8271	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:57	Between 5% and 10% of Europeans and approximately 1% of Asians are poor metabolizers via CYP2D6. 	CYP2D6	8265	8271	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:57	Between 5% and 10% of Europeans and approximately 1% of Asians are poor metabolizers via CYP2D6. 	CYP2D6	8265	8271	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:57	Between 5% and 10% of Europeans and approximately 1% of Asians are poor metabolizers via CYP2D6. 	CYP2D6	8265	8271	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:188	Genetic polymorphisms of the CYPs contribute to drug clearance, particularly for CYP2D6 and CYP2C19. 	CYP2D6	27715	27721	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:188	Genetic polymorphisms of the CYPs contribute to drug clearance, particularly for CYP2D6 and CYP2C19. 	CYP2D6	27715	27721	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:188	Genetic polymorphisms of the CYPs contribute to drug clearance, particularly for CYP2D6 and CYP2C19. 	CYP2D6	27715	27721	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6444415_OgerInput.txtOger_out.csv:188	Genetic polymorphisms of the CYPs contribute to drug clearance, particularly for CYP2D6 and CYP2C19. 	CYP2D6	27715	27721	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1204	1210	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1204	1210	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1204	1210	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1204	1210	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1244	1250	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1244	1250	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1244	1250	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:8	However, PharmG+ patients treated with CYP2D6 substrates that were carriers of CYP2D6 UMs or PMs variants showed a significantly higher improvement in global, psychic and other UKU side effects than PharmG patients (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	1244	1250	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP2D6	3394	3400	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP2D6	3394	3400	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP2D6	3394	3400	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP2D6	3394	3400	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP2D6	8077	8083	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP2D6	8077	8083	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP2D6	8077	8083	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:52	A commercial pharmacogenetic test (Brainchip, Brainco, Bilbao, Spain) was used to characterise common and functional polymorphisms in CYP1A2, CYP2D6, CYP2C19 and CYP3A5 enzymes, the main metabolic pathways of currently available antipsychotics. 	CYP2D6	8077	8083	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP2D6	9744	9750	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP2D6	9744	9750	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP2D6	9744	9750	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:62	Doses were adjusted according to main metabolic pathways:^, clozapine doses were adjusted according to the genotypic variants observed in CYP1A2 and CYP2C19; olanzapine doses were adjusted according to CYP1A2 polymorphisms; risperidone, aripiprazole, haloperidol, pimozide and trifluoperazine doses were adjusted according to CYP2D6 polymorphisms; finally, quetiapine and ziprasidone doses were adjusted according to CYP3A5 genetic variants. 	CYP2D6	9744	9750	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:79	Analyses within the subgroup of patients treated with drugs mainly metabolised by the enzyme CYP2D6 (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) also showed no differences with PharmG+ and PharmG patients showing similar variations in PANSS scores (24.33  3 vs 26.47  2). 	CYP2D6	12537	12543	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:79	Analyses within the subgroup of patients treated with drugs mainly metabolised by the enzyme CYP2D6 (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) also showed no differences with PharmG+ and PharmG patients showing similar variations in PANSS scores (24.33  3 vs 26.47  2). 	CYP2D6	12537	12543	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:79	Analyses within the subgroup of patients treated with drugs mainly metabolised by the enzyme CYP2D6 (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) also showed no differences with PharmG+ and PharmG patients showing similar variations in PANSS scores (24.33  3 vs 26.47  2). 	CYP2D6	12537	12543	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:79	Analyses within the subgroup of patients treated with drugs mainly metabolised by the enzyme CYP2D6 (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) also showed no differences with PharmG+ and PharmG patients showing similar variations in PANSS scores (24.33  3 vs 26.47  2). 	CYP2D6	12537	12543	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:81	When analysing patients with functional variants in CYP1A2, CYP2D6 and/or CYP2C19 (N = 155), no differences were observed between PharmG+ and PharmG patients in PANSS improvement, nor was it observed in the subgroups of patients treated with clozapine (p > 0.05 for all comparisons, see Table. 	CYP2D6	12939	12945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:81	When analysing patients with functional variants in CYP1A2, CYP2D6 and/or CYP2C19 (N = 155), no differences were observed between PharmG+ and PharmG patients in PANSS improvement, nor was it observed in the subgroups of patients treated with clozapine (p > 0.05 for all comparisons, see Table. 	CYP2D6	12939	12945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:81	When analysing patients with functional variants in CYP1A2, CYP2D6 and/or CYP2C19 (N = 155), no differences were observed between PharmG+ and PharmG patients in PANSS improvement, nor was it observed in the subgroups of patients treated with clozapine (p > 0.05 for all comparisons, see Table. 	CYP2D6	12939	12945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:81	When analysing patients with functional variants in CYP1A2, CYP2D6 and/or CYP2C19 (N = 155), no differences were observed between PharmG+ and PharmG patients in PANSS improvement, nor was it observed in the subgroups of patients treated with clozapine (p > 0.05 for all comparisons, see Table. 	CYP2D6	12939	12945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:82	However, there was a significant difference when analysing PANSS score improvement between PharmG+ patients (26.6  3.5) and PharmG patients (28.63  3.7) treated with CYP2D6 substrates. 	CYP2D6	13339	13345	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:82	However, there was a significant difference when analysing PANSS score improvement between PharmG+ patients (26.6  3.5) and PharmG patients (28.63  3.7) treated with CYP2D6 substrates. 	CYP2D6	13339	13345	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:82	However, there was a significant difference when analysing PANSS score improvement between PharmG+ patients (26.6  3.5) and PharmG patients (28.63  3.7) treated with CYP2D6 substrates. 	CYP2D6	13339	13345	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:82	However, there was a significant difference when analysing PANSS score improvement between PharmG+ patients (26.6  3.5) and PharmG patients (28.63  3.7) treated with CYP2D6 substrates. 	CYP2D6	13339	13345	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:85	Analyses of patients with functional variants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer improvements in the profile of side effects in the PharmG+ patients in comparison to PharmG patients. 	CYP2D6	13865	13871	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:85	Analyses of patients with functional variants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer improvements in the profile of side effects in the PharmG+ patients in comparison to PharmG patients. 	CYP2D6	13865	13871	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:85	Analyses of patients with functional variants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer improvements in the profile of side effects in the PharmG+ patients in comparison to PharmG patients. 	CYP2D6	13865	13871	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:85	Analyses of patients with functional variants in CYP1A2, CYP2D6 or CYP2C19 revealed clearer improvements in the profile of side effects in the PharmG+ patients in comparison to PharmG patients. 	CYP2D6	13865	13871	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:87	The PI was significantly associated to improvements in total (6.92 improvement in PharmG+ vs 1.27 in PharmG, Wald = 5.56, p = 0.02), psychic (2.50 vs 0.53 improvement, Wald = 3.96, p = 0.05) and other UKU side effects (1.08 vs 0.3, Wald = 6.19, p = 0.01) in the subgroup of patients treated with CYP2D6 substrates (see Table. 	CYP2D6	14498	14504	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:87	The PI was significantly associated to improvements in total (6.92 improvement in PharmG+ vs 1.27 in PharmG, Wald = 5.56, p = 0.02), psychic (2.50 vs 0.53 improvement, Wald = 3.96, p = 0.05) and other UKU side effects (1.08 vs 0.3, Wald = 6.19, p = 0.01) in the subgroup of patients treated with CYP2D6 substrates (see Table. 	CYP2D6	14498	14504	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:87	The PI was significantly associated to improvements in total (6.92 improvement in PharmG+ vs 1.27 in PharmG, Wald = 5.56, p = 0.02), psychic (2.50 vs 0.53 improvement, Wald = 3.96, p = 0.05) and other UKU side effects (1.08 vs 0.3, Wald = 6.19, p = 0.01) in the subgroup of patients treated with CYP2D6 substrates (see Table. 	CYP2D6	14498	14504	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:87	The PI was significantly associated to improvements in total (6.92 improvement in PharmG+ vs 1.27 in PharmG, Wald = 5.56, p = 0.02), psychic (2.50 vs 0.53 improvement, Wald = 3.96, p = 0.05) and other UKU side effects (1.08 vs 0.3, Wald = 6.19, p = 0.01) in the subgroup of patients treated with CYP2D6 substrates (see Table. 	CYP2D6	14498	14504	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17709	17715	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17709	17715	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17709	17715	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17709	17715	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17820	17826	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17820	17826	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17820	17826	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:109	The subgroup of patients treated with CYP2D6 substrates (risperidone, haloperidol, aripiprazole, pimozide and trifluoperazine) that were carriers of CYP2D6 UMs or PMs variants clearly benefited from the intervention: model regression analyses showed that the PI resulted in a significant improvement in global, psychic and other UKU side effects (p = 0.02, p = 0.05 and p = 0.01, respectively). 	CYP2D6	17820	17826	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:114	Several studies have proven the clinical value of a commercial array combining genetic information in metabolic enzymes (CYP1A2, CYP2D6 and CYP2C19) and antidepressant targets (serotonin transporter, SLC6A4 and serotonin receptor 2A, HTR2A). 	CYP2D6	18823	18829	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:114	Several studies have proven the clinical value of a commercial array combining genetic information in metabolic enzymes (CYP1A2, CYP2D6 and CYP2C19) and antidepressant targets (serotonin transporter, SLC6A4 and serotonin receptor 2A, HTR2A). 	CYP2D6	18823	18829	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:114	Several studies have proven the clinical value of a commercial array combining genetic information in metabolic enzymes (CYP1A2, CYP2D6 and CYP2C19) and antidepressant targets (serotonin transporter, SLC6A4 and serotonin receptor 2A, HTR2A). 	CYP2D6	18823	18829	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:114	Several studies have proven the clinical value of a commercial array combining genetic information in metabolic enzymes (CYP1A2, CYP2D6 and CYP2C19) and antidepressant targets (serotonin transporter, SLC6A4 and serotonin receptor 2A, HTR2A). 	CYP2D6	18823	18829	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:118	A recent study in which clinicians were provided pharmacogenetic information based on CYP2D6 and CYP2C19 variants to adjust antipsychotic and antidepressant treatments in 80 psychiatric patients suggested a favourable opinion on the outcome of the intervention, although no control group was considered in the study^. 	CYP2D6	19600	19606	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:118	A recent study in which clinicians were provided pharmacogenetic information based on CYP2D6 and CYP2C19 variants to adjust antipsychotic and antidepressant treatments in 80 psychiatric patients suggested a favourable opinion on the outcome of the intervention, although no control group was considered in the study^. 	CYP2D6	19600	19606	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:118	A recent study in which clinicians were provided pharmacogenetic information based on CYP2D6 and CYP2C19 variants to adjust antipsychotic and antidepressant treatments in 80 psychiatric patients suggested a favourable opinion on the outcome of the intervention, although no control group was considered in the study^. 	CYP2D6	19600	19606	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:118	A recent study in which clinicians were provided pharmacogenetic information based on CYP2D6 and CYP2C19 variants to adjust antipsychotic and antidepressant treatments in 80 psychiatric patients suggested a favourable opinion on the outcome of the intervention, although no control group was considered in the study^. 	CYP2D6	19600	19606	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:120	showed in a previous study that the adjustment of clinical doses according to CYP2D6 and CYP2C19 polymorphisms resulted in a reduction of treatment costs in schizophrenia patients showing poor or ultra-rapid metabolism^. 	CYP2D6	19939	19945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:120	showed in a previous study that the adjustment of clinical doses according to CYP2D6 and CYP2C19 polymorphisms resulted in a reduction of treatment costs in schizophrenia patients showing poor or ultra-rapid metabolism^. 	CYP2D6	19939	19945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:120	showed in a previous study that the adjustment of clinical doses according to CYP2D6 and CYP2C19 polymorphisms resulted in a reduction of treatment costs in schizophrenia patients showing poor or ultra-rapid metabolism^. 	CYP2D6	19939	19945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:120	showed in a previous study that the adjustment of clinical doses according to CYP2D6 and CYP2C19 polymorphisms resulted in a reduction of treatment costs in schizophrenia patients showing poor or ultra-rapid metabolism^. 	CYP2D6	19939	19945	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:129	Nevertheless, we performed analyses on the subgroups of patients carrying CYPs functional variants (either UMs or PMs), and investigated the two largest antipsychotic groups within the study (clozapine and CYP2D6 substrates). 	CYP2D6	21326	21332	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_514', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:129	Nevertheless, we performed analyses on the subgroups of patients carrying CYPs functional variants (either UMs or PMs), and investigated the two largest antipsychotic groups within the study (clozapine and CYP2D6 substrates). 	CYP2D6	21326	21332	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_404', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:129	Nevertheless, we performed analyses on the subgroups of patients carrying CYPs functional variants (either UMs or PMs), and investigated the two largest antipsychotic groups within the study (clozapine and CYP2D6 substrates). 	CYP2D6	21326	21332	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_513', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:129	Nevertheless, we performed analyses on the subgroups of patients carrying CYPs functional variants (either UMs or PMs), and investigated the two largest antipsychotic groups within the study (clozapine and CYP2D6 substrates). 	CYP2D6	21326	21332	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:137	On the other hand, a study of six Parkinsons Disease patients showed a lower DNA methylation at the promoter region of CYP2E1 gene in both cortex and putamen, and an increase of mRNA levels in cortex, suggesting that epigenetic variations of this isoform may contribute to Parkinsons Disease susceptibility, but they did not study the correlation between mRNA levels and proteins or enzymatic activity. 	CYP2E1	20216	20222	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:137	On the other hand, a study of six Parkinsons Disease patients showed a lower DNA methylation at the promoter region of CYP2E1 gene in both cortex and putamen, and an increase of mRNA levels in cortex, suggesting that epigenetic variations of this isoform may contribute to Parkinsons Disease susceptibility, but they did not study the correlation between mRNA levels and proteins or enzymatic activity. 	CYP2E1	20216	20222	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:155	In contrast, CYP2E1 appeared to partially localize in the Endoplasmic Reticulum, as it has been reported in other cell types and tissues. 	CYP2E1	23496	23502	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:155	In contrast, CYP2E1 appeared to partially localize in the Endoplasmic Reticulum, as it has been reported in other cell types and tissues. 	CYP2E1	23496	23502	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:158	Moreover, other groups have indicated the possibility that CYP2E1, and other isoforms, may target the mitochondria in other in vitro and in vivo models. 	CYP2E1	24023	24029	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:158	Moreover, other groups have indicated the possibility that CYP2E1, and other isoforms, may target the mitochondria in other in vitro and in vivo models. 	CYP2E1	24023	24029	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:159	However, the intracellular location of CYP2E1 is still a subject of debate. 	CYP2E1	24156	24162	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:159	However, the intracellular location of CYP2E1 is still a subject of debate. 	CYP2E1	24156	24162	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:167	On the other hand, CYP2E1 has been proposed to be involved in the intracellular accumulation of this toxin rather than in the metabolism itself. 	CYP2E1	25467	25473	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:167	On the other hand, CYP2E1 has been proposed to be involved in the intracellular accumulation of this toxin rather than in the metabolism itself. 	CYP2E1	25467	25473	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	CYP2E1	28846	28852	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	CYP2E1	28846	28852	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP2E1	30855	30861	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP2E1	30855	30861	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:233	In conclusion, the present study demonstrates that in SH-SY5Y cells, CYP2D6 can be induced by EtOH and CYP2E1 by BETA-NF and EtOH. 	CYP2E1	36161	36167	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:233	In conclusion, the present study demonstrates that in SH-SY5Y cells, CYP2D6 can be induced by EtOH and CYP2E1 by BETA-NF and EtOH. 	CYP2E1	36161	36167	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2E1	18453	18459	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP2E1	18453	18459	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:188	General downregulation of the genes was especially visible in HepaRG cells, which probably results from a weaker expression of genes encoding enzymes of Phases I and II of the xenobiotic metabolism in the HepG2 cell line, making HepaRG a more suitable model for drug metabolism studies.- The strongest downregulation of CYP genes was induced by GO, which influenced not only CYP1A2 and CYP3A4 genes, but also CYP2B6, CYP2E1 and AhR, CAR and PXR, which are responsive elements regulating the expression of CYP genes. 	CYP2E1	31205	31211	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:188	General downregulation of the genes was especially visible in HepaRG cells, which probably results from a weaker expression of genes encoding enzymes of Phases I and II of the xenobiotic metabolism in the HepG2 cell line, making HepaRG a more suitable model for drug metabolism studies.- The strongest downregulation of CYP genes was induced by GO, which influenced not only CYP1A2 and CYP3A4 genes, but also CYP2B6, CYP2E1 and AhR, CAR and PXR, which are responsive elements regulating the expression of CYP genes. 	CYP2E1	31205	31211	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:50	456217), CYP2E1 (Lot No. 	CYP2E1	8447	8453	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:50	456217), CYP2E1 (Lot No. 	CYP2E1	8447	8453	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2E1	13027	13033	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP2E1	13027	13033	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2E1	14292	14298	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP2E1	14292	14298	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2E1	19953	19959	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP2E1	19953	19959	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP2E1	24539	24545	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP2E1	24539	24545	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:8	Employing mice with genetic ablation of CHIP and gp78/AMFR E3 ubiquitin-ligases that stabilize hepatic CYP2E1, we document why this stabilization not always leads to non-alcoholic fatty liver disease: It requires concomitantly enhanced hepatic lipogenesis.Image 1 The ubiquitous hemoproteins cytochromes P450 (P450s or CYPs; MW 50 kDa) are enzymes engaged both in synthetic and degradative functions critically important to the cellular integrity, physiology and defense,. 	CYP2E1	1869	1875	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:8	Employing mice with genetic ablation of CHIP and gp78/AMFR E3 ubiquitin-ligases that stabilize hepatic CYP2E1, we document why this stabilization not always leads to non-alcoholic fatty liver disease: It requires concomitantly enhanced hepatic lipogenesis.Image 1 The ubiquitous hemoproteins cytochromes P450 (P450s or CYPs; MW 50 kDa) are enzymes engaged both in synthetic and degradative functions critically important to the cellular integrity, physiology and defense,. 	CYP2E1	1869	1875	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:24	Accordingly, the dominant human liver/intestinal CYP3A4 and human liver CYP2E1 are found to be prototypic ERAD-C substrates. 	CYP2E1	5137	5143	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:24	Accordingly, the dominant human liver/intestinal CYP3A4 and human liver CYP2E1 are found to be prototypic ERAD-C substrates. 	CYP2E1	5137	5143	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:25	CYP3A4, accounting for 30% of the hepatic P450 content, is engaged in the metabolism of >50% of clinically relevant drugs and other xenobiotics, whereas CYP2E1 biotransforms clinically relevant drugs (acetaminophen, halothane), EtOH, and other xenobiotics, carcinogens (nitrosamines), endogenous acetone and fatty acids (arachidonic acid) to toxic/reactive intermediates,. 	CYP2E1	5343	5349	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:25	CYP3A4, accounting for 30% of the hepatic P450 content, is engaged in the metabolism of >50% of clinically relevant drugs and other xenobiotics, whereas CYP2E1 biotransforms clinically relevant drugs (acetaminophen, halothane), EtOH, and other xenobiotics, carcinogens (nitrosamines), endogenous acetone and fatty acids (arachidonic acid) to toxic/reactive intermediates,. 	CYP2E1	5343	5349	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:28	Hepatic CYP2E1 similarly exhibits a high propensity for ROS generation and is labile in the absence of relevant substrates and/or inducers that stabilize the protein,. 	CYP2E1	5990	5996	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:28	Hepatic CYP2E1 similarly exhibits a high propensity for ROS generation and is labile in the absence of relevant substrates and/or inducers that stabilize the protein,. 	CYP2E1	5990	5996	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:30	Systematic dissection of the hepatic CYP3A and CYP2E1 ERAD-C process employing various in vivo and in vitro reconstituted eukaryotic systems has revealed that it involves initial post-translational phosphorylation by cytosolic protein kinases A and C of P450 Ser/Thr residues,. 	CYP2E1	6282	6288	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:30	Systematic dissection of the hepatic CYP3A and CYP2E1 ERAD-C process employing various in vivo and in vitro reconstituted eukaryotic systems has revealed that it involves initial post-translational phosphorylation by cytosolic protein kinases A and C of P450 Ser/Thr residues,. 	CYP2E1	6282	6288	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:43	In vitro functional reconstitution studies,  of E1/E2/E3-mediated CYP3A4 and CYP2E1 ubiquitination have identified UbcH5a/Hsc70/Hsp40/CHIP and UBC7/AMFR/gp78 complexes as two relevant E2/E3 systems in CYP3A4 and CYP2E1 ubiquitination:(i)CHIP (carboxy-terminus of Hsc70-interacting protein), a cytoplasmic Hsc70-cochaperone, functions with its cognate UbcH5a E2 and Hsc70/Hsp40 co-chaperones in substrate ubiquitination,. 	CYP2E1	9257	9263	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:43	In vitro functional reconstitution studies,  of E1/E2/E3-mediated CYP3A4 and CYP2E1 ubiquitination have identified UbcH5a/Hsc70/Hsp40/CHIP and UBC7/AMFR/gp78 complexes as two relevant E2/E3 systems in CYP3A4 and CYP2E1 ubiquitination:(i)CHIP (carboxy-terminus of Hsc70-interacting protein), a cytoplasmic Hsc70-cochaperone, functions with its cognate UbcH5a E2 and Hsc70/Hsp40 co-chaperones in substrate ubiquitination,. 	CYP2E1	9257	9263	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:43	In vitro functional reconstitution studies,  of E1/E2/E3-mediated CYP3A4 and CYP2E1 ubiquitination have identified UbcH5a/Hsc70/Hsp40/CHIP and UBC7/AMFR/gp78 complexes as two relevant E2/E3 systems in CYP3A4 and CYP2E1 ubiquitination:(i)CHIP (carboxy-terminus of Hsc70-interacting protein), a cytoplasmic Hsc70-cochaperone, functions with its cognate UbcH5a E2 and Hsc70/Hsp40 co-chaperones in substrate ubiquitination,. 	CYP2E1	9392	9398	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:43	In vitro functional reconstitution studies,  of E1/E2/E3-mediated CYP3A4 and CYP2E1 ubiquitination have identified UbcH5a/Hsc70/Hsp40/CHIP and UBC7/AMFR/gp78 complexes as two relevant E2/E3 systems in CYP3A4 and CYP2E1 ubiquitination:(i)CHIP (carboxy-terminus of Hsc70-interacting protein), a cytoplasmic Hsc70-cochaperone, functions with its cognate UbcH5a E2 and Hsc70/Hsp40 co-chaperones in substrate ubiquitination,. 	CYP2E1	9392	9398	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:50	The individual roles of CHIP and gp78 in CYP3A and CYP2E1 ubiquitination and Endoplasmic Reticulum-Associated Degradation were verified upon lentiviral shRNA interference analyses targeted individually against each of these E3s in cultured rat hepatocytes,. 	CYP2E1	11378	11384	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:73	Therefore, in the current study, we screened for the inhibitory potential of the extracts and compounds using co-incubation (reversible inhibition) and pre-incubation (time-dependent inhibition) with CYP2C8, CYP2C9, and CYP3A4 Vivid^@ recombinant enzymes. 	CYP3A	10840	10845	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:75	Plant extracts containing high levels of polyphenols are expected to have inhibitory effects on various CYPs including CYP2C8, CYP2C9, CYP2D6, and CYP3A4. 	CYP3A	11179	11184	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:76	Of these, CYP3A4 is commonly involved in herb-drug interactions as it metabolizes about 50% of clinically-prescribed medications. 	CYP3A	11197	11202	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:78	for rats ingesting rooibos tea for two weeks suggested a possible interaction between rooibos tea and medicines mediated by CYP3A. 	CYP3A	11476	11481	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:81	GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC_50 values of 31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively. 	CYP3A	11865	11870	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:82	ASP, as the major compound, moderately inhibited CYP3A4 activity with an IC_50 value of 69.57  4.03 g/mL. 	CYP3A	12013	12018	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:83	Luteolin, the aglycone of rooibos flavone glucosides, orientin and isoorientin, and quercetin, the aglycone of rooibos flavonol glycosides, quercetin-3-O-robinobioside, rutin, hyperoside, and isoquercitrin, have previously been shown to inhibit CYP3A4. 	CYP3A	12315	12320	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:84	Quercetin is a more effective inhibitor of CYP3A4 than its 3-O-rutinoside, rutin. 	CYP3A	12366	12371	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:85	The inhibition of CYP3A4 was also demonstrated to be both dose- and time-dependent. 	CYP3A	12423	12428	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:86	Therefore, they could potentially interfere with the metabolism and alter the pharmacodynamics of drugs, such as atorvastatin, cyclosporine, felodopine, simvastatin, midazolam, erythromycin, and doxorubicin, known to be metabolized by CYP3A4. 	CYP3A	12724	12729	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:104	This study demonstrates that GRT and FRE inhibited CYP2C8 and CYP3A4 activity in a dose- and time-dependent manner, whilst inhibiting CYP2C9 activity in a time-dependent manner only. 	CYP3A	15300	15305	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:105	ASP could only be implicated in CYP3A4 inhibition. 	CYP3A	15453	15458	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:120	Vivid^ CYP2C8 Green Screening Kit with Vivid^ substrate, di-[benzyl-O-methyl]-fluorescein (DBOMF) and Vivid^ CYP3A4 and CYP2C9 Blue Screening Kits with Vivid^ substrate, 7-benzyl-oxymethyloxy-3-cyanocoumarin (BOMCC) were purchased from Life Technologies^ (Carlsbad, CA, USA). 	CYP3A	17181	17186	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:122	The effect of organic solvents such as methanol, acetonitrile and DMSO on Vivid^ recombinant CYP2C8, CYP2C9, and CYP3A4 assays was determined. 	CYP3A	17557	17562	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:123	A mixture containing 0.1% of organic solvent, reaction buffer (200 mM potassium phosphate (reaction buffer I) or 100 mM potassium phosphate (reaction buffer II)) and regeneration system (333 mM glucose-6-phosphate and 30 U/mL glucose-6-phosphate dehydrogenase in 100 mM potassium phosphate, pH 8.0) solution with the addition of each enzyme (CYP2C8, CYP2C9, or CYP3A4) was prepared. 	CYP3A	17948	17953	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:128	Compounds, PPAG and ASP, and the rooibos extracts, GRT and FRE, were screened for their inhibitory effects on CYP2C8, CYP2C9, and CYP3A4 using one-point screening kinetics. 	CYP3A	18718	18723	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:130	Briefly, inhibitors, extracts, and compounds were pre-incubated with either CYP2C8 or CYP2C9 at a concentration of 100 g/mL, or CYP3A4 at a concentration of 200 g/mL. 	CYP3A	18989	18994	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:132	As per the manufacturers instruction, 50 L of Vivid^ Master Pre-Mix (BACULOSOMES^ enzymes (CYP2C8, CYP2C9 or CYP3A4), regeneration system, reaction buffer (I/II), and NADP^+) was added to each well. 	CYP3A	19249	19254	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:134	After incubation, 10 L reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II were added to each well and incubated for 30 min at 37 C. Fluorescence was measured on a SpectraMax i3 plate reader at 5 min intervals to determine reaction kinetics. 	CYP3A	19460	19465	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:136	Enzyme activity was measured by formation of the metabolites at excitation and emission wavelengths of 485/530 nm (CYP2C8) and 406/460 nm (CYP2C9 and CYP3A4), respectively. 	CYP3A	19895	19900	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:137	A three-fold serial dilution of PPAG, ASP, GRT, and FRE was added to CYP2C8 and CYP2C9 (concentration range 100-0.41 g/mL) and CYP3A4 (concentration range 200-0.82 g/mL) to determine their respective IC_50 concentrations. 	CYP3A	20045	20050	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP3A	20159	20164	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP3A	20496	20501	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:139	Time-dependent inhibition (TDI) using the respective serial dilutions employed for IC_50 determination (CYP2C8 and CYP2C9; 100-0.41 g/mL and for CYP3A4; 200-0.82 g/mL) was performed. 	CYP3A	20878	20883	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:140	The extracts and compounds were pre-incubated with CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ and NADPH for 30 min. 	CYP3A	20986	20991	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:145	Inhibition of CYP2C8, CYP2C9, and CYP3A4 BACULOSOMES^ was quantified, as described in. 	CYP3A	21599	21604	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:146	The data generated were exported to an Excel (Microsoft Headquarters, One Microsoft Way, Redmond, WA, USA) worksheet and the amount of metabolite formed at various concentrations relative to the control was calculated using the following equation: The relative percentage activity was plotted against the log transformed concentrations of the extracts, compounds and positive controls, ie quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor). 	CYP3A	22151	22156	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:152	This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs. 	CYP3A	22957	22962	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:33	CYP3A4 is a well-known oxidative enzyme that is mostly involved in the metabolism of xenobiotics, and is the most expressed isoform in human liver. 	CYP3A	4290	4295	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:64	CYP3A4 was not analyzed because it was included in the study during the Western Blot analysis and we did not find any change of expression with the treatments. 	CYP3A	9081	9086	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:68	The Western Blot results of CYP1A1 showed the same non-induction pattern by both treatments, as well as for CYP3A4 (c,d). 	CYP3A	9960	9965	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:71	Neither CYP1A1 nor CYP3A4 were affected by both treatments in differentiated cells. 	CYP3A	10328	10333	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:92	We also observed that the fluorescent images of CYP3A4 did not report a preferential localization between mitochondria and Endoplasmic Reticulum. 	CYP3A	13555	13560	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP3A	30930	30935	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:1	 Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells. 	CYP3A	83	88	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:5	The objective of this study was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver. 	CYP3A	708	713	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:26	The most important members of the CYP family are CYP3A isoforms, especially CYP3A4 which is responsible for ~30% of the total hepatic activity of CYP. 	CYP3A	4071	4076	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:26	The most important members of the CYP family are CYP3A isoforms, especially CYP3A4 which is responsible for ~30% of the total hepatic activity of CYP. 	CYP3A	4098	4103	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:31	The problem with disturbances of CYP reactions caused by nanomaterials is a new topic, studied most recently on metallic nanoparticles (gold or silver) and using the CYP3A4 isoform. 	CYP3A	4934	4939	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:37	Single-walled carbon nanotubes (SWCNT) inhibited the activity of the CYP3A4 enzyme by direct interaction between SWCNT and the enzyme. 	CYP3A	5631	5636	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:39	We turned our attention to other carbon nanostructures, such as diamond nanoparticles (DN), graphene oxide (GO) and graphite nanoparticles (GN), which were previously shown to be nontoxic or low toxic; however, no data are available on their potential interactions with CYP isoenzymes.,, We hypothesized that a physicochemical interaction occurs between employed carbon nanostructures and CYP1A2, CYP2D6 and CYP3A4 enzymes. 	CYP3A	6220	6225	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:69	Additionally, the control Baculosomes without CYP450 expression were mixed in the same manner as the Baculosomes with CYP1A2, CYP2D6 and CYP3A4 expression. 	CYP3A	10344	10349	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:80	Known inhibitors of CYP450 enzymes were used as positive controls: miconazole for CYP1A2, quinidine for CYP2D6 and ketoconazole for CYP3A4. 	CYP3A	11820	11825	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:82	In the first step, Vivid Substrates (EOMCC for CYP1A2 and CYP2D6, BOMCC for CYP3A4) were reconstituted in anhydrous acetonitrile, and then 40 L of tested compounds (DN, GO, GN or inhibitors) or working buffer (control) was added to each well on 96-well black-bottom plate (Corning, New York, NY, USA). 	CYP3A	12142	12147	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:83	Then, 50 L of Master Pre-Mix consisting of Baculosomes (containing either CYP1A2, CYP2D6 or CYP3A4 isoenzyme and NADPH reductase) in working buffer and the regeneration system (consisting of glucose-6-phosphate and glucose-6- phosphate dehydrogenase) were added to each well. 	CYP3A	12460	12465	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:121	In the experiment, the expression levels of genes for the previously studied cytochromes CYP1A2, CYP2D6 and CYP3A4, for two other cytochromes vastly expressed in the liver: CYP2B6 and CYP2E1, as well as the receptors responsible for cytochrome gene expression regulation: pregnane X receptor (PXR), constitutive androstane receptor (CAR) and aryl hydrocarbon receptor (AhR) were measured. 	CYP3A	18377	18382	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP3A	20657	20662	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:135	DN almost did not affect the diameter or zeta potential of the microsomes expressing CYP1A2, CYP2D6 and CYP3A4 isoenzymes, whereas GO and GN visibly increased the diameter of the microsomes, especially for the Baculosomes expressing CYP1A2 and CYP3A4 isoenzymes (>1,000 nm in comparison to ~300 nm in 0 mg/L samples). 	CYP3A	20797	20802	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP3A	20982	20987	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:136	GN also shifted zeta potential of the microsomes from highly negative (37, 31 and 42 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) toward more positive values (2, 16 and 30 mV for CYP1A2, CYP2D6 and CYP3A4, respectively) and GO shifted the values toward more negative values (43, 44 and 48 mV for 1A2, 2D6 and 3A4, respectively), which indicates the impact of GO and GN on the stability of microsome hydrocolloids and the occurrence of physicochemical interactions between the nanostructures and microsomes expressing the CYP enzymes. 	CYP3A	21072	21077	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:140	However, additional measurements performed with the control Baculosomes, which did not express any recombinant CYP isoenzyme, revealed that the binding might not be specific for the CYP1A2, CYP2D6 or CYP3A4 proteins, since a similar decrease in the protein level was observed. 	CYP3A	22077	22082	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:141	In the enzymatic test based on Baculosomes, all three types of nanostructures inhibited reactions by CYP1A2, CYP2D6 and CYP3A4 isoenzymes. 	CYP3A	22274	22279	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:142	Inhibition rate was compared to inhibition in positive control samples with the known specific inhibitors miconazole, quinidine and ketoconazole for CYP1A2, CYP2D6 and CYP3A4, respectively. 	CYP3A	22461	22466	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:147	The inhibition rate of CYP3A4 was comparable for DN, GO and GN at all concentrations (50%-60% inhibition); however, at the highest concentration, we observed an effect similar to the one in CYP1A2. 	CYP3A	23218	23223	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:159	The level of CYP3A4 was decreased in all nanostructure groups in both cell lines (<40% of the control, reaching only 1% in the GO group in HepaRG cells), except the GN group in HepaRG cells, where no changes occurred. 	CYP3A	25136	25141	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:162	In this study, we presented interactions among three nanostructures of different carbon allotropes, namely, DN, GO and GN, and isoenzymes of CYP450, namely, CYP1A2, CYP2D6 and CYP3A4, in the model of Baculosomes. 	CYP3A	25847	25852	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:174	The most important evidence for the direct interaction between CYP-expressing microsomes and DN, GO and GN is inhibition of the catalytic activity of CYP1A2, CYP2D6 and CYP3A4 measured separately for all three isoforms and revealing subtle differences among the isoenzymes. 	CYP3A	28403	28408	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:175	Product formation on CYP1A2 was highly inhibited by DN and GN, while on CYP2D6 and CYP3A4, all nanostructures inhibited the reaction at similar levels. 	CYP3A	28591	28596	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:176	Interestingly, inhibition of CYP1A2 and CYP3A4 was lower in the presence of the highest concentration of DN and GN (100 mg/L), which could be related to the formation of nanoparticle agglomerates in higher concentrations and then reduction of their surface area available to interact. 	CYP3A	28700	28705	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:188	General downregulation of the genes was especially visible in HepaRG cells, which probably results from a weaker expression of genes encoding enzymes of Phases I and II of the xenobiotic metabolism in the HepG2 cell line, making HepaRG a more suitable model for drug metabolism studies.- The strongest downregulation of CYP genes was induced by GO, which influenced not only CYP1A2 and CYP3A4 genes, but also CYP2B6, CYP2E1 and AhR, CAR and PXR, which are responsive elements regulating the expression of CYP genes. 	CYP3A	31174	31179	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:202	It was previously reported that SWCNT inhibited the most important of the isoenzymes, CYP3A4, mostly due to the occurrence of - stacking interactions between the nanotube walls and aromatic residues of the enzyme. 	CYP3A	33903	33908	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6310986_OgerInput.txtOger_out.csv:155	These two encoding enzymes were highly expressed in roots than stems, followed by CYP3A family members (6.1%) and CYP4 family members (4.8%). 	CYP3A	23319	23324	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6310986_OgerInput.txtOger_out.csv:234	The CYP3A subfamily of enzymes is the most important to drug metabolism in humans because these enzymes metabolize the majority of commercially available drugs. 	CYP3A	35522	35527	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:4	Recombinant CYPs showing the highest specific activity were CYP3A4, CYP3A7 and to lower extent CYP2C9 and CTP2C8. 	CYP3A	703	708	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:4	Recombinant CYPs showing the highest specific activity were CYP3A4, CYP3A7 and to lower extent CYP2C9 and CTP2C8. 	CYP3A	711	716	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:5	Michaelis-Menten enzyme kinetics were determined for pooled human liver microsomes, recombinant CYP3A4, CYP3A7 and CYP2C9. 	CYP3A	853	858	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:5	Michaelis-Menten enzyme kinetics were determined for pooled human liver microsomes, recombinant CYP3A4, CYP3A7 and CYP2C9. 	CYP3A	861	866	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:6	Surprisingly, sulfaphenazole appeared to be a potent inhibitor of 5hydroxylation of flucloxacillin by both recombinant CYP3A4 and CYP3A7. 	CYP3A	999	1004	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:6	Surprisingly, sulfaphenazole appeared to be a potent inhibitor of 5hydroxylation of flucloxacillin by both recombinant CYP3A4 and CYP3A7. 	CYP3A	1010	1015	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:7	The combined results show that the 5hydroxylation of flucloxacillin is primarily catalysed by CYP3A4, CYP3A7 and CYP2C9. 	CYP3A	1112	1117	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:7	The combined results show that the 5hydroxylation of flucloxacillin is primarily catalysed by CYP3A4, CYP3A7 and CYP2C9. 	CYP3A	1120	1125	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:10	There are large interindividual differences in plasma concentrations of flucloxacillin and 5hydroxymethyl flucloxacillin.5Hydroxymethyl flucloxacillin is much more toxic to biliary epithelial cells than flucloxacillin.A previous study on four human CYPs showed that CYP3A4 exerted the highest activity of flucloxacillin hydroxylation. 	CYP3A	1812	1817	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:12	Quantification of specific activities and enzyme kinetics of flucloxacillin hydroxylation by HLM and 14 recombinant human CYPs.Next to CYP3A4, CYP3A7 and CYP2C9 may contribute significantly to flucloxacillin hydroxylation.Sulfaphenazole, considered as a selective CYP2C9 inhibitor, strongly inhibits CYP3Amediated flucloxacillin hydroxylation. 	CYP3A	2154	2159	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:12	Quantification of specific activities and enzyme kinetics of flucloxacillin hydroxylation by HLM and 14 recombinant human CYPs.Next to CYP3A4, CYP3A7 and CYP2C9 may contribute significantly to flucloxacillin hydroxylation.Sulfaphenazole, considered as a selective CYP2C9 inhibitor, strongly inhibits CYP3Amediated flucloxacillin hydroxylation. 	CYP3A	2162	2167	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:13	Interindividual variability and drugdrug interactions at the level of CYP3A4, CYP3A7 and CYP2C9 may be important factors determining the risk of flucloxacillininduced liver injury. 	CYP3A	2433	2438	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:13	Interindividual variability and drugdrug interactions at the level of CYP3A4, CYP3A7 and CYP2C9 may be important factors determining the risk of flucloxacillininduced liver injury. 	CYP3A	2441	2446	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:29	Nonrenal clearance of flucloxacillin occurs predominantly by cytochrome P450mediated hydroxylation of flucloxacillin to 5HMFLX and partly by hydrolysis to the corresponding penicilloic acid, showed that CYP3A4 was able to catalyse the 5hydroxylation of flucloxacillin. 	CYP3A	6146	6151	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:31	Another study showed that flucloxacillin induces CYP3A4 in cell lines exposed to 200-400 M flucloxacillin (Huwyler et al.,. 	CYP3A	6398	6403	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:36	Furthermore, a major involvement of CYP3A4 in drug metabolism complicates prediction of pharmacokinetics based on enzyme kinetics because of the occurrence of atypical enzyme kinetics, such as substrate activation (Houston and Kenworthy, ; Ekins et al., ; Atkins, ; Houston and Galetin,. 	CYP3A	7245	7250	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:37	Furthermore, inhibition of CYP3A4 by drugs appears to be substratedependent, further complicating prediction of drug-drug interactions (Stresser et al.,. 	CYP3A	7524	7529	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:52	456264), CYP3A4 (Lot No. 	CYP3A	8497	8502	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:53	456207), CYP3A5 (Lot No. 	CYP3A	8522	8527	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:54	456256) and CYP3A7 (Lot No. 	CYP3A	8550	8555	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:78	Because these incubations were only performed to identify the most active enzymes, duplicate experiments were deemed sufficient since reproducibility of incubations with recombinant enzymes from the same source was always within 5%, For the most active Gentest Supersomes and pooled HLM, the enzyme kinetics of the formation of 5HMFLX were determined by incubating with 11 concentrations of flucloxacillin, ranging from 0 to 500 M. Each flucloxacillin concentration was incubated in duplicate for 10 min with 0.5 mgmL^1 pooled HLM, 100 nM CYP3A4, CYP3A7 and CYP2C9 Supersomes in 100 mM potassium phosphate buffer, pH 7.4 supplemented with 5 mM MgCl_2 and 2 mM EDTA. 	CYP3A	12223	12228	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:78	Because these incubations were only performed to identify the most active enzymes, duplicate experiments were deemed sufficient since reproducibility of incubations with recombinant enzymes from the same source was always within 5%, For the most active Gentest Supersomes and pooled HLM, the enzyme kinetics of the formation of 5HMFLX were determined by incubating with 11 concentrations of flucloxacillin, ranging from 0 to 500 M. Each flucloxacillin concentration was incubated in duplicate for 10 min with 0.5 mgmL^1 pooled HLM, 100 nM CYP3A4, CYP3A7 and CYP2C9 Supersomes in 100 mM potassium phosphate buffer, pH 7.4 supplemented with 5 mM MgCl_2 and 2 mM EDTA. 	CYP3A	12231	12236	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP3A	13056	13061	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP3A	13081	13086	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP3A	13107	13112	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:81	Flucloxacillin was incubated at substrate concentrations of 10 and 100 M with 0.5 mgmL^1 HLM, as described above, and in the absence or presence of the following inhibitors: 10 M ALPHAnaphtoflavone (CYP1A2), 3 M ticlopidine (CYP2B6), 15 M quercetin (CYP2C8), 10 M sulfaphenazole (CYP2C9), 10 M fluvoxamine (CYP2C9/CYP1A2), 1 M (+)N3benzylnirvanol (CYP2C19), 2 M quinidine (CYP2D6), 20 M diethylthiocarbamate (CYP2E1), 3 M troleandomycin (CYP3A4); 2 M miconazole (CYP3A4/CYP2C9) and 0.1 M (CYP3A4) and 1 M (CYP3A) ketoconazole respectively. 	CYP3A	13124	13129	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:85	Because the CYP2C9specific inhibitor sulfaphenazole appeared to almost completely block formation of 5HMFLX by pooled HLM, it was also added at different concentrations to incubations of CYP3A4 and CYP3A7 Supersomes with flucloxacillin (10 M) and testosterone (50 M). 	CYP3A	13733	13738	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:85	Because the CYP2C9specific inhibitor sulfaphenazole appeared to almost completely block formation of 5HMFLX by pooled HLM, it was also added at different concentrations to incubations of CYP3A4 and CYP3A7 Supersomes with flucloxacillin (10 M) and testosterone (50 M). 	CYP3A	13744	13749	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:86	To determine the variability of 5hydroxylation of flucloxacillin, the substrate was incubated (10 and 100 M) with a panel of individual HLM fractions from 16 donors (0.5 mgmL^1) which were phenotyped with respect to activities of CYP1A2 (phenacetin Odeethylation), CYP2A6 (coumarin 7hydroxylation), CYP2B6 (bupropion hydroxylation), CYP2C8 (amodiaquine Ndeethylation), CYP2C9 (diclofenac 4hydroxylation), CYP2C19 (mephenytoin 4hydroxylation), CYP2D6 (bufuralol 1hydroxylation), CYP2E1 (chlorzoxazone 6hydroxylation) and CYP3A4 (midazolam 1hydroxylation and testosterone 6BETAhydroxylation) using the concentrations described previously (den BraverSewradj et al.,. 	CYP3A	14334	14339	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:118	At a flucloxacillin concentration of 10 M, recombinant CYP3A4, CYP3A7 and to a lesser extent CYP2C9 showed the highest activity, in terms of the formation of 5HMFLX. 	CYP3A	19651	19656	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:118	At a flucloxacillin concentration of 10 M, recombinant CYP3A4, CYP3A7 and to a lesser extent CYP2C9 showed the highest activity, in terms of the formation of 5HMFLX. 	CYP3A	19659	19664	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:119	At 100 M flucloxacillin, CYP3A7 was the most active CYP followed by CYP3A4. 	CYP3A	19787	19792	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:119	At 100 M flucloxacillin, CYP3A7 was the most active CYP followed by CYP3A4. 	CYP3A	19830	19835	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP3A	19961	19966	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:121	As CYP3A4, CYP3A7 and CYP2C9 Supersomes showed highest activity at both concentrations, the enzyme kinetics of 5HMFLX formation was also determined for these recombinant CYPs. 	CYP3A	19999	20004	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:121	As CYP3A4, CYP3A7 and CYP2C9 Supersomes showed highest activity at both concentrations, the enzyme kinetics of 5HMFLX formation was also determined for these recombinant CYPs. 	CYP3A	20007	20012	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:123	Using the Michaelis-Menten model, the following enzyme kinetic parameters were determined: CYP3A4, K _M 124  15 M, V_max 197  9 pmolmin^1nmol^1 P450; CYP3A7: K _M 65  8 M, V_max 193  7 pmolmin^1nmol^1 P450; and CYP2C9: K _M of 508  82 M, V_max 67  7 pmolmin^1nmol^1 P450. 	CYP3A	20348	20353	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:123	Using the Michaelis-Menten model, the following enzyme kinetic parameters were determined: CYP3A4, K _M 124  15 M, V_max 197  9 pmolmin^1nmol^1 P450; CYP3A7: K _M 65  8 M, V_max 193  7 pmolmin^1nmol^1 P450; and CYP2C9: K _M of 508  82 M, V_max 67  7 pmolmin^1nmol^1 P450. 	CYP3A	20407	20412	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:125	The three inhibitors of CYP3A isoforms, KCZ, miconazole and troleandomycin, showed a relatively modest and differential inhibitory effect on 5HMFLX formation. 	CYP3A	20677	20682	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:126	Even at the highest concentration of ketoconazole, which inhibits the CYP3A family, still only 50% inhibition was observed at both concentrations of flucloxacillin. 	CYP3A	20882	20887	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:127	The other CYP3A4 inhibitors showed only 20 to 40% inhibition at 10 M flucloxacillin concentration. 	CYP3A	20987	20992	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:128	Although recombinant CYP2C9 showed much lower activity when compared to CYP3A4, an almost 90% inhibition of 5HMFLX formation was observed in the presence of sulfaphenazole, which is considered to be a selective CYP2C9 inhibitor. 	CYP3A	21148	21153	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:130	To study whether sulfaphenazole has the ability to inhibit CYP3Amediated hydroxylation of flucloxacillin, the inhibitor was added at different concentrations to incubations of CYP3A4 and CYP3A7, with flucloxacillin and testosterone as substrates. 	CYP3A	21593	21598	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:130	To study whether sulfaphenazole has the ability to inhibit CYP3Amediated hydroxylation of flucloxacillin, the inhibitor was added at different concentrations to incubations of CYP3A4 and CYP3A7, with flucloxacillin and testosterone as substrates. 	CYP3A	21604	21609	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:131	As shown in Figure A, B, sulfaphenazole appeared to be a potent inhibitor of flucloxacillin hydroxylation by recombinant CYP3A4 and CYP3A7 with an IC_50 of 4.1  0.4 M and 6.1  0.5 M respectively. 	CYP3A	21785	21790	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:131	As shown in Figure A, B, sulfaphenazole appeared to be a potent inhibitor of flucloxacillin hydroxylation by recombinant CYP3A4 and CYP3A7 with an IC_50 of 4.1  0.4 M and 6.1  0.5 M respectively. 	CYP3A	21796	21801	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:132	At these sulfaphenazole concentrations, no inhibition of CYP3A4catalysed 6BETAhydroxylation of testosterone was observed. 	CYP3A	21917	21922	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:145	By using recombinant CYPs, at both substrate concentrations used, CYP3A4 and CYP3A7 appeared to be the most active enzymes. 	CYP3A	24325	24330	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:145	By using recombinant CYPs, at both substrate concentrations used, CYP3A4 and CYP3A7 appeared to be the most active enzymes. 	CYP3A	24336	24341	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP3A	24558	24563	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:149	did not detect 5HMFLX in incubations with recombinant CYP1A2, CYP2C9 and CYP3A5 might be attributed to the less sensitive analytical method used (HPLC-UV detection versus LC-MS) and/or the use of yeastexpressed CYPs with lower specific activity than the Supersomes used in the present study. 	CYP3A	24668	24673	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:152	that CYP3A4 is likely to play a major role in the formation of 5HMFLX, as it is, on average, the most abundant CYP in human liver (mean 93 pmolmg^1 protein) (Achour et al.,. 	CYP3A	25138	25143	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:149	These results bring attention to possible flavonoid-drug interactions on the level of CYP3A4. 	CYP3A4	22041	22047	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6222669_OgerInput.txtOger_out.csv:150	As CYP3A4 is the most significant enzyme for the metabolism of xenobiotics including drugs, further in vivo studies are needed to assess clinical significance of the observed inhibitions, and possible drug-flavonoid interactions.	CYP3A4	22052	22058	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:1	 Effects of Flavonoids in Lysimachia clethroides Duby on the Activities of Cytochrome P450 CYP2E1 and CYP3A4 in Rat Liver Microsomes. 	CYP3A4	102	108	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:2	Incubation systems were established to investigate the effects of quercetin, kaempferol, isoquercitrin and astragalin in Lysimachia clethroides Duby on the activities of CYP2E1 and CYP3A4 in rat liver microsomes in vitro. 	CYP3A4	315	321	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:5	The results suggested that kaempferol exhibited a weak inhibition of CYP2E1 activity with an IC50 of 60.26  2.54 M, while quercetin and kaempferol caused a moderate inhibition of CYP3A4 activity with IC50 values of 18.77  1.69 M and 32.65  1.32 M, respectively. 	CYP3A4	821	827	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:6	Isoquercitrin and astragalin had no effects on the activities of either CYP2E1 or CYP3A4. 	CYP3A4	986	992	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:7	It could be speculated from these results that the inhibitory effects of quercetin and kaempferol on the activities of CYP2E1 and CYP3A4 could be the mechanisms underlying the hepatoprotective effects of L. clethroides. 	CYP3A4	1124	1130	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:18	CYP3A4, a major enzyme that is expressed in adult liver, has been considered to be an important factor affecting drug absorption. 	CYP3A4	3132	3138	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:19	CYP2E1 and CYP3A4 are not only the metabolic enzymes directly involved in hepatic oxidative damage, but they also are two important targets of the oxidation mechanism of acute liver injury. 	CYP3A4	3273	3279	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:21	On the basis of previous studies, the impacts of quercetin, kaempferol, isoquercitrin and astragalin on the activities of enzymes CYP2E1 and CYP3A4 in rat liver microsomes were examined, aiming to investigate the correlation between the hepatoprotective effects of L. clethroides and the antioxidant activities of these four compounds. 	CYP3A4	3949	3955	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:36	The regressive equations obtained by the Lineweaver-Burk method for CYP2E1 and CYP3A4 were Y = 835.9883X + 9.1943 (r = 0.9864) and Y = 2388.0110X + 14.1598 (r = 0.9961) respetively. 	CYP3A4	6018	6024	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:42	The effects of quercetin, kaempferol, isoquercitrin and astragalin in L. clethroides and ketoconazole (positive control) on CYP3A4 activity are shown in  and. 	CYP3A4	7139	7145	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:43	Ketoconazole strongly inhibited the production of 6BETA-hydroxytestosterone (IC_50 = 0.25  0.01 M), but the effects of the four flavonoids in L. clethroides on CYP3A4 were very weak and their IC_50 values could not be calculated. 	CYP3A4	7334	7340	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:45	CYP2E1 and CYP3A4 are two important metabolic enzymes involved in liver injury. 	CYP3A4	7648	7654	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:48	Radix Glycyrrhizae could protect the liver injury caused by Rhizoma dioscorea bulbifera, possibly due to its induction of activity of CYP2E1 and CYP3A4 and inhibition of the mRNA expression. 	CYP3A4	8245	8251	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:49	Clomethiazole and ketoconazole act as the positive inhibitors for CYP2E1 and CYP3A4 can significantly inhibit the formation of metabolites. 	CYP3A4	8368	8374	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:50	The IC_50 values of clomethiazole and ketoconazole were 1.07  0.01 M and 0.25  0.01 M, respectively, which are consistent with literature values, suggesting that the incubation systems in vitro can meet the activities of measurement of CYP2E1 and CYP3A4. 	CYP3A4	8678	8684	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:52	Thus, kaempferol has a weakly inhibitory effect on CYP2E1, while quercetin and kaempferol have moderate inhibitory effects on CYP3A4. 	CYP3A4	9016	9022	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:53	The results of this study showed that the two flavone glycosides (isoquercitrin and astragalin) had no effect on the activities of CYP2E1 and CYP3A4. 	CYP3A4	9166	9172	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:59	Cytochromes P450, especially CYP2E1 and CYP3A4, are responsible for metabolism of ethanol, CCl_4 and other solvents in the body. 	CYP3A4	9940	9946	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:60	In the model of alcohol-induced liver injury, the expression levels of CYP2E1 and CYP3A4 were enhanced. 	CYP3A4	10111	10117	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:66	The occurrence of liver injury can be reduced or even suppressed by minimizing the activities of CYP2E1 and CYP3A4, making the discovery of more compounds with anti-oxidative stress from natural products of important significance. 	CYP3A4	11155	11161	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:112	The incubation conditions of CYP3A4 were basically the same as those described in  but the volume of incubation mixture was 500 L and the reactions were terminated by adding 700 L of ice-cold acetonitrile containing 25 M phenacetin. 	CYP3A4	16109	16115	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:133	The effects of flavonoids in L. clethroides on CYP3A4 activity were basically the same as CYP2E1. 	CYP3A4	19367	19373	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:134	The positive control was ketoconazole, and Groups 2 and 3 experiments were performed at concentrations of 0.02, 0.1, 0.2, 1 and 5 M. In vitro rat liver microsomes incubation assay methods were adopted for determining the effects of quercetin, kaempferol, isoquercitrin and astragalin in L. clethroides on the activities of CYP2E1 and CYP3A4. 	CYP3A4	19752	19758	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:135	In conclusion, kaempferol has a weakly inhibitory effect on CYP2E1, while quercetin and kaempferol had moderate inhibitory effects on CYP3A4 activity. 	CYP3A4	19894	19900	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:136	Based on these results, it can be speculated that the active hepatoprotective ingredients of L. clethroides include quercetin and kaempferol, which confer the inhibitory effects on the activities of CYP2E1 and CYP3A4. 	CYP3A4	20121	20127	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273018_OgerInput.txtOger_out.csv:137	The reduction of CYP2E1 and CYP3A4 activities can mitigate the biotransformation of CC1_4 and prevent the production of liver damaging substances to exert a liver protective role. 	CYP3A4	20157	20163	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:4	Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin. 	CYP3A4	505	511	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:6	Unfermented (GRT) and fermented (FRE) rooibos extracts inhibited the activity of CYP2C8 (7.69  8.85 g/mL and 8.93  8.88 g/mL, respectively) and CYP3A4 (31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively) based on their respective IC50 concentrations. 	CYP3A4	1100	1106	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:8	CYP3A4 showed concentration-dependent inhibition by ASP, GRT, and FRE at 25, 50, and 100 g/mL concentrations. 	CYP3A4	1320	1326	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:9	ASP, GRT, and FRE time-dependently inhibited CYP3A4 activity with GRT and FRE showing a more potent time-dependent inhibition, comparable to erythromycin. 	CYP3A4	1475	1481	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:30	Approximately 80% of conventional drugs are metabolized by specific enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) belonging to subfamilies, CYP1, CYP2, and CYP3. 	CYP3A4	4645	4651	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:31	Metformin, a first-line anti-diabetic drug, is metabolized by CYP2C11, CYP2D1, and CYP3A1/2, while glyburide and pioglitazone, other known hypoglycemic drugs, are metabolized by CYP2C9, CYP3A4, and CYP2C8. 	CYP3A4	4887	4893	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:32	Atorvastatin used to treat hypercholesterolemia is metabolized by CYP3A4. 	CYP3A4	4973	4979	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:35	Most drugs and xenobiotics including dietary polyphenols have the ability to bind to CYP3A4 as substrates. 	CYP3A4	5540	5546	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:37	Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes. 	CYP3A4	5801	5807	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:39	The purpose of this study was, therefore, to investigate the inhibitory effects of polyphenol-enriched unfermented rooibos extract (GRT), and fermented rooibos extract (FRE), (Z-2-(BETA-d-glucopyranosyloxy)-3-phenylpropenoic acid (PPAG) and aspalathin (ASP) on Vivid^ recombinant CYP450 enzymes CYP2C8, CYP2C9, and CYP3A4. 	CYP3A4	6319	6325	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:50	Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4. 	CYP3A4	7235	7241	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:52	Quercetin, sulfaphenazole, and ketoconazole were the selected positive inhibitors for CYP2C8, CYP2C9, and CYP3A4, respectively. 	CYP3A4	7466	7472	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:53	GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (a-c). 	CYP3A4	7551	7557	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:54	ASP showed 24% inhibition of CYP2C9 at 100 g/mL and 23% inhibition of CYP3A4 at 200 g/mL activity, while PPAG had no effect on any of these enzymes. 	CYP3A4	7659	7665	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:56	Both extracts moderately inhibited CYP3A4 activity (31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively) (b), while ASP displayed weak inhibition of CYP3A4 activity (69.57  4.03 g/mL) (b). 	CYP3A4	7886	7892	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:56	Both extracts moderately inhibited CYP3A4 activity (31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively) (b), while ASP displayed weak inhibition of CYP3A4 activity (69.57  4.03 g/mL) (b). 	CYP3A4	8000	8006	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:60	ASP, GRT, and FRE reduced CYP3A4 activity at 25 g/mL (62.9%, 36.9% and 61.4%, respectively; p < 0.001), 50 g/mL (44.5%, 13.5% and 29.7%, respectively; p < 0.001), and 100 g/mL (28.1%, 1.7% and 9.2%, respectively; p < 0.001) (c). 	CYP3A4	8574	8580	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:64	PPAG demonstrated time-dependent inhibition (p < 0.05) of only CYP3A4 (c). 	CYP3A4	9248	9254	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:66	An interesting finding, however, is the time-dependent inhibition of CYP3A4 activity by GRT (p < 0.01) and FRE (p < 0.01), displaying a similar effect to that of erythromycin (c). 	CYP3A4	9382	9388	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:70	These constituents include various bioactive compounds that can either activate or inhibit CYP3A4. 	CYP3A4	10094	10100	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:71	Echinacea purpurea, a known plant-based product with constituents such as caffeic acid derivatives, amides, flavonoids, and glycosides, displayed weak inhibitory effects of CYP3A4 activity with IC_50 values of 354-5394 g/mL, and modestly induced hepatic CYP3A4 activity, thereby lowering the effective concentration of drugs, such as midazolam. 	CYP3A4	10275	10281	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:71	Echinacea purpurea, a known plant-based product with constituents such as caffeic acid derivatives, amides, flavonoids, and glycosides, displayed weak inhibitory effects of CYP3A4 activity with IC_50 values of 354-5394 g/mL, and modestly induced hepatic CYP3A4 activity, thereby lowering the effective concentration of drugs, such as midazolam. 	CYP3A4	10356	10362	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:73	Therefore, in the current study, we screened for the inhibitory potential of the extracts and compounds using co-incubation (reversible inhibition) and pre-incubation (time-dependent inhibition) with CYP2C8, CYP2C9, and CYP3A4 Vivid^@ recombinant enzymes. 	CYP3A4	10840	10846	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:75	Plant extracts containing high levels of polyphenols are expected to have inhibitory effects on various CYPs including CYP2C8, CYP2C9, CYP2D6, and CYP3A4. 	CYP3A4	11179	11185	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:76	Of these, CYP3A4 is commonly involved in herb-drug interactions as it metabolizes about 50% of clinically-prescribed medications. 	CYP3A4	11197	11203	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:81	GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC_50 values of 31.33  4.69 g/mL and 51.44  4.31 g/mL, respectively. 	CYP3A4	11865	11871	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:82	ASP, as the major compound, moderately inhibited CYP3A4 activity with an IC_50 value of 69.57  4.03 g/mL. 	CYP3A4	12013	12019	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:83	Luteolin, the aglycone of rooibos flavone glucosides, orientin and isoorientin, and quercetin, the aglycone of rooibos flavonol glycosides, quercetin-3-O-robinobioside, rutin, hyperoside, and isoquercitrin, have previously been shown to inhibit CYP3A4. 	CYP3A4	12315	12321	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:84	Quercetin is a more effective inhibitor of CYP3A4 than its 3-O-rutinoside, rutin. 	CYP3A4	12366	12372	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:85	The inhibition of CYP3A4 was also demonstrated to be both dose- and time-dependent. 	CYP3A4	12423	12429	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:86	Therefore, they could potentially interfere with the metabolism and alter the pharmacodynamics of drugs, such as atorvastatin, cyclosporine, felodopine, simvastatin, midazolam, erythromycin, and doxorubicin, known to be metabolized by CYP3A4. 	CYP3A4	12724	12730	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:104	This study demonstrates that GRT and FRE inhibited CYP2C8 and CYP3A4 activity in a dose- and time-dependent manner, whilst inhibiting CYP2C9 activity in a time-dependent manner only. 	CYP3A4	15300	15306	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:105	ASP could only be implicated in CYP3A4 inhibition. 	CYP3A4	15453	15459	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:120	Vivid^ CYP2C8 Green Screening Kit with Vivid^ substrate, di-[benzyl-O-methyl]-fluorescein (DBOMF) and Vivid^ CYP3A4 and CYP2C9 Blue Screening Kits with Vivid^ substrate, 7-benzyl-oxymethyloxy-3-cyanocoumarin (BOMCC) were purchased from Life Technologies^ (Carlsbad, CA, USA). 	CYP3A4	17181	17187	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:122	The effect of organic solvents such as methanol, acetonitrile and DMSO on Vivid^ recombinant CYP2C8, CYP2C9, and CYP3A4 assays was determined. 	CYP3A4	17557	17563	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:123	A mixture containing 0.1% of organic solvent, reaction buffer (200 mM potassium phosphate (reaction buffer I) or 100 mM potassium phosphate (reaction buffer II)) and regeneration system (333 mM glucose-6-phosphate and 30 U/mL glucose-6-phosphate dehydrogenase in 100 mM potassium phosphate, pH 8.0) solution with the addition of each enzyme (CYP2C8, CYP2C9, or CYP3A4) was prepared. 	CYP3A4	17948	17954	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:128	Compounds, PPAG and ASP, and the rooibos extracts, GRT and FRE, were screened for their inhibitory effects on CYP2C8, CYP2C9, and CYP3A4 using one-point screening kinetics. 	CYP3A4	18718	18724	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:130	Briefly, inhibitors, extracts, and compounds were pre-incubated with either CYP2C8 or CYP2C9 at a concentration of 100 g/mL, or CYP3A4 at a concentration of 200 g/mL. 	CYP3A4	18989	18995	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:132	As per the manufacturers instruction, 50 L of Vivid^ Master Pre-Mix (BACULOSOMES^ enzymes (CYP2C8, CYP2C9 or CYP3A4), regeneration system, reaction buffer (I/II), and NADP^+) was added to each well. 	CYP3A4	19249	19255	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:134	After incubation, 10 L reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II were added to each well and incubated for 30 min at 37 C. Fluorescence was measured on a SpectraMax i3 plate reader at 5 min intervals to determine reaction kinetics. 	CYP3A4	19460	19466	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:136	Enzyme activity was measured by formation of the metabolites at excitation and emission wavelengths of 485/530 nm (CYP2C8) and 406/460 nm (CYP2C9 and CYP3A4), respectively. 	CYP3A4	19895	19901	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:137	A three-fold serial dilution of PPAG, ASP, GRT, and FRE was added to CYP2C8 and CYP2C9 (concentration range 100-0.41 g/mL) and CYP3A4 (concentration range 200-0.82 g/mL) to determine their respective IC_50 concentrations. 	CYP3A4	20045	20051	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP3A4	20159	20165	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:138	CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ plus reagent and regeneration system in Vivid^ reaction buffer I/II added to a black Costar 96-well plate containing test extracts and compounds were incubated for 15 min at 37 C. Thereafter, as previously described, the reaction was initiated by adding a mixture of reconstituted DBOMF (CYP2C8) or BOMCC (CYP2C9 and CYP3A4) and NADP^+ in Vivid^ reaction buffer I/II and incubated for 30 min at 37 C. After addition of the stop solution to terminate the reaction, fluorescence was determined at the relative excitation/emission wavelengths described in. 	CYP3A4	20496	20502	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:139	Time-dependent inhibition (TDI) using the respective serial dilutions employed for IC_50 determination (CYP2C8 and CYP2C9; 100-0.41 g/mL and for CYP3A4; 200-0.82 g/mL) was performed. 	CYP3A4	20878	20884	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:140	The extracts and compounds were pre-incubated with CYP2C8, CYP2C9, or CYP3A4 BACULOSOMES^ and NADPH for 30 min. 	CYP3A4	20986	20992	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:145	Inhibition of CYP2C8, CYP2C9, and CYP3A4 BACULOSOMES^ was quantified, as described in. 	CYP3A4	21599	21605	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:146	The data generated were exported to an Excel (Microsoft Headquarters, One Microsoft Way, Redmond, WA, USA) worksheet and the amount of metabolite formed at various concentrations relative to the control was calculated using the following equation: The relative percentage activity was plotted against the log transformed concentrations of the extracts, compounds and positive controls, ie quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor). 	CYP3A4	22151	22157	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6273468_OgerInput.txtOger_out.csv:152	This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs. 	CYP3A4	22957	22963	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:33	CYP3A4 is a well-known oxidative enzyme that is mostly involved in the metabolism of xenobiotics, and is the most expressed isoform in human liver. 	CYP3A4	4290	4296	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:64	CYP3A4 was not analyzed because it was included in the study during the Western Blot analysis and we did not find any change of expression with the treatments. 	CYP3A4	9081	9087	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:68	The Western Blot results of CYP1A1 showed the same non-induction pattern by both treatments, as well as for CYP3A4 (c,d). 	CYP3A4	9960	9966	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:71	Neither CYP1A1 nor CYP3A4 were affected by both treatments in differentiated cells. 	CYP3A4	10328	10334	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:92	We also observed that the fluorescent images of CYP3A4 did not report a preferential localization between mitochondria and Endoplasmic Reticulum. 	CYP3A4	13555	13561	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:202	They were incubated with one of the following primary antibodies overnight, anti-CYP1A1 (Life Technologies, # PA515213, 1:1000, polyclonal rabbit), anti-CYP2D6 (Life Technologies, # PA535148, 1:1000, polyclonal rabbit), anti-CYP2E1 (Life Technologies, # PA535351, 1:1000, polyclonal rabbit), or anti-CYP3A4 (Life Technologies, # PA514896, 1:1000, polyclonal rabbit) mixed with anti-BETA-actin primary antibody (Life Technologies, # PA516914, 1:1000, polyclonal mouse) as an endogenous housekeeping protein. 	CYP3A4	30930	30936	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:1	 Nanostructures of diamond, graphene oxide and graphite inhibit CYP1A2, CYP2D6 and CYP3A4 enzymes and downregulate their genes in liver cells. 	CYP3A4	83	89	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:5	The objective of this study was to assess if DN, GO and GN affect three isoforms of cytochrome P450 (CYP) enzymes, namely, CYP1A2, CYP2D6 and CYP3A4, expressed in the liver. 	CYP3A4	708	714	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:26	The most important members of the CYP family are CYP3A isoforms, especially CYP3A4 which is responsible for ~30% of the total hepatic activity of CYP. 	CYP3A4	4098	4104	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:31	The problem with disturbances of CYP reactions caused by nanomaterials is a new topic, studied most recently on metallic nanoparticles (gold or silver) and using the CYP3A4 isoform. 	CYP3A4	4934	4940	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6300366_OgerInput.txtOger_out.csv:37	Single-walled carbon nanotubes (SWCNT) inhibited the activity of the CYP3A4 enzyme by direct interaction between SWCNT and the enzyme. 	CYP3A4	5631	5637	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_603', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:508	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin in SkinEthik^ RHE: 2.8, in Episkin^: 9.1, in Episkin^ FTM: 2.6, compared with human skin: 3.0;7-benzoxy 4-trifluoromethylcoumarin O-deethylase activities (CYP3A5/3A7-selective) in SkinEthik^ RHE: 13.3, in Episkin^: 3.6, in Episkin^ FTM: 3.3, compared with human skin: 3.8;7-methoxy-4-trifluoromethylcoumarin O-dealkylase activity was close to the Limit Of Quantitation of 0.5 in all three skin models and in human skin. 	CYP3A5	78751	78757	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:668	CYP3A4 and CYP3A5 Baron et al. 	CYP3A5	102324	102330	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:669	showed that CYP3A5, but not CYP3A4 mRNA was constitutively present in proliferating human skin keratinocytes in culture, while the expression of CYP3A4 mRNA was induced by treatment with dexamethasone. 	CYP3A5	102356	102362	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:671	Cyp3A4 mRNA was very variably expressed in various skin systems, whereby it was not clear whether CYP3A4 was distinguished from CYP3A5. 	CYP3A5	102710	102716	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:53	456207), CYP3A5 (Lot No. 	CYP3A5	8522	8528	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:120	Low activities of 5HMFLX formation were observed, in decreasing order, in incubations with CYP2C9, CYP2J2, CYP2C8, CYP2E1, CYP3A5, CYP1A1, CYP2D6 and CYP1A2. 	CYP3A5	19961	19967	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:147	At 100 M flucloxacillin, low activities were also observed with CYP1A1, CYP1A2, CYP2C8, CYP2E1, CYP2J2 and CYP3A5. 	CYP3A5	24558	24564	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6329626_OgerInput.txtOger_out.csv:149	did not detect 5HMFLX in incubations with recombinant CYP1A2, CYP2C9 and CYP3A5 might be attributed to the less sensitive analytical method used (HPLC-UV detection versus LC-MS) and/or the use of yeastexpressed CYPs with lower specific activity than the Supersomes used in the present study. 	CYP3A5	24668	24674	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:21	CYPs are responsible for the biotransformation of widely used antipsychotics such as clozapine (CYP1A2 and CYP2C19), olanzapine (CYP1A2), risperidone and haloperidol (CYP2D6), quetiapine and ziprasidone (CYP3A5) amongst others^,. 	CYP3A5	3431	3437	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_604', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:134	It has been reported that elevated concentration of S-Adenosylmethionine reduces CYP2E1^ and CYP39A^, but markedly induces CYP4A^ in Glycine N-Methyltransferase Knockout mice. 	CYP4A	23201	23206	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC5934382_OgerInput.txtOger_out.csv:136	Interestingly, in our microarray data, CYP4A were significantly induced up to 4- to 6-fold by AAI. 	CYP4A	23380	23385	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:138	In order to study the metabolic capability of SH-SY5Y cells after the induction of Cytochrome P450 isoforms, we used 7-ethoxycoumarin as substrate for a broad number of Cytochrome P450 isozymes. 	Cytochrome P450	20669	20684	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:147	The localization of Cytochrome P450 in mitochondria can contribute to the bioactivation/detoxification processes of neurotoxins. 	Cytochrome P450	22126	22141	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:147	The localization of Cytochrome P450 in mitochondria can contribute to the bioactivation/detoxification processes of neurotoxins. 	Cytochrome P450	22126	22141	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:163	Therefore, other Cytochrome P450 isoforms can have an important role in xenobiotic metabolism in other brain regions, and at the same time, they do not have to necessarily be associate with positive effects. 	Cytochrome P450	24830	24845	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:163	Therefore, other Cytochrome P450 isoforms can have an important role in xenobiotic metabolism in other brain regions, and at the same time, they do not have to necessarily be associate with positive effects. 	Cytochrome P450	24830	24845	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:165	This toxin can be metabolized by the Cytochrome P450 system as already reported. 	Cytochrome P450	25211	25226	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:165	This toxin can be metabolized by the Cytochrome P450 system as already reported. 	Cytochrome P450	25211	25226	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:171	Since Cytochrome P450 is not able to metabolize this compound, we confirmed that the effects observed were not produced by the inducers itself, but by the promotion of the Cytochrome P450 system. 	Cytochrome P450	26035	26050	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:171	Since Cytochrome P450 is not able to metabolize this compound, we confirmed that the effects observed were not produced by the inducers itself, but by the promotion of the Cytochrome P450 system. 	Cytochrome P450	26035	26050	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:171	Since Cytochrome P450 is not able to metabolize this compound, we confirmed that the effects observed were not produced by the inducers itself, but by the promotion of the Cytochrome P450 system. 	Cytochrome P450	26201	26216	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:171	Since Cytochrome P450 is not able to metabolize this compound, we confirmed that the effects observed were not produced by the inducers itself, but by the promotion of the Cytochrome P450 system. 	Cytochrome P450	26201	26216	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	Cytochrome P450	28680	28695	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:189	The following probes for Cytochrome P450 isoforms were used, CYP1A1 (Life Technologies, Assay ID Hs01054797_g1, # 4331182), CYP2D6 (Life Technologies, Assay ID Hs03043790_g1, # 4331182), and CYP2E1 (Life Technologies, Assay ID Hs00559368_m1, # 4453320). 	Cytochrome P450	28680	28695	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:206	The CYPs activities were assayed using 7-ethoxycoumarin (Sigma-Aldrich) as substrate of multiple Cytochrome P450 isoforms or dextromethorphan (Sigma-Aldrich) as CYP2D6 marker substrate. 	Cytochrome P450	31730	31745	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:206	The CYPs activities were assayed using 7-ethoxycoumarin (Sigma-Aldrich) as substrate of multiple Cytochrome P450 isoforms or dextromethorphan (Sigma-Aldrich) as CYP2D6 marker substrate. 	Cytochrome P450	31730	31745	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:212	The enzyme activities were expressed as pmol metabolite per mg of protein in 24 h. A staining approach to evaluate the Cytochrome P450 location in SH-SY5Y was carried out by confocal imaging. 	Cytochrome P450	33037	33052	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6274691_OgerInput.txtOger_out.csv:212	The enzyme activities were expressed as pmol metabolite per mg of protein in 24 h. A staining approach to evaluate the Cytochrome P450 location in SH-SY5Y was carried out by confocal imaging. 	Cytochrome P450	33037	33052	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6310986_OgerInput.txtOger_out.csv:228	Cytochrome P450, a superfamily of monooxygenase, plays critical roles in biosynthesis of plant secondary metabolites such as triterpenes, alkaloids, and sterols. 	Cytochrome P450	34773	34788	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6310986_OgerInput.txtOger_out.csv:228	Cytochrome P450, a superfamily of monooxygenase, plays critical roles in biosynthesis of plant secondary metabolites such as triterpenes, alkaloids, and sterols. 	Cytochrome P450	34773	34788	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:4	Influence of mentioned extracts and their key constituents on warfarin pharmacodynamic and kinetic actions and Cytochrome P450 Enzymes activity were evaluated. 	Cytochrome P450	794	809	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:4	Influence of mentioned extracts and their key constituents on warfarin pharmacodynamic and kinetic actions and Cytochrome P450 Enzymes activity were evaluated. 	Cytochrome P450	794	809	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:6	Furthermore, potential involvement in Cytochrome P450 Enzymes inhibition was also investigated in vitro on isolated primary rat hepatocytes. 	Cytochrome P450	1146	1161	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:6	Furthermore, potential involvement in Cytochrome P450 Enzymes inhibition was also investigated in vitro on isolated primary rat hepatocytes. 	Cytochrome P450	1146	1161	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:11	Significant reduction in CYP2C8, 2C9, and 3A4 was seen upon concomitant use of warfarin with ellagic acid, guava leaves and quercetin, unlike pomegranate that insignificantly affected Cytochrome P450 Enzymes activities. 	Cytochrome P450	2129	2144	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:11	Significant reduction in CYP2C8, 2C9, and 3A4 was seen upon concomitant use of warfarin with ellagic acid, guava leaves and quercetin, unlike pomegranate that insignificantly affected Cytochrome P450 Enzymes activities. 	Cytochrome P450	2129	2144	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:34	In addition, the potential inhibition of selected Cytochrome P450 Enzymes enzymes that are responsible for warfarin metabolism is investigated with the herbal drugs in vitro on rat isolated primary hepatocytes. 	Cytochrome P450	6154	6169	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:34	In addition, the potential inhibition of selected Cytochrome P450 Enzymes enzymes that are responsible for warfarin metabolism is investigated with the herbal drugs in vitro on rat isolated primary hepatocytes. 	Cytochrome P450	6154	6169	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:100	After 16 h of incubation, each well of cultured rat hepatocytes were treated with 25 l of warfarin, guava leaves extract, quercetin, pomegranate peel extract, ellagic acid, a combination of warfarin with each test compound in addition to the control Cytochrome P450 Enzymes inhibitors namely; ketoconazole, sulfamethoxazole or trimethoprim. 	Cytochrome P450	15835	15850	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:100	After 16 h of incubation, each well of cultured rat hepatocytes were treated with 25 l of warfarin, guava leaves extract, quercetin, pomegranate peel extract, ellagic acid, a combination of warfarin with each test compound in addition to the control Cytochrome P450 Enzymes inhibitors namely; ketoconazole, sulfamethoxazole or trimethoprim. 	Cytochrome P450	15835	15850	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	Cytochrome P450	21875	21890	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	Cytochrome P450	21875	21890	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	Cytochrome P450	22027	22042	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:136	Noteworthy, the evaluation of CYP450 enzymes, namely, CYP2C9, 2C8, 3A4 was based on cell-based investigations and sufficient inhibition of corresponding well-known Cytochrome P450 Enzymes control inhibitors including, sulfamethoxazole, trimethoprim and ketoconazole confirms that in vitro investigation of mentioned Cytochrome P450 Enzymes isoforms on rat hepatocyte is possible, as raised in the literature [,. 	Cytochrome P450	22027	22042	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:137	In regard to results presented for ellagic acid, and since it is known to exert inhibition on CYP2C9, its effect may be due to a decrease in hepatic first-pass metabolism of warfarin due to its ability to inhibit such Cytochrome P450 Enzymes isoform. 	Cytochrome P450	22341	22356	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:137	In regard to results presented for ellagic acid, and since it is known to exert inhibition on CYP2C9, its effect may be due to a decrease in hepatic first-pass metabolism of warfarin due to its ability to inhibit such Cytochrome P450 Enzymes isoform. 	Cytochrome P450	22341	22356	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:143	Furthermore, the ability of guava leaves extract and quercetin to inhibit some of hepatic Cytochrome P450 Enzymes isoforms associated with warfarin metabolism such as CYP2C9, 2C8 and 3A4 may be responsible for increasing warfarin plasma concentration [,. 	Cytochrome P450	23497	23512	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:143	Furthermore, the ability of guava leaves extract and quercetin to inhibit some of hepatic Cytochrome P450 Enzymes isoforms associated with warfarin metabolism such as CYP2C9, 2C8 and 3A4 may be responsible for increasing warfarin plasma concentration [,. 	Cytochrome P450	23497	23512	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:145	In vitro warfarin-herb interactions and their effects on hepatic Cytochrome P450 Enzymes isoforms showed that CYP2C9, 2C8 and 3A4 activities in primary isolated and cultured rat hepatocytes were not affected by warfarin. 	Cytochrome P450	23884	23899	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:145	In vitro warfarin-herb interactions and their effects on hepatic Cytochrome P450 Enzymes isoforms showed that CYP2C9, 2C8 and 3A4 activities in primary isolated and cultured rat hepatocytes were not affected by warfarin. 	Cytochrome P450	23884	23899	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:147	Since Cytochrome P450 Enzymes isoforms other than 2C9, 2C8 and 3A4 are involved in warfarin metabolism, further study with more focus on pomegranate peel and its constituents is therefore suggested. 	Cytochrome P450	24189	24204	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:147	Since Cytochrome P450 Enzymes isoforms other than 2C9, 2C8 and 3A4 are involved in warfarin metabolism, further study with more focus on pomegranate peel and its constituents is therefore suggested. 	Cytochrome P450	24189	24204	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	Cytochrome P450	38170	38185	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	Cytochrome P450	38170	38185	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	Cytochrome P450	38205	38220	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:236	To achieve this, the hit compounds evaluated for either substrate or inhibitors of Cytochrome P450 Enzymes along with Cytochrome P450 Enzymes of Human Liver Microsomes. 	Cytochrome P450	38205	38220	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:252	These metabolism properties were explored in silico and summarized by predicting the metabolic sites as well as metabolites, and type of Cytochrome P450 Enzymes involved enzymes, which catalyzes xenobiotics/drugs in phase II metabolism and transform the small molecules to water-soluble form, which may lead to the easy elimination of xenobiotics. 	Cytochrome P450	41220	41235	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6443786_OgerInput.txtOger_out.csv:252	These metabolism properties were explored in silico and summarized by predicting the metabolic sites as well as metabolites, and type of Cytochrome P450 Enzymes involved enzymes, which catalyzes xenobiotics/drugs in phase II metabolism and transform the small molecules to water-soluble form, which may lead to the easy elimination of xenobiotics. 	Cytochrome P450	41220	41235	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:93	Cytochrome P450s, which comprise one of the largest and oldest gene superfamilies, are known to be involved in the biosynthesis of secondary metabolites such as flavonoids. 	Cytochrome P450	16042	16057	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:93	Cytochrome P450s, which comprise one of the largest and oldest gene superfamilies, are known to be involved in the biosynthesis of secondary metabolites such as flavonoids. 	Cytochrome P450	16042	16057	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:94	In this study, 78 unigene Differentially Expressed Genes were annotated as Cytochrome P450s. 	Cytochrome P450	16290	16305	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:94	In this study, 78 unigene Differentially Expressed Genes were annotated as Cytochrome P450s. 	Cytochrome P450	16290	16305	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:144	Cytochrome P450s are known to play central roles in the evolution of metabolic complexity and in the production of secondary metabolites, including flavonoid metabolites. 	Cytochrome P450	23127	23142	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:144	Cytochrome P450s are known to play central roles in the evolution of metabolic complexity and in the production of secondary metabolites, including flavonoid metabolites. 	Cytochrome P450	23127	23142	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:146	Two Cytochrome P450s (CfCYP93B and CfCYP706C) isolated from Coleus forskohlii are involved in the biosynthesis of flavonoids and CYP93B isolated from hybrid Gerbera encodes flavone synthase II, which catalyzes flavanones into flavones. 	Cytochrome P450	23446	23461	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:146	Two Cytochrome P450s (CfCYP93B and CfCYP706C) isolated from Coleus forskohlii are involved in the biosynthesis of flavonoids and CYP93B isolated from hybrid Gerbera encodes flavone synthase II, which catalyzes flavanones into flavones. 	Cytochrome P450	23446	23461	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:147	The expression of Cytochrome P450s also has a significant effect on the content of flavonoids in plants. 	Cytochrome P450	23696	23711	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6480179_OgerInput.txtOger_out.csv:147	The expression of Cytochrome P450s also has a significant effect on the content of flavonoids in plants. 	Cytochrome P450	23696	23711	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:64	Several enzymes including those belonging to the Cytochrome P450 family play crucial roles in the generation of either a stable plaque or progression to an unstable plaque with poor prognosis for atherosclerosis outcome (Silvestre-Roig et al., ; Song et al., ; Stefanadis et al.,. 	Cytochrome P450	12470	12485	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:64	Several enzymes including those belonging to the Cytochrome P450 family play crucial roles in the generation of either a stable plaque or progression to an unstable plaque with poor prognosis for atherosclerosis outcome (Silvestre-Roig et al., ; Song et al., ; Stefanadis et al.,. 	Cytochrome P450	12470	12485	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:75	Cholesterol also acts as a substrate for various enzyme activities including those belonging to the Cytochrome P450 family (Pikuleva, ; Rogers et al.,. 	Cytochrome P450	15379	15394	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:75	Cholesterol also acts as a substrate for various enzyme activities including those belonging to the Cytochrome P450 family (Pikuleva, ; Rogers et al.,. 	Cytochrome P450	15379	15394	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:106	The lipophilic sterol metabolites produced by IFN signaling including oxysterols are substrates for Cytochrome P450 enzymes and they profoundly influence cellular metabolism (Newmark et al., ) which in turn has been shown to influence Mycobacterium Tuberculosis replication inside cells (Huang et al.,. 	Cytochrome P450	22639	22654	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:106	The lipophilic sterol metabolites produced by IFN signaling including oxysterols are substrates for Cytochrome P450 enzymes and they profoundly influence cellular metabolism (Newmark et al., ) which in turn has been shown to influence Mycobacterium Tuberculosis replication inside cells (Huang et al.,. 	Cytochrome P450	22639	22654	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:160	The Cytochrome P450 system has been implicated in the pathogenesis of various CVDs including atherosclerosis and aneurysms (Song et al., ; Thirunavukkarasu et al.,. 	Cytochrome P450	34601	34616	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:160	The Cytochrome P450 system has been implicated in the pathogenesis of various CVDs including atherosclerosis and aneurysms (Song et al., ; Thirunavukkarasu et al.,. 	Cytochrome P450	34601	34616	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:161	The Cytochrome P450 enzymes are heme containing monooxygenases involved in the pathways associated with the metabolism of fatty acids, steroids and other lipophilic molecules (Pikuleva,. 	Cytochrome P450	34766	34781	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:161	The Cytochrome P450 enzymes are heme containing monooxygenases involved in the pathways associated with the metabolism of fatty acids, steroids and other lipophilic molecules (Pikuleva,. 	Cytochrome P450	34766	34781	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:162	The loss of Cytochrome P450 enzymes prevents Apolipoprotein (Apo) A1 synthesis thus affecting the removal of cholesterol from the cells to the liver for biliary excretion (Rubin et al., ; Nebert and Russell, ; Guan et al.,. 	Cytochrome P450	34961	34976	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:162	The loss of Cytochrome P450 enzymes prevents Apolipoprotein (Apo) A1 synthesis thus affecting the removal of cholesterol from the cells to the liver for biliary excretion (Rubin et al., ; Nebert and Russell, ; Guan et al.,. 	Cytochrome P450	34961	34976	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:163	The cholesterol metabolizing ability of Cytochrome P450 family members varies depending on the physiological requirements of different organs and in vivo cholesterol levels. 	Cytochrome P450	35213	35228	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:163	The cholesterol metabolizing ability of Cytochrome P450 family members varies depending on the physiological requirements of different organs and in vivo cholesterol levels. 	Cytochrome P450	35213	35228	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:164	Since the activity of the Cytochrome P450 enzymes can be modulated post-translationally, they are targets to manipulate cholesterol homeostasis (Luoma,. 	Cytochrome P450	35373	35388	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:164	Since the activity of the Cytochrome P450 enzymes can be modulated post-translationally, they are targets to manipulate cholesterol homeostasis (Luoma,. 	Cytochrome P450	35373	35388	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:165	The importance of Cytochrome P450 in mycobacteria is known. 	Cytochrome P450	35518	35533	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:165	The importance of Cytochrome P450 in mycobacteria is known. 	Cytochrome P450	35518	35533	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:166	For example, Mycobacterium Tuberculosis has about 20 different Cytochrome P450 enzymes, and several Cytochrome P450 genes have been associated with mycobacterial viability (Mclean et al.,. 	Cytochrome P450	35623	35638	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:166	For example, Mycobacterium Tuberculosis has about 20 different Cytochrome P450 enzymes, and several Cytochrome P450 genes have been associated with mycobacterial viability (Mclean et al.,. 	Cytochrome P450	35623	35638	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:166	For example, Mycobacterium Tuberculosis has about 20 different Cytochrome P450 enzymes, and several Cytochrome P450 genes have been associated with mycobacterial viability (Mclean et al.,. 	Cytochrome P450	35660	35675	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:166	For example, Mycobacterium Tuberculosis has about 20 different Cytochrome P450 enzymes, and several Cytochrome P450 genes have been associated with mycobacterial viability (Mclean et al.,. 	Cytochrome P450	35660	35675	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:168	have reported that the Mycobacterium Tuberculosis genome sequence has a very high number of Cytochrome P450 enzymes, with Cyp128 contributing to synthesis of cell wall sulpholipid and being necessary for in-vitro growth of the bacterium (Cole et al., ; Holsclaw et al., ; Sogi et al.,. 	Cytochrome P450	35853	35868	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:168	have reported that the Mycobacterium Tuberculosis genome sequence has a very high number of Cytochrome P450 enzymes, with Cyp128 contributing to synthesis of cell wall sulpholipid and being necessary for in-vitro growth of the bacterium (Cole et al., ; Holsclaw et al., ; Sogi et al.,. 	Cytochrome P450	35853	35868	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:169	Iron is necessary for mycobacterial Cytochrome P450 (Ouellet et al., ) activity and iron has been recognized as a crucial element for the survival of intracellular mycobacteria (Ratledge, ; Janagama et al., ; Lamont et al.,. 	Cytochrome P450	36083	36098	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:169	Iron is necessary for mycobacterial Cytochrome P450 (Ouellet et al., ) activity and iron has been recognized as a crucial element for the survival of intracellular mycobacteria (Ratledge, ; Janagama et al., ; Lamont et al.,. 	Cytochrome P450	36083	36098	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:170	Thus, the importance of Cytochrome P450 from the pathogen perspective has been explored albeit not in depth. 	Cytochrome P450	36296	36311	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:170	Thus, the importance of Cytochrome P450 from the pathogen perspective has been explored albeit not in depth. 	Cytochrome P450	36296	36311	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:171	From the host perspective, a transcriptomic analysis of Tuberculosis granulomas has revealed a characteristic downregulation of several Cytochrome P450 genes in cells within these granulomas (Eisenreich et al.,. 	Cytochrome P450	36517	36532	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:171	From the host perspective, a transcriptomic analysis of Tuberculosis granulomas has revealed a characteristic downregulation of several Cytochrome P450 genes in cells within these granulomas (Eisenreich et al.,. 	Cytochrome P450	36517	36532	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:172	Cytochrome P450 monooxygenases are involved in biosynthesis of oxysterols (Pikuleva, ), however the dynamics between the expression of Cytochrome P450 genes in granuloma formation and cholesterol metabolism has not been assessed in Mycobacterium Tuberculosis infection. 	Cytochrome P450	36593	36608	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:172	Cytochrome P450 monooxygenases are involved in biosynthesis of oxysterols (Pikuleva, ), however the dynamics between the expression of Cytochrome P450 genes in granuloma formation and cholesterol metabolism has not been assessed in Mycobacterium Tuberculosis infection. 	Cytochrome P450	36593	36608	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:172	Cytochrome P450 monooxygenases are involved in biosynthesis of oxysterols (Pikuleva, ), however the dynamics between the expression of Cytochrome P450 genes in granuloma formation and cholesterol metabolism has not been assessed in Mycobacterium Tuberculosis infection. 	Cytochrome P450	36728	36743	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:172	Cytochrome P450 monooxygenases are involved in biosynthesis of oxysterols (Pikuleva, ), however the dynamics between the expression of Cytochrome P450 genes in granuloma formation and cholesterol metabolism has not been assessed in Mycobacterium Tuberculosis infection. 	Cytochrome P450	36728	36743	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:175	Apart from their direct role in modulating host cholesterol metabolism, members of the Cytochrome P450 family such as Cyp4501b1(Cyp1b1) are involved in the metabolism of sex steroidal hormones with the resultant metabolites produced being implicated to play a role in the gender differences noticed to the susceptibility to cardiac and renal diseases (Jennings et al., ; Pingili et al., ; Song et al., ; Thirunavukkarasu et al.,. 	Cytochrome P450	37224	37239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:175	Apart from their direct role in modulating host cholesterol metabolism, members of the Cytochrome P450 family such as Cyp4501b1(Cyp1b1) are involved in the metabolism of sex steroidal hormones with the resultant metabolites produced being implicated to play a role in the gender differences noticed to the susceptibility to cardiac and renal diseases (Jennings et al., ; Pingili et al., ; Song et al., ; Thirunavukkarasu et al.,. 	Cytochrome P450	37224	37239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:183	Therefore, extrapolating from the evidence for Cyp1b1 in gender specific pathogeneis of CVDs, it would be worthwhile to explore further the role of Cytochrome P450 family members in mycobacterial infections due to a necessity for a sex-tailored therapeutic approach in view of the gender related susceptibility to disease. 	Cytochrome P450	39476	39491	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6482252_OgerInput.txtOger_out.csv:183	Therefore, extrapolating from the evidence for Cyp1b1 in gender specific pathogeneis of CVDs, it would be worthwhile to explore further the role of Cytochrome P450 family members in mycobacterial infections due to a necessity for a sex-tailored therapeutic approach in view of the gender related susceptibility to disease. 	Cytochrome P450	39476	39491	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6508646_OgerInput.txtOger_out.csv:5	Cytochrome P450 enzymes (P450s) of the MPB are thought to be involved in the metabolism of at least some of these defense compounds. 	Cytochrome P450	545	560	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6508646_OgerInput.txtOger_out.csv:5	Cytochrome P450 enzymes (P450s) of the MPB are thought to be involved in the metabolism of at least some of these defense compounds. 	Cytochrome P450	545	560	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:4	Kistamicin contains three crosslinks, including an unusual 15-membered A-O-B ring, despite the presence of only two Cytochrome P450 Oxy enzymes thought to catalyse formation of such crosslinks within the biosynthetic gene cluster. 	Cytochrome P450	642	657	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6565677_OgerInput.txtOger_out.csv:4	Kistamicin contains three crosslinks, including an unusual 15-membered A-O-B ring, despite the presence of only two Cytochrome P450 Oxy enzymes thought to catalyse formation of such crosslinks within the biosynthetic gene cluster. 	Cytochrome P450	642	657	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:19	Cytochrome P450 enzymes, responsible for the biotransformation of more than 85% of existing drugs, may contain genetic variants that result in poor, intermediate, extensive or ultra-rapid metabolic rates^,. 	Cytochrome P450	2803	2818	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6658489_OgerInput.txtOger_out.csv:19	Cytochrome P450 enzymes, responsible for the biotransformation of more than 85% of existing drugs, may contain genetic variants that result in poor, intermediate, extensive or ultra-rapid metabolic rates^,. 	Cytochrome P450	2803	2818	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:96	The most abundant in the plasma is sorafenib N-oxide (M2), which is produced by Cytochrome P450 3a4 and exhibits an in vitro potency similar to the parental drug. 	Cytochrome P450	18034	18049	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:96	The most abundant in the plasma is sorafenib N-oxide (M2), which is produced by Cytochrome P450 3a4 and exhibits an in vitro potency similar to the parental drug. 	Cytochrome P450	18034	18049	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:98	Given the key role of Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 in sorafenib metabolism, inducers or inhibitors of these enzymes, such as some foods and co-administered drugs (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, rifabutin, St. 	Cytochrome P450	18347	18362	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:98	Given the key role of Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 in sorafenib metabolism, inducers or inhibitors of these enzymes, such as some foods and co-administered drugs (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, rifabutin, St. 	Cytochrome P450	18347	18362	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:191	The liver metabolism of regorafenib, even if less well-characterized, is comparable with that of sorafenib and occurs through an oxidative process mediated by Cytochrome P450 3a4 and glucuronidation mediated by Udp Glucuronosyltransferase 1a9. 	Cytochrome P450	39064	39079	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:191	The liver metabolism of regorafenib, even if less well-characterized, is comparable with that of sorafenib and occurs through an oxidative process mediated by Cytochrome P450 3a4 and glucuronidation mediated by Udp Glucuronosyltransferase 1a9. 	Cytochrome P450	39064	39079	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	Cytochrome P450	39811	39826	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:195	Regorafenib and its major metabolites are also reported to inhibit a number of cytochromes (CYP2C8, CYP2C9, CYP2B6, Cytochrome P450 3a4, CYP2D6), UGT1A enzymes (UGT1A9, UGT1A1), and transporters (BCRP) and induce others (CYP1A2, CYP2B6, CYP2C19, CYP3A4) with potential alteration in the exposure of co-administered drugs. 	Cytochrome P450	39811	39826	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:201	A descriptive study assessed Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 genetic variability by sequencing the germline DNA of three patients with metastatic colorectal cancer experiencing severe toxic hepatitis after sorafenib treatment and reported that two patients were heterozygous for the UGT1A9*22 (rs3832043) polymorphism. 	Cytochrome P450	41236	41251	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:201	A descriptive study assessed Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 genetic variability by sequencing the germline DNA of three patients with metastatic colorectal cancer experiencing severe toxic hepatitis after sorafenib treatment and reported that two patients were heterozygous for the UGT1A9*22 (rs3832043) polymorphism. 	Cytochrome P450	41236	41251	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:245	This drug undergoes hepatic metabolism by Cytochrome P450 3a4 and, to a minor extent, by CYP2C9. 	Cytochrome P450	50224	50239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:245	This drug undergoes hepatic metabolism by Cytochrome P450 3a4 and, to a minor extent, by CYP2C9. 	Cytochrome P450	50224	50239	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:257	Lenvatinib is metabolized in liver microsomes mostly through Cytochrome P450 3a4 (> 80%) and, to a minor extent, by aldehyde oxidase and acts as a substrate for Atp-Binding Cassette transporters, encoded by the ABCB1 and ABCG2 genes, such as BCRP and P-glycoprotein. 	Cytochrome P450	52236	52251	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:257	Lenvatinib is metabolized in liver microsomes mostly through Cytochrome P450 3a4 (> 80%) and, to a minor extent, by aldehyde oxidase and acts as a substrate for Atp-Binding Cassette transporters, encoded by the ABCB1 and ABCG2 genes, such as BCRP and P-glycoprotein. 	Cytochrome P450	52236	52251	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:1	 Overexpression of a Novel Cytochrome P450 Promotes Flavonoid Biosynthesis and Osmotic Stress Tolerance in Transgenic Arabidopsis. 	Cytochrome P450	27	42	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:1	 Overexpression of a Novel Cytochrome P450 Promotes Flavonoid Biosynthesis and Osmotic Stress Tolerance in Transgenic Arabidopsis. 	Cytochrome P450	27	42	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:4	However, the explicit regulation mechanism of Cytochrome P450s related to flavonoid biosynthesis largely remains elusive. 	Cytochrome P450	479	494	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:4	However, the explicit regulation mechanism of Cytochrome P450s related to flavonoid biosynthesis largely remains elusive. 	Cytochrome P450	479	494	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:206	The result of the qRT-PCR assays indicated that the expression level of most of the flavonoid pathway genes, including PAL (Phenylalanine ammonia lyase), Chalcone Isomerase (Chalcone isomerase), CYP82G1 (Cytochrome P450 monooxygenase), F3H (flavonoid 3-hydroxylase), and FLS (Flavonol synthase) were more abundantly up-regulated in the ARB3-CtCYP82G24 overexpression line than that of wild-type plant. 	Cytochrome P450	33395	33410	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6826380_OgerInput.txtOger_out.csv:206	The result of the qRT-PCR assays indicated that the expression level of most of the flavonoid pathway genes, including PAL (Phenylalanine ammonia lyase), Chalcone Isomerase (Chalcone isomerase), CYP82G1 (Cytochrome P450 monooxygenase), F3H (flavonoid 3-hydroxylase), and FLS (Flavonol synthase) were more abundantly up-regulated in the ARB3-CtCYP82G24 overexpression line than that of wild-type plant. 	Cytochrome P450	33395	33410	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:31	The heme-containing Cytochrome P450 enzymes activate molecular oxygen utilizing NADPH as an electron donor. 	Cytochrome P450	5147	5162	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:31	The heme-containing Cytochrome P450 enzymes activate molecular oxygen utilizing NADPH as an electron donor. 	Cytochrome P450	5147	5162	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:34	Cytochrome P450 enzymes involved in steroidogenesis can be divided into two groups based on their intracellular location and mode of electron transfer. 	Cytochrome P450	5516	5531	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:34	Cytochrome P450 enzymes involved in steroidogenesis can be divided into two groups based on their intracellular location and mode of electron transfer. 	Cytochrome P450	5516	5531	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:35	Cytochrome P450 type I enzymes are located within the inner mitochondrial membrane and are dependent on ferredoxin and ferredoxin reductase for the delivery of their electrons from NADPH. 	Cytochrome P450	5668	5683	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:35	Cytochrome P450 type I enzymes are located within the inner mitochondrial membrane and are dependent on ferredoxin and ferredoxin reductase for the delivery of their electrons from NADPH. 	Cytochrome P450	5668	5683	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:36	Ferredoxin reductase is a flavoprotein that oxidizes NADPH and transfers electrons to ferredoxin, a small iron-sulfur protein, which acts as a mobile electron carrier, delivering the electrons to the Cytochrome P450. 	Cytochrome P450	6056	6071	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:36	Ferredoxin reductase is a flavoprotein that oxidizes NADPH and transfers electrons to ferredoxin, a small iron-sulfur protein, which acts as a mobile electron carrier, delivering the electrons to the Cytochrome P450. 	Cytochrome P450	6056	6071	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:38	Cytochrome P450 type II enzymes are found in the Endoplasmic Reticulum and are dependent on the electron donor enzyme cytochrome P450 oxidoreductase for electron delivery. 	Cytochrome P450	6214	6229	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:38	Cytochrome P450 type II enzymes are found in the Endoplasmic Reticulum and are dependent on the electron donor enzyme cytochrome P450 oxidoreductase for electron delivery. 	Cytochrome P450	6214	6229	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:34	Cytochrome P450 enzymes involved in steroidogenesis can be divided into two groups based on their intracellular location and mode of electron transfer. 	Cytochrome P450 enzymes	5516	5539	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:186	In addition to the steroidogenic Cytochrome P450 enzymes described in Section, hepatic xenobiotic-metabolizing members of the Cytochrome P450 superfamily are able to modify steroid hormones and generate a plethora of minor steroid metabolites. 	Cytochrome P450 enzymes	31612	31635	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:126	Cytochrome P450 enzymes have potential uses in the synthesis and discovery of drugs, as well as drug development. 	Cytochrome P450 enzymes	23658	23681	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:127	Cytochrome P450 enzymes metabolize thousands of endogenous and exogenous chemicals. 	Cytochrome P450 enzymes	23772	23795	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:131	Cytochrome P450 enzymes are bound to membranes within a cell and contain a heme pigment that absorbs light at a wavelength of 450 nm when exposed to carbon monoxide. 	Cytochrome P450 enzymes	24528	24551	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:132	There are more than 50 Cytochrome P450 enzymes, but the CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 enzymes metabolize 90 percent of drugs. 	Cytochrome P450 enzymes	24717	24740	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6862182_OgerInput.txtOger_out.csv:133	Cytochrome P450 enzymes play a role in the synthesis of many molecules including steroid hormones, certain Fatty Acids (cholesterol and other fatty acids), and acids used to digest Fatty Acids (bile acids). 	Cytochrome P450 enzymes	24842	24865	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	Cyp2e1	8412	8418	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	Cyp2e1	8412	8418	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_522', 'CUI-less')
PMC5705655_OgerInput.txtOger_out.csv:53	Liver mRNA expression of Cyp1a2, Cyp3a11 (human CYP3A4) and Cyp2e1 was increased in mice treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (100, 200, 400, 800 mg/kg) for 12 h for different times, liver mRNA expression of Cyp1a2, Cyp2e1 and Cyp3a11 was increased in mice treated with 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (800 mg/kg) for 4 h, 8 h, and 12 h enhanced hepatic CYP1A2 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP1A2 expression after treated mice for 8 h and 12 h enhanced hepatic CYP2E1 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside only increased hepatic CYP2E1 expression after treated mice for 12 h enhanced hepatic CYP3A4 protein expression when mice were treated with different doses of 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside for 12 h for different times, 2,3,4,5-Tetrahydroxystilbene-2-O-Beta-D-Glucoside increased hepatic CYP3A4 expression after treated mice for 4 h, 8 h and 12 h (Fig. 	Cyp2e1	8613	8619	('Cytochromes', 'Cytochrome P-450 CYP2E1', 'NCCS', 'NCCS_524', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:182	Determination of (CD-1) mouse cutaneous RNA levels by real-time polymerase chain reaction showed transcripts arising from Cyp4f13 and 4f16(most abundant), Cyp4f18 and 4f39 (intermediate), Cyp4f14, 4f17, and 4f37 (low), and from Cyp4f15 and Cyp4f40 (highly variable or too low to measure in some animals) (Du et al.. In addition, the expression of the Cyp1a1, Cyp1b1, Cyp2e1 genes was observed in (C57BL/6J) mouse skin (Flowers et al.. Interestingly, recent studies by Borland et al. 	Cyp1a1	30329	30335	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:182	Determination of (CD-1) mouse cutaneous RNA levels by real-time polymerase chain reaction showed transcripts arising from Cyp4f13 and 4f16(most abundant), Cyp4f18 and 4f39 (intermediate), Cyp4f14, 4f17, and 4f37 (low), and from Cyp4f15 and Cyp4f40 (highly variable or too low to measure in some animals) (Du et al.. In addition, the expression of the Cyp1a1, Cyp1b1, Cyp2e1 genes was observed in (C57BL/6J) mouse skin (Flowers et al.. Interestingly, recent studies by Borland et al. 	Cyp1a1	30329	30335	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_366', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:187	Cyp1a1, Cyp1b1 and Cyp3a11, but not Ahr expression in the skin also were enhanced by 7,12-Dimethylbenz[A]Anthracene. 	Cyp1a1	31335	31341	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC5219702_OgerInput.txtOger_out.csv:184	Despite a lower constitutive expression of Cyp4a10 in the female hearts, acute DOX-induced cardiotoxicity caused a marked induction of Cyp4a10 in the hearts of both male and female mice, suggesting that this enzyme may not play an important role in the sexual dimorphism of DOX-induced cardiotoxicity. 	Cyp4a	32564	32569	('Cytochromes', 'Cytochrome P-450 CYP4A', 'NCCS', 'NCCS_618', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:300	Such a study would lead to a better knowledge of what combination of amino acid residues in a P450 enzyme distinguishes a ligand (a bound molecule that not reaches easily the productive step of the catalytic cycle) from a substrate (a bound molecule that reaches the productive step). 	P450 enzyme	52771	52782	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:21	For example, St Johns wort induces microsomal cytochrome P450 enzyme-mediated metabolism of warfarin, particularly CYP2C9 and increases warfarin clearance. 	P450 enzyme	3621	3632	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:21	For example, St Johns wort induces microsomal cytochrome P450 enzyme-mediated metabolism of warfarin, particularly CYP2C9 and increases warfarin clearance. 	P450 enzyme	3621	3632	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:39	P450 Oxidoreductase contains a flavin adenine dinucleotide and a flavin mononucleotide allowing the enzyme to oxidize NADPH and reduce the Cytochrome P450 enzyme in a stepwise manner. 	P450 enzyme	6536	6547	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:39	P450 Oxidoreductase contains a flavin adenine dinucleotide and a flavin mononucleotide allowing the enzyme to oxidize NADPH and reduce the Cytochrome P450 enzyme in a stepwise manner. 	P450 enzyme	6536	6547	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:9	CYP1A plays an important role in maintaining the health in the body.Image 1 The cytochrome P450 enzyme is one of the most abundant and diverse superfamilies, which contains hemoprotein. 	P450 enzyme	1199	1210	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:9	CYP1A plays an important role in maintaining the health in the body.Image 1 The cytochrome P450 enzyme is one of the most abundant and diverse superfamilies, which contains hemoprotein. 	P450 enzyme	1199	1210	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:62	The levels and ratio of the novel constituents varied depending on the P450 enzyme, with CYP712K1 favoring formation of 6 and CYP712K2 favoring formation of 5. 	P450 enzyme	11024	11035	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_357', 'CUI-less')
PMC6988343_OgerInput.txtOger_out.csv:62	The levels and ratio of the novel constituents varied depending on the P450 enzyme, with CYP712K1 favoring formation of 6 and CYP712K2 favoring formation of 5. 	P450 enzyme	11024	11035	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_355', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:85	The O-conformation is the one observed with substrate-free P450cam at low potassium ion concentration. 	P450cam	14629	14636	('Cytochromes', 'Camphor 5-Monooxygenase', 'NCCS', 'NCCS_417', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:147	To be helpful for drug development, we combined the descriptive models and the CBC-IVIVE further to extrapolate the CL_H of probe drugs for six Cytochrome P450 Enzymes. 	Cytochrome P450 Enzymes	27866	27889	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:130	A drug should not be rapidly metabolized by Cytochrome P450 Enzymes if it is to maintain an effective concentration. 	Cytochrome P450 Enzymes	20661	20684	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:131	In addition, it should not inhibit drug-metabolizing Cytochrome P450 Enzymes, because such an effect could elevate the concentration of a co-administered drug and potentially lead to drug overdose-an effect known as a drug-drug interaction (Murray,. 	Cytochrome P450 Enzymes	20787	20810	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:132	In drug development, in vitro assays are routinely used to assess interactions between drug candidates and Cytochrome P450 Enzymes. 	Cytochrome P450 Enzymes	21091	21114	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:133	However, there is a need for in silico models that assess potential interactions with Cytochrome P450 Enzymes in the early stages of drug development. 	Cytochrome P450 Enzymes	21202	21225	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:136	For all Cytochrome P450 Enzymes, we classified inhibitors and non-inhibitors as positives and negatives, respectively. 	Cytochrome P450 Enzymes	21699	21722	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:1	 Ligand Access Channels in Cytochrome P450 Enzymes: A Review. 	Cytochrome P450 Enzymes	27	50	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_346', 'CUI-less')
PMC5696450_OgerInput.txtOger_out.csv:147	To be helpful for drug development, we combined the descriptive models and the CBC-IVIVE further to extrapolate the CL_H of probe drugs for six Cytochrome P450 Enzymes. 	P450 Enzymes	27877	27889	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:130	A drug should not be rapidly metabolized by Cytochrome P450 Enzymes if it is to maintain an effective concentration. 	P450 Enzymes	20672	20684	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:130	A drug should not be rapidly metabolized by Cytochrome P450 Enzymes if it is to maintain an effective concentration. 	P450 Enzymes	20672	20684	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:131	In addition, it should not inhibit drug-metabolizing Cytochrome P450 Enzymes, because such an effect could elevate the concentration of a co-administered drug and potentially lead to drug overdose-an effect known as a drug-drug interaction (Murray,. 	P450 Enzymes	20798	20810	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:131	In addition, it should not inhibit drug-metabolizing Cytochrome P450 Enzymes, because such an effect could elevate the concentration of a co-administered drug and potentially lead to drug overdose-an effect known as a drug-drug interaction (Murray,. 	P450 Enzymes	20798	20810	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:132	In drug development, in vitro assays are routinely used to assess interactions between drug candidates and Cytochrome P450 Enzymes. 	P450 Enzymes	21102	21114	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:132	In drug development, in vitro assays are routinely used to assess interactions between drug candidates and Cytochrome P450 Enzymes. 	P450 Enzymes	21102	21114	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:133	However, there is a need for in silico models that assess potential interactions with Cytochrome P450 Enzymes in the early stages of drug development. 	P450 Enzymes	21213	21225	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:133	However, there is a need for in silico models that assess potential interactions with Cytochrome P450 Enzymes in the early stages of drug development. 	P450 Enzymes	21213	21225	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:136	For all Cytochrome P450 Enzymes, we classified inhibitors and non-inhibitors as positives and negatives, respectively. 	P450 Enzymes	21710	21722	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC5722789_OgerInput.txtOger_out.csv:136	For all Cytochrome P450 Enzymes, we classified inhibitors and non-inhibitors as positives and negatives, respectively. 	P450 Enzymes	21710	21722	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:1	 Ligand Access Channels in Cytochrome P450 Enzymes: A Review. 	P450 Enzymes	38	50	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC6032366_OgerInput.txtOger_out.csv:1	 Ligand Access Channels in Cytochrome P450 Enzymes: A Review. 	P450 Enzymes	38	50	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_356', 'CUI-less')
PMC6344987_OgerInput.txtOger_out.csv:4	Influence of mentioned extracts and their key constituents on warfarin pharmacodynamic and kinetic actions and Cytochrome P450 Enzymes activity were evaluated. 	P450 Enzymes	805	817	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_358', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:121	Nevertheless, the molecular mechanisms underlying this dual effect of Carbon Monoxide on cytochrome c oxidase activity is not yet clearly disclosed. 	cytochrome c	21224	21236	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:121	Nevertheless, the molecular mechanisms underlying this dual effect of Carbon Monoxide on cytochrome c oxidase activity is not yet clearly disclosed. 	cytochrome c	21224	21236	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7049654_OgerInput.txtOger_out.csv:229	The fact that Carbon Monoxide targets mitochondria, in particular cytochrome c oxidase, originates several consequences: (i) generation of ROS for downstream signaling, (ii) alterations in oxygen consumption implying uncoupling effects and/or improvement of mitochondrial respiration and ATP production, (iii) regulation of mitochondrial quality control, including mitochondrial biogenesis, Mitochondria Via Autophagy and fusion/fission. 	cytochrome c	39270	39282	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7049654_OgerInput.txtOger_out.csv:229	The fact that Carbon Monoxide targets mitochondria, in particular cytochrome c oxidase, originates several consequences: (i) generation of ROS for downstream signaling, (ii) alterations in oxygen consumption implying uncoupling effects and/or improvement of mitochondrial respiration and ATP production, (iii) regulation of mitochondrial quality control, including mitochondrial biogenesis, Mitochondria Via Autophagy and fusion/fission. 	cytochrome c	39270	39282	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7069944_OgerInput.txtOger_out.csv:301	Citrate synthase and complex I-IV activities were determined by monitoring appearance or disappearance of specific substrates at specific wavelengths using spectrophotometry (eg, oxidation of NADH for complex I activity at 340 nm in the presence and absence of rotenone to evaluate complex I-specific activity, reduction of cytochrome c for complex III activity at 550 nm). 	cytochrome c	53382	53394	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7069944_OgerInput.txtOger_out.csv:301	Citrate synthase and complex I-IV activities were determined by monitoring appearance or disappearance of specific substrates at specific wavelengths using spectrophotometry (eg, oxidation of NADH for complex I activity at 340 nm in the presence and absence of rotenone to evaluate complex I-specific activity, reduction of cytochrome c for complex III activity at 550 nm). 	cytochrome c	53382	53394	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:1	 Porcine deltacoronavirus induces caspase-dependent apoptosis through activation of the cytochrome c-mediated intrinsic mitochondrial pathway. 	cytochrome c	88	100	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:1	 Porcine deltacoronavirus induces caspase-dependent apoptosis through activation of the cytochrome c-mediated intrinsic mitochondrial pathway. 	cytochrome c	88	100	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:4	PDCoV-mediated Mitochondrial Outer Membrane Permeabilization resulted in apoptogenic cytochrome c release into the cytoplasm. 	cytochrome c	498	510	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:4	PDCoV-mediated Mitochondrial Outer Membrane Permeabilization resulted in apoptogenic cytochrome c release into the cytoplasm. 	cytochrome c	498	510	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:5	Mitochondrial cytochrome c leakage executed apoptotic cell death in Porcine Deltacoronavirus infection. 	cytochrome c	553	565	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:5	Mitochondrial cytochrome c leakage executed apoptotic cell death in Porcine Deltacoronavirus infection. 	cytochrome c	553	565	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:9	PDCoV-mediated Mitochondrial Outer Membrane Permeabilization resulted in apoptogenic cytochrome c release into the cytoplasm. 	cytochrome c	1102	1114	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:9	PDCoV-mediated Mitochondrial Outer Membrane Permeabilization resulted in apoptogenic cytochrome c release into the cytoplasm. 	cytochrome c	1102	1114	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:10	Mitochondrial cytochrome c leakage executed apoptotic cell death in Porcine Deltacoronavirus infection. 	cytochrome c	1157	1169	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:10	Mitochondrial cytochrome c leakage executed apoptotic cell death in Porcine Deltacoronavirus infection. 	cytochrome c	1157	1169	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:16	Experimental data indicated that Porcine Deltacoronavirus infection led to Bax-mediated mitochondrial outer membrane permeabilization, resulting in specific relocation of the mitochondrial cytochrome c (cyt c) into the cytoplasm. 	cytochrome c	2279	2291	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:16	Experimental data indicated that Porcine Deltacoronavirus infection led to Bax-mediated mitochondrial outer membrane permeabilization, resulting in specific relocation of the mitochondrial cytochrome c (cyt c) into the cytoplasm. 	cytochrome c	2279	2291	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7114866_OgerInput.txtOger_out.csv:42	Antibodies specific for cytochrome c (cyt c), apoptosis-inducing factor, Bax, Sp1, and BETA-actin and horseradish peroxidase (HRP)-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 	cytochrome c	6588	6600	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7114866_OgerInput.txtOger_out.csv:42	Antibodies specific for cytochrome c (cyt c), apoptosis-inducing factor, Bax, Sp1, and BETA-actin and horseradish peroxidase (HRP)-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). 	cytochrome c	6588	6600	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:4	In a proof-of-concept study, confocal Raman microscopy with excitation resonant to the heme c moiety of cytochrome c was used to compare the cytochrome c content and activity of stressed and unstressed Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) in vivo. 	cytochrome c	623	635	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:4	In a proof-of-concept study, confocal Raman microscopy with excitation resonant to the heme c moiety of cytochrome c was used to compare the cytochrome c content and activity of stressed and unstressed Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) in vivo. 	cytochrome c	623	635	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:4	In a proof-of-concept study, confocal Raman microscopy with excitation resonant to the heme c moiety of cytochrome c was used to compare the cytochrome c content and activity of stressed and unstressed Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) in vivo. 	cytochrome c	660	672	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:4	In a proof-of-concept study, confocal Raman microscopy with excitation resonant to the heme c moiety of cytochrome c was used to compare the cytochrome c content and activity of stressed and unstressed Nitrosomonas europaea (Nm 50), Nitrosomonas eutropha (Nm 57), Nitrosospira briensis (Nsp 10), and Nitrosospira species (Nsp 02) in vivo. 	cytochrome c	660	672	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:8	In addition, cells with predominantly ferrous cytochrome c content were found in deprived Nitrosomonas eutropha and Nitrosospira samples, which may be indicative of ongoing electron storage at the time of measurement. 	cytochrome c	1285	1297	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:8	In addition, cells with predominantly ferrous cytochrome c content were found in deprived Nitrosomonas eutropha and Nitrosospira samples, which may be indicative of ongoing electron storage at the time of measurement. 	cytochrome c	1285	1297	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:24	The electron transport along these pathways is predominantly performed by several cytochrome c proteins, some of which hold more than one heme c in their protic matrix. 	cytochrome c	4191	4203	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:24	The electron transport along these pathways is predominantly performed by several cytochrome c proteins, some of which hold more than one heme c in their protic matrix. 	cytochrome c	4191	4203	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:25	For a scheme of the electron transport and the ammonia oxidation pathways for N. europaea, including the associated cytochrome c proteins, see Sedlacek et al.. A comparative quantitative proteomic study of growing and ammonia-starved N. europaea cells by Pellitteri-Hahn et al. 	cytochrome c	4394	4406	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:25	For a scheme of the electron transport and the ammonia oxidation pathways for N. europaea, including the associated cytochrome c proteins, see Sedlacek et al.. A comparative quantitative proteomic study of growing and ammonia-starved N. europaea cells by Pellitteri-Hahn et al. 	cytochrome c	4394	4406	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:26	found that energy-starved cells shifted their cellular activity from biosynthesis toward cellular survival functions, reporting a significantly increased abundance of cytochrome c in the ammonia-starved cells as compared to growing cells, which was interpreted as a cellular strategy for a rapid growth response. 	cytochrome c	4723	4735	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:26	found that energy-starved cells shifted their cellular activity from biosynthesis toward cellular survival functions, reporting a significantly increased abundance of cytochrome c in the ammonia-starved cells as compared to growing cells, which was interpreted as a cellular strategy for a rapid growth response. 	cytochrome c	4723	4735	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:29	The mRNA levels for cytochrome c reported by Wei et al. 	cytochrome c	5150	5162	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:29	The mRNA levels for cytochrome c reported by Wei et al. 	cytochrome c	5150	5162	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:44	While the crucial enzymes AMO, HAO, and NOR of the ammonia oxidation pathways were not directly accessible with Raman microscopy in vivo, it was possible to target the cytochrome c responsible for the required electron transport along these pathways with resonance Raman micro-spectroscopy, a technique also uniquely positioned to determine conformational changes of cytochrome c and its redox state (ferrous versus ferric hemes c). 	cytochrome c	7569	7581	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:44	While the crucial enzymes AMO, HAO, and NOR of the ammonia oxidation pathways were not directly accessible with Raman microscopy in vivo, it was possible to target the cytochrome c responsible for the required electron transport along these pathways with resonance Raman micro-spectroscopy, a technique also uniquely positioned to determine conformational changes of cytochrome c and its redox state (ferrous versus ferric hemes c). 	cytochrome c	7569	7581	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:44	While the crucial enzymes AMO, HAO, and NOR of the ammonia oxidation pathways were not directly accessible with Raman microscopy in vivo, it was possible to target the cytochrome c responsible for the required electron transport along these pathways with resonance Raman micro-spectroscopy, a technique also uniquely positioned to determine conformational changes of cytochrome c and its redox state (ferrous versus ferric hemes c). 	cytochrome c	7768	7780	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:44	While the crucial enzymes AMO, HAO, and NOR of the ammonia oxidation pathways were not directly accessible with Raman microscopy in vivo, it was possible to target the cytochrome c responsible for the required electron transport along these pathways with resonance Raman micro-spectroscopy, a technique also uniquely positioned to determine conformational changes of cytochrome c and its redox state (ferrous versus ferric hemes c). 	cytochrome c	7768	7780	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:45	Hu et al., in their annotation of the resonance Raman spectra of extracted cytochrome c, previously reported large changes in both the resonant excitation wavelength and the specifically enhanced molecular vibrations dependent on the redox state of the protein. 	cytochrome c	7909	7921	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:45	Hu et al., in their annotation of the resonance Raman spectra of extracted cytochrome c, previously reported large changes in both the resonant excitation wavelength and the specifically enhanced molecular vibrations dependent on the redox state of the protein. 	cytochrome c	7909	7921	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:48	cm^1, which at 532 nm excitation is one of the strongest Raman lines in ferrous cytochrome c, but is very weak if the protein is in ferric state. 	cytochrome c	8328	8340	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:48	cm^1, which at 532 nm excitation is one of the strongest Raman lines in ferrous cytochrome c, but is very weak if the protein is in ferric state. 	cytochrome c	8328	8340	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:50	used Raman microscopy with cytochrome-c-resonant excitation at 532 nm, using the redox state of cytochrome c as a crucial indicator for cell apoptosis, while Kakita et al. 	cytochrome c	8513	8525	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:50	used Raman microscopy with cytochrome-c-resonant excitation at 532 nm, using the redox state of cytochrome c as a crucial indicator for cell apoptosis, while Kakita et al. 	cytochrome c	8513	8525	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:53	monitored photothermally induced mitochondrially mediated apoptosis in situ based on the Raman spectrum of cytochrome c, using surface-enhanced resonant Raman microscopy with gold nanoparticles and 785 nm excitation. 	cytochrome c	8792	8804	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:53	monitored photothermally induced mitochondrially mediated apoptosis in situ based on the Raman spectrum of cytochrome c, using surface-enhanced resonant Raman microscopy with gold nanoparticles and 785 nm excitation. 	cytochrome c	8792	8804	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:55	for the quantitative detection of cytochrome c in living cells, and Zhu et al. 	cytochrome c	9003	9015	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:55	for the quantitative detection of cytochrome c in living cells, and Zhu et al. 	cytochrome c	9003	9015	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:56	studied the influence of redox state on cytochrome c release in apoptosis using Raman microscopy with nickel substrates. 	cytochrome c	9088	9100	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:56	studied the influence of redox state on cytochrome c release in apoptosis using Raman microscopy with nickel substrates. 	cytochrome c	9088	9100	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:57	In this work, we present a proof of concept of the use of straightforward confocal Raman microscopy with 532 nm excitation, resonant to the Q-band of the heme c moiety in cytochrome c, to non-invasively and in vivo analyze the response of four species of AOB, Nitrosomonas europaea, Nitrosomonas eutropha, Nitrosospira briensis, and Nitrosospira species. 	cytochrome c	9340	9352	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:57	In this work, we present a proof of concept of the use of straightforward confocal Raman microscopy with 532 nm excitation, resonant to the Q-band of the heme c moiety in cytochrome c, to non-invasively and in vivo analyze the response of four species of AOB, Nitrosomonas europaea, Nitrosomonas eutropha, Nitrosospira briensis, and Nitrosospira species. 	cytochrome c	9340	9352	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:58	to oxygen deprivation in comparison to non-oxygen-deprived cultures based on 1000 individual cells per sampling, confirming elevated cytochrome c content and activity following oxygen deprivation in a purely optical measurement with low impact on culture volumes. 	cytochrome c	9657	9669	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:58	to oxygen deprivation in comparison to non-oxygen-deprived cultures based on 1000 individual cells per sampling, confirming elevated cytochrome c content and activity following oxygen deprivation in a purely optical measurement with low impact on culture volumes. 	cytochrome c	9657	9669	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:79	A frequency-doubled continuous-wave Nd:YAG laser at 531.9 nm, suitable for resonantly enhancing the Q-band of the heme c moiety of cytochrome c in its ferrous (Fe^2+) state, was used for excitation. 	cytochrome c	13036	13048	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:79	A frequency-doubled continuous-wave Nd:YAG laser at 531.9 nm, suitable for resonantly enhancing the Q-band of the heme c moiety of cytochrome c in its ferrous (Fe^2+) state, was used for excitation. 	cytochrome c	13036	13048	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:105	The Raman lines of the four main vibrations of resonantly excited cytochrome c, _15, _22, _21, and _19 at 750, 1130, 1314, and 1587 rel. 	cytochrome c	16061	16073	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:105	The Raman lines of the four main vibrations of resonantly excited cytochrome c, _15, _22, _21, and _19 at 750, 1130, 1314, and 1587 rel. 	cytochrome c	16061	16073	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:111	This fit perfectly with the results of Hu et al., who analyzed reconstituted cytochrome c protein in potassium phosphate buffer solution, identifying the lines in the complete resonance Raman spectra of ferrous and ferric cytochrome c. With 532 nm excitation, they found the Raman line of the _15 vibration at 750 rel. 	cytochrome c	16670	16682	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:111	This fit perfectly with the results of Hu et al., who analyzed reconstituted cytochrome c protein in potassium phosphate buffer solution, identifying the lines in the complete resonance Raman spectra of ferrous and ferric cytochrome c. With 532 nm excitation, they found the Raman line of the _15 vibration at 750 rel. 	cytochrome c	16670	16682	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:111	This fit perfectly with the results of Hu et al., who analyzed reconstituted cytochrome c protein in potassium phosphate buffer solution, identifying the lines in the complete resonance Raman spectra of ferrous and ferric cytochrome c. With 532 nm excitation, they found the Raman line of the _15 vibration at 750 rel. 	cytochrome c	16815	16827	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:111	This fit perfectly with the results of Hu et al., who analyzed reconstituted cytochrome c protein in potassium phosphate buffer solution, identifying the lines in the complete resonance Raman spectra of ferrous and ferric cytochrome c. With 532 nm excitation, they found the Raman line of the _15 vibration at 750 rel. 	cytochrome c	16815	16827	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:112	cm^1 to be among the strongest lines in the spectrum of ferrous cytochrome c, but among the weakest lines in ferric cytochrome c, whereas the Raman line of the _19 vibration at 1587 rel. 	cytochrome c	16976	16988	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:112	cm^1 to be among the strongest lines in the spectrum of ferrous cytochrome c, but among the weakest lines in ferric cytochrome c, whereas the Raman line of the _19 vibration at 1587 rel. 	cytochrome c	16976	16988	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:112	cm^1 to be among the strongest lines in the spectrum of ferrous cytochrome c, but among the weakest lines in ferric cytochrome c, whereas the Raman line of the _19 vibration at 1587 rel. 	cytochrome c	17028	17040	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:112	cm^1 to be among the strongest lines in the spectrum of ferrous cytochrome c, but among the weakest lines in ferric cytochrome c, whereas the Raman line of the _19 vibration at 1587 rel. 	cytochrome c	17028	17040	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:118	cm^1 and used it to differentiate between healthy and apoptotic and pre-apoptotic brain cells of Mongolian gerbils, associating the line shift with cytochrome c deformation due to the protein binding to membrane elements. 	cytochrome c	17507	17519	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:118	cm^1 and used it to differentiate between healthy and apoptotic and pre-apoptotic brain cells of Mongolian gerbils, associating the line shift with cytochrome c deformation due to the protein binding to membrane elements. 	cytochrome c	17507	17519	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:119	A similar observation was reported earlier by Murgida and Hildebrandt, who saw a 10 cm^1 upshift in the line of the _19 vibration in ferrous compared to ferric cytochrome c adsorbed to a surface-enhanced Raman active substrate. 	cytochrome c	17741	17753	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:119	A similar observation was reported earlier by Murgida and Hildebrandt, who saw a 10 cm^1 upshift in the line of the _19 vibration in ferrous compared to ferric cytochrome c adsorbed to a surface-enhanced Raman active substrate. 	cytochrome c	17741	17753	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:121	cm^1, which would be caused by such a shift in the spectra of some but not all the cytochrome c within the respective cell, therefore indicated that the observed differences in the summarized cytochrome c resonant Raman spectra of the bacteria were indeed primarily due to the redox state of the cytochrome c, as analyzed by Hu et al., and thus to their electron transport function, and not due to deformations caused by other stress reactions of the respective cells. 	cytochrome c	17961	17973	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:121	cm^1, which would be caused by such a shift in the spectra of some but not all the cytochrome c within the respective cell, therefore indicated that the observed differences in the summarized cytochrome c resonant Raman spectra of the bacteria were indeed primarily due to the redox state of the cytochrome c, as analyzed by Hu et al., and thus to their electron transport function, and not due to deformations caused by other stress reactions of the respective cells. 	cytochrome c	17961	17973	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:121	cm^1, which would be caused by such a shift in the spectra of some but not all the cytochrome c within the respective cell, therefore indicated that the observed differences in the summarized cytochrome c resonant Raman spectra of the bacteria were indeed primarily due to the redox state of the cytochrome c, as analyzed by Hu et al., and thus to their electron transport function, and not due to deformations caused by other stress reactions of the respective cells. 	cytochrome c	18070	18082	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:121	cm^1, which would be caused by such a shift in the spectra of some but not all the cytochrome c within the respective cell, therefore indicated that the observed differences in the summarized cytochrome c resonant Raman spectra of the bacteria were indeed primarily due to the redox state of the cytochrome c, as analyzed by Hu et al., and thus to their electron transport function, and not due to deformations caused by other stress reactions of the respective cells. 	cytochrome c	18070	18082	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:121	cm^1, which would be caused by such a shift in the spectra of some but not all the cytochrome c within the respective cell, therefore indicated that the observed differences in the summarized cytochrome c resonant Raman spectra of the bacteria were indeed primarily due to the redox state of the cytochrome c, as analyzed by Hu et al., and thus to their electron transport function, and not due to deformations caused by other stress reactions of the respective cells. 	cytochrome c	18174	18186	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:121	cm^1, which would be caused by such a shift in the spectra of some but not all the cytochrome c within the respective cell, therefore indicated that the observed differences in the summarized cytochrome c resonant Raman spectra of the bacteria were indeed primarily due to the redox state of the cytochrome c, as analyzed by Hu et al., and thus to their electron transport function, and not due to deformations caused by other stress reactions of the respective cells. 	cytochrome c	18174	18186	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:122	Therefore, the relative intensity (I_Raman) of the two Raman lines (relRI) could be used as a functional marker for the summarized redox state (ferrous versus ferric) of all the cytochrome c of the respective bacterial cell, and thus its ongoing electron transport activity at the time of measurement  with I_Raman being the intensity of the Raman line associated with the respective vibration in the spectrum of that individual bacterial cell. 	cytochrome c	18525	18537	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:122	Therefore, the relative intensity (I_Raman) of the two Raman lines (relRI) could be used as a functional marker for the summarized redox state (ferrous versus ferric) of all the cytochrome c of the respective bacterial cell, and thus its ongoing electron transport activity at the time of measurement  with I_Raman being the intensity of the Raman line associated with the respective vibration in the spectrum of that individual bacterial cell. 	cytochrome c	18525	18537	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:136	The elevated cytochrome c activity of oxygen-deprived N. eutropha and Nitrosospira fit well with the results reported by Sedlacek et al. 	cytochrome c	22228	22240	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:136	The elevated cytochrome c activity of oxygen-deprived N. eutropha and Nitrosospira fit well with the results reported by Sedlacek et al. 	cytochrome c	22228	22240	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:137	and Pellitteri-Hahn et al., whose works indicated a significant increase in the cytochrome c content of stressed cells, but contradicted Wei et al., who reported mRNA levels for cytochrome c in growing cells to exceed those of energy-starved cells by a factor of 10. 	cytochrome c	22432	22444	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:137	and Pellitteri-Hahn et al., whose works indicated a significant increase in the cytochrome c content of stressed cells, but contradicted Wei et al., who reported mRNA levels for cytochrome c in growing cells to exceed those of energy-starved cells by a factor of 10. 	cytochrome c	22432	22444	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:137	and Pellitteri-Hahn et al., whose works indicated a significant increase in the cytochrome c content of stressed cells, but contradicted Wei et al., who reported mRNA levels for cytochrome c in growing cells to exceed those of energy-starved cells by a factor of 10. 	cytochrome c	22530	22542	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:137	and Pellitteri-Hahn et al., whose works indicated a significant increase in the cytochrome c content of stressed cells, but contradicted Wei et al., who reported mRNA levels for cytochrome c in growing cells to exceed those of energy-starved cells by a factor of 10. 	cytochrome c	22530	22542	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:139	used transcriptomics on stressed N. europaea to elucidate the stress response to either ammonia or oxygen limitation, reporting that the transcripts for protein-encoding genes related to energy production and conservation, including for the proteins AMO, HAO, and NOR, were increased during oxygen-deprived growth, while three cytochrome c proteins associated with the ammonia-oxidizing pathway were even among the top 20% of genes transcribed under stress conditions. 	cytochrome c	22962	22974	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:139	used transcriptomics on stressed N. europaea to elucidate the stress response to either ammonia or oxygen limitation, reporting that the transcripts for protein-encoding genes related to energy production and conservation, including for the proteins AMO, HAO, and NOR, were increased during oxygen-deprived growth, while three cytochrome c proteins associated with the ammonia-oxidizing pathway were even among the top 20% of genes transcribed under stress conditions. 	cytochrome c	22962	22974	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:140	Kozlowski et al., who compared the metabolism pathways of several AOB based on micro-respirometry and genome analysis, confirmed that these enzymes and cytochrome c proteins are encoded in multiple copies by N. europaea, N. eutropha, and Nitrosospira, including the associated cytochrome c proteins. 	cytochrome c	23256	23268	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:140	Kozlowski et al., who compared the metabolism pathways of several AOB based on micro-respirometry and genome analysis, confirmed that these enzymes and cytochrome c proteins are encoded in multiple copies by N. europaea, N. eutropha, and Nitrosospira, including the associated cytochrome c proteins. 	cytochrome c	23256	23268	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:140	Kozlowski et al., who compared the metabolism pathways of several AOB based on micro-respirometry and genome analysis, confirmed that these enzymes and cytochrome c proteins are encoded in multiple copies by N. europaea, N. eutropha, and Nitrosospira, including the associated cytochrome c proteins. 	cytochrome c	23381	23393	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:140	Kozlowski et al., who compared the metabolism pathways of several AOB based on micro-respirometry and genome analysis, confirmed that these enzymes and cytochrome c proteins are encoded in multiple copies by N. europaea, N. eutropha, and Nitrosospira, including the associated cytochrome c proteins. 	cytochrome c	23381	23393	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:141	The observed differences in cytochrome c activity of Nitrosospira briensis and Nitrosospira species (Nsp 02) correlated well with their respective oxygenation histories (compare. 	cytochrome c	23432	23444	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:141	The observed differences in cytochrome c activity of Nitrosospira briensis and Nitrosospira species (Nsp 02) correlated well with their respective oxygenation histories (compare. 	cytochrome c	23432	23444	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:142	Nitrosospira briensis has been reported to have decreasing AMO mRNA expression during starvation, but to rapidly recover after starvation periods of up to two weeks, with only small changes in the soluble proteins, including cytochrome c, between growing and ammonium-starved cells. 	cytochrome c	23808	23820	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:142	Nitrosospira briensis has been reported to have decreasing AMO mRNA expression during starvation, but to rapidly recover after starvation periods of up to two weeks, with only small changes in the soluble proteins, including cytochrome c, between growing and ammonium-starved cells. 	cytochrome c	23808	23820	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:147	However, the relRI trends of N. europaea did not show an elevated cytochrome c activity indicative of a noticeable stress response in its cells at all (see b). 	cytochrome c	24385	24397	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:147	However, the relRI trends of N. europaea did not show an elevated cytochrome c activity indicative of a noticeable stress response in its cells at all (see b). 	cytochrome c	24385	24397	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:153	Interestingly, the oxygen-deprived N. eutropha appeared to have a significantly more evenly distributed cytochrome c activity, with its relRI ranging from 1.7 to 1.9, than non-deprived N. eutropha, with a relRI range from 1.2 to 1.75 (see. 	cytochrome c	25536	25548	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:153	Interestingly, the oxygen-deprived N. eutropha appeared to have a significantly more evenly distributed cytochrome c activity, with its relRI ranging from 1.7 to 1.9, than non-deprived N. eutropha, with a relRI range from 1.2 to 1.75 (see. 	cytochrome c	25536	25548	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7143505_OgerInput.txtOger_out.csv:96	Since cytochrome-c-resonant Raman spectra always contain a fluorescent background originating from the cytochrome itself, the Raman spectra were baseline corrected using the IMM algorithm developed by Koch et al., which combines computational efficiency with reliable maintaining of line shapes and relative intensities against the background of strong fluorescence often found in Raman spectra recorded in vivo. 	cytochrome-c	14664	14676	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7143505_OgerInput.txtOger_out.csv:96	Since cytochrome-c-resonant Raman spectra always contain a fluorescent background originating from the cytochrome itself, the Raman spectra were baseline corrected using the IMM algorithm developed by Koch et al., which combines computational efficiency with reliable maintaining of line shapes and relative intensities against the background of strong fluorescence often found in Raman spectra recorded in vivo. 	cytochrome-c	14664	14676	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:12	Human thromboxane synthase belongs to the cytochrome P450 superfamily (CYP5A1). 	cytochrome P450 superfamily	1915	1942	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_353', 'CUI-less')
PMC5947935_OgerInput.txtOger_out.csv:107	^ While MCF-7 cells used to develop the ER-Luc cells express metabolic enzymes from the cytochrome P450 superfamily (and thus possess the ability for endogenous biotransformation of chemicals), formation of MBP was dependent on the presence of S9 enzymes. 	cytochrome P450 superfamily	23273	23300	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_350', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:179	and the highest andrographolide was detected in leaf as compared to other panchang (Pandey and Mandal ; Sharma et al.. Therefore, some other isomers of cytochrome p450 (cytochrome p450 98, cytochrome p450 706, etc.) 	cytochrome p450	27113	27128	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:179	and the highest andrographolide was detected in leaf as compared to other panchang (Pandey and Mandal ; Sharma et al.. Therefore, some other isomers of cytochrome p450 (cytochrome p450 98, cytochrome p450 706, etc.) 	cytochrome p450	27130	27145	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC7648546_OgerInput.txtOger_out.csv:179	and the highest andrographolide was detected in leaf as compared to other panchang (Pandey and Mandal ; Sharma et al.. Therefore, some other isomers of cytochrome p450 (cytochrome p450 98, cytochrome p450 706, etc.) 	cytochrome p450	27130	27145	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:69	Ellipticine oxidation does not only occur in the presence of the coenzymes of POR, NADPH, but also in the presence of NADH, which is the exclusive coenzyme of another microsomal reductase, NADH:cytochrome b _5 reductase. 	cytochrome b	14427	14439	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b	14487	14499	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b	14631	14643	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b	14661	14673	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:71	Our data confirmed previous results found for CYP3A4 and for CYP1A1 that NADH:cytochrome b _5 reductase/cytochrome b _5/NADH can replace NADPH/POR in the catalytic cycle of the CYP reactions in the monooxygenase system [,. 	cytochrome b	14814	14826	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:71	Our data confirmed previous results found for CYP3A4 and for CYP1A1 that NADH:cytochrome b _5 reductase/cytochrome b _5/NADH can replace NADPH/POR in the catalytic cycle of the CYP reactions in the monooxygenase system [,. 	cytochrome b	14840	14852	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:77	The results of our present study as well as those reported previously indicated that cytochrome b _5 can play a dual role in the CYP3A4-mediated oxidation of ellipticine. 	cytochrome b	15979	15991	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:79	The finding that cytochrome b _5 with its reductase, NADH:cytochrome b _5 reductase, functions as an exclusive donor for both electrons in the first and second reduction steps of the CYP3A4-catalyzed oxidation of ellipticine opens the door for further research. 	cytochrome b	16256	16268	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:79	The finding that cytochrome b _5 with its reductase, NADH:cytochrome b _5 reductase, functions as an exclusive donor for both electrons in the first and second reduction steps of the CYP3A4-catalyzed oxidation of ellipticine opens the door for further research. 	cytochrome b	16297	16309	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:85	However, because they are microsomes (particles of broken endoplasmic reticulum), other enzymes (proteins) of the endoplasmic reticulum membrane (ie NADH:cytochrome b _5 reductase and cytochrome b _5) are also expressed at basal levels in these Supersomes (Gentest Corp., Woburn, MI, USA). 	cytochrome b	17248	17260	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:85	However, because they are microsomes (particles of broken endoplasmic reticulum), other enzymes (proteins) of the endoplasmic reticulum membrane (ie NADH:cytochrome b _5 reductase and cytochrome b _5) are also expressed at basal levels in these Supersomes (Gentest Corp., Woburn, MI, USA). 	cytochrome b	17278	17290	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:86	We also utilized CYP3A4-Supersomes which also contained over-expressed cytochrome b _5, in a molar ratio of CYP3A4 to cytochrome b _5 of 1-5 (Gentest Corp., Woburn, MI, USA). 	cytochrome b	17455	17467	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:86	We also utilized CYP3A4-Supersomes which also contained over-expressed cytochrome b _5, in a molar ratio of CYP3A4 to cytochrome b _5 of 1-5 (Gentest Corp., Woburn, MI, USA). 	cytochrome b	17502	17514	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:89	Incubation mixtures used to study the ellipticine metabolism by human hepatic microsomes or Supersomes contained in a final volume of 0.5 cm^3 100 mmol dm^3 potassium phosphate buffer (pH 7.4), 1 mmol dm^3 NADPH or NADH, 0.025 mmol dm^3 ellipticine (dissolved in 0.005 cm^3 dimethyl sulfoxide, DMSO) and 0.5 mg protein of human hepatic microsomes or 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5. 	cytochrome b	18060	18072	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:97	The incubation mixtures for measuring the testosterone metabolism contained in a final volume of 0.5 cm^3: 100 mmol dm^3 potassium phosphate buffer (pH 7.4), 50 mol dm^3 testosterone (0.0025 cm^3 of stock methanol solution per incubation), 1 mmol dm^3 NADPH or NADH, and 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5. 	cytochrome b	19426	19438	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:107	Incubation mixtures used to assess DNA adduct formation by ellipticine contained 0.5 mg protein of human hepatic microsomes or 100 nmol dm^3 human recombinant CYP3A4 in Supersomes either with or without cytochrome b _5, 0.1 mmol dm^3 ellipticine (dissolved in 0.0075 cm^3 methanol), and 0.5 mg of calf thymus DNA in a final volume of 0.75 cm^3 as described previously [,. 	cytochrome b	20690	20702	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:50	The incubation mixture included 5 pmol wild-type CYP3A4*1 or other CYP3A4 mutants, 5 pmol purified cytochrome b5, lidocaine and 100 mmol/L potassium phosphate buffer (pH 7.4). 	cytochrome b	8452	8464	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5754280_OgerInput.txtOger_out.csv:114	However, reduction of CoM-S-S-CoB is catalyzed by a membrane-bound heterodisulfide reductase, which obtains electrons from reduced methanophenazine (MPhH_2, functionally analogous to quinoles) via its cytochrome b subunit, which is coupled to the generation of a proton motive force. 	cytochrome b	17621	17633	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5754280_OgerInput.txtOger_out.csv:115	During hydrogenotrophic methanogenesis, a membrane-bound (F_420 non-reducing) hydrogenase (Vho) oxidizes H_2 and transfers electrons via cytochrome b to oxidized methanophenazine, again generating a proton motive force. 	cytochrome b	17841	17853	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:62	Sort=Bait, cytochromes P450 (limonene 6-monooxygenase (CYP2C19), steroid-20,22-lyase (CYP11A1), steroid-11BETA-hydroxylase (CYP11V1), aldosterone synthase (CYP11B2), taurochenodeoxycholate-6ALPHA-monooxygenase (CYP3A4), cyclic hydrocarbon hydroxylase (CYP3A5), 4-nitrophenol-2-hydroxylase (CYP2E1), microsomal cytochrome b5 (CYB5A), NADPH-cytochrome-P450-reductase, NADPH-adrenodoxin reductase, adrenodoxin, and ferrochelatase, SMAD4, RAB27B) were prepared at the Institute of Bioorganic Chemistry (Republic of Belarus) by molecular cloning and heterologous expression in a bacterial system (E. coli), followed by purification using metal-affinity and ion exchange chromatography [,. 	cytochrome b	9006	9018	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6052406_OgerInput.txtOger_out.csv:84	The electron leakage in the electron transport chain during respiration is generally considered as the main source of mitochondrial Reactive Oxygen Species but other mitochondrial enzymatic systems, such as monoamine oxidase and cytochrome b5 reductase in the outer membranes, cytochromes P450 enzymes in the inner membranes, or several matrix enzymes such as aconitase, can also produce Reactive Oxygen Species (Andreyev, Kushnareva, Murphy, & Starkov, ; Andreyev, Kushnareva, & Starkov,. 	cytochrome b	15689	15701	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:196	(presence of CYP and cytochrome b5). 	cytochrome b	32182	32194	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:5	Here we demonstrate the feasibility of dynamic nuclear polarization (DNP) magic-angle-spinning NMR techniques, along with a judiciously designed stable isotope labeling scheme, to measure atomistic-resolution transmembrane-transmembrane interactions of full-length mammalian ~72-kDa cytochrome P450-cytochrome b5 complex in lipid bilayers. 	cytochrome b5	1296	1309	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:6	Additionally, the DNP sensitivity-enhanced two-dimensional 13C/13C chemical shift correlations via proton driven spin diffusion provided distance constraints to characterize protein-lipid interactions and revealed the transmembrane topology of cytochrome b5. 	cytochrome b5	1581	1594	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:6	Additionally, the DNP sensitivity-enhanced two-dimensional 13C/13C chemical shift correlations via proton driven spin diffusion provided distance constraints to characterize protein-lipid interactions and revealed the transmembrane topology of cytochrome b5. 	cytochrome b5	1581	1594	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:50	The incubation mixture included 5 pmol wild-type CYP3A4*1 or other CYP3A4 mutants, 5 pmol purified cytochrome b5, lidocaine and 100 mmol/L potassium phosphate buffer (pH 7.4). 	cytochrome b5	8452	8465	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:50	The incubation mixture included 5 pmol wild-type CYP3A4*1 or other CYP3A4 mutants, 5 pmol purified cytochrome b5, lidocaine and 100 mmol/L potassium phosphate buffer (pH 7.4). 	cytochrome b5	8452	8465	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:95	However, the CYP1A1 protein level and microsomal EROD activity were induced by B(a)P in the liver, but not the ovaries. 	EROD	13010	13014	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:99	Our findings revealed that neither CYP1A1/1B1 protein levels nor EROD activity in MCF-7 cells were significantly affected by protoberberines at a non-cytotoxic concentration (10 M). 	EROD	13518	13522	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_370', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:136	In this experiment, the natural-abundance ^13C magnetizations of U-^15N cytochrome P450 selected by the ^15N-^13C REDOR scheme, which are encoded during the t _1 evolution, and are subsequently correlated to the neighboring ^13C nuclei of selectively ^13C-labeled cytochrome b_5 during a long PDSD mixing time (~3 s) in order to obtain the ^13C-^13C chemical shift correlation shown in Fig . 	cytochrome b_5	30631	30645	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:136	In this experiment, the natural-abundance ^13C magnetizations of U-^15N cytochrome P450 selected by the ^15N-^13C REDOR scheme, which are encoded during the t _1 evolution, and are subsequently correlated to the neighboring ^13C nuclei of selectively ^13C-labeled cytochrome b_5 during a long PDSD mixing time (~3 s) in order to obtain the ^13C-^13C chemical shift correlation shown in Fig . 	cytochrome b_5	30631	30645	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:137	Purified labeled proteins, both rabbit cytochrome b_5 and cytochrome 2B4, were first assembled into a complex, and then reconstituted into DMPC lipid bilayers hydrated with AMUPol solutions containing [D_8]glycerol/D_2O/H_2O (60:30:10 volume ratio) as described in the materials and methods section. 	cytochrome b_5	30798	30812	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:137	Purified labeled proteins, both rabbit cytochrome b_5 and cytochrome 2B4, were first assembled into a complex, and then reconstituted into DMPC lipid bilayers hydrated with AMUPol solutions containing [D_8]glycerol/D_2O/H_2O (60:30:10 volume ratio) as described in the materials and methods section. 	cytochrome b_5	30798	30812	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:138	The full-length cytochrome P450 2B4 is known to form the functional complex with the second electron donor, cytochrome b_5, in lipid bilayer environments as confirmed by the alternation of spin states, termed type I spectral changes under the sample preparation in this study^,. 	cytochrome b_5	31167	31181	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:138	The full-length cytochrome P450 2B4 is known to form the functional complex with the second electron donor, cytochrome b_5, in lipid bilayer environments as confirmed by the alternation of spin states, termed type I spectral changes under the sample preparation in this study^,. 	cytochrome b_5	31167	31181	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:140	At these cryogenic temperatures, cytochrome b_5 maintains its topology and ALPHA-helical structure in the transmembrane region, hence the functional transmembrane complex of cytochromes can be retained under the experimental conditions employed in this study. 	cytochrome b_5	31553	31567	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:140	At these cryogenic temperatures, cytochrome b_5 maintains its topology and ALPHA-helical structure in the transmembrane region, hence the functional transmembrane complex of cytochromes can be retained under the experimental conditions employed in this study. 	cytochrome b_5	31553	31567	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:143	These structural constraints from transmembrane-transmembrane interactions obtained from DNP-MAS-ssNMR spectroscopy allow us to construct a structural model for the full-length cytochrome P450-cytochrome b_5 complex, as shown in Fig. 	cytochrome b_5	32398	32412	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:143	These structural constraints from transmembrane-transmembrane interactions obtained from DNP-MAS-ssNMR spectroscopy allow us to construct a structural model for the full-length cytochrome P450-cytochrome b_5 complex, as shown in Fig. 	cytochrome b_5	32398	32412	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:144	In this structural model, high-resolution NMR structure of the full-length rabbit cytochrome b_5 in lipid bilayers, soluble domain interactions, and the transmembrane ALPHA-helix of cytochrome P450 were obtained from our previous studies^,. 	cytochrome b_5	32521	32535	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:144	In this structural model, high-resolution NMR structure of the full-length rabbit cytochrome b_5 in lipid bilayers, soluble domain interactions, and the transmembrane ALPHA-helix of cytochrome P450 were obtained from our previous studies^,. 	cytochrome b_5	32521	32535	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:145	According to these studies, the molecular interactions in the soluble domains of cytochromes exhibit dynamic encounter complexes mediated by both hydrophobic and electrostatic interactions with multiple complex formations, which were explained through the mutagenesis studies and line-broadening of unformly-^15N labeled cytochrome b_5 using solution NMR spectroscopy^. 	cytochrome b_5	33001	33015	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:145	According to these studies, the molecular interactions in the soluble domains of cytochromes exhibit dynamic encounter complexes mediated by both hydrophobic and electrostatic interactions with multiple complex formations, which were explained through the mutagenesis studies and line-broadening of unformly-^15N labeled cytochrome b_5 using solution NMR spectroscopy^. 	cytochrome b_5	33001	33015	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:147	In fact, based on our reported complex structural model in the soluble domain, some labeled positions (eg, Leu41, Ala59, Val66, Ala72, and Leu75) can be close to the cytochrome P450-cytochrome b_5 complex interface^. 	cytochrome b_5	33353	33367	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:147	In fact, based on our reported complex structural model in the soluble domain, some labeled positions (eg, Leu41, Ala59, Val66, Ala72, and Leu75) can be close to the cytochrome P450-cytochrome b_5 complex interface^. 	cytochrome b_5	33353	33367	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5482851_OgerInput.txtOger_out.csv:151	Interestingly, the presence of highly conserved LxxxL motif between L121 and L125 was observed in the amino acid sequences of cytochrome b_5 from various eukaryotes, as shown in Fig. 	cytochrome b_5	34181	34195	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:18	Based on previous in vitro studies, cytochrome P450 3A4 (CYP3A4) has been regarded as the main CYP isoform responsible for the de-ethylation of lidocaine to its primary metabolite, MEGX., CYP3A4, as a member of P450 enzyme superfamily, is the most important drug-metabolizing enzyme in human liver and gastrointestinal tract. 	cytochrome P450 3A	2490	2508	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5724423_OgerInput.txtOger_out.csv:18	Based on previous in vitro studies, cytochrome P450 3A4 (CYP3A4) has been regarded as the main CYP isoform responsible for the de-ethylation of lidocaine to its primary metabolite, MEGX., CYP3A4, as a member of P450 enzyme superfamily, is the most important drug-metabolizing enzyme in human liver and gastrointestinal tract. 	cytochrome P450 3A4	2490	2509	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC6165893_OgerInput.txtOger_out.csv:10	Various molecules such as heme, fatty acid 2-hydroxylase, cytochrome P-450 enzymes, insulin receptor, epidermal growth factor receptor, Erbb2, and membrane progestin receptor ALPHA (mPRALPHA, PAQR7) can interact and associate with Pgrmc1. 	cytochrome P-450	1729	1745	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_352', 'CUI-less')
PMC6358801_OgerInput.txtOger_out.csv:74	Similarly, the blue light induced the expression of putative LDA enzymes including aryl-alcohol dehydrogenase (XLOC_008717), pyranose 2-oxidase (XLOC_009983), and monooxygenase (XLOC_003435) and the red light influenced the expression of cytochrome P-450 (XLOC_007791, XLOC_00671, XLOC_006683, XLOC_001969, and XLOC_007717). 	cytochrome P-450	15561	15577	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_344', 'CUI-less')
PMC6328497_OgerInput.txtOger_out.csv:109	Cytochrome c release from the mitochondria to the cytoplasm is a crucial event, which activates metacaspase, thereby inducing apoptosis (Wu et al.,. 	Cytochrome c	15217	15229	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6328497_OgerInput.txtOger_out.csv:109	Cytochrome c release from the mitochondria to the cytoplasm is a crucial event, which activates metacaspase, thereby inducing apoptosis (Wu et al.,. 	Cytochrome c	15217	15229	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6468925_OgerInput.txtOger_out.csv:27	The following primary antibodies were used: Rabbit anti-LC3B antibody (PM063) from MBL, Nagoya, Japan; rabbit anti-PINK1 (BC100-494), rabbit anti-Parkin (NB100-91921), and mouse anti-p62 (H00008878-M01) antibodies from Novus Biologicals (Briarwood Avenue, Building IV Centennial, CO, USA); goat anti-pan-cathepsin (sc-6499), mouse anti-Parkin (sc-32282), mouse anti-Actin (sc-47778), and mouse anti-cytochrome c (7H8):(sc-13560) antibodies from Santa Cruz Biologicals (Dallas, TX, USA); rabbit anti-inducible nitric oxide synthase (iNOS) and rabbit anti-iNOS (ab15323) antibodies from Abcam Biologicals (Cambridge, MA, USA); rabbit anti-TFEB (MBS9125929) from MyBioSource Biologicals (San Diego, CA, USA); and rabbit anti-Cytochrome c oxidase (COX) IV (3E11) from cell signaling Biologicals (Danvers, MA, USA). 	Cytochrome c	6149	6161	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6468925_OgerInput.txtOger_out.csv:27	The following primary antibodies were used: Rabbit anti-LC3B antibody (PM063) from MBL, Nagoya, Japan; rabbit anti-PINK1 (BC100-494), rabbit anti-Parkin (NB100-91921), and mouse anti-p62 (H00008878-M01) antibodies from Novus Biologicals (Briarwood Avenue, Building IV Centennial, CO, USA); goat anti-pan-cathepsin (sc-6499), mouse anti-Parkin (sc-32282), mouse anti-Actin (sc-47778), and mouse anti-cytochrome c (7H8):(sc-13560) antibodies from Santa Cruz Biologicals (Dallas, TX, USA); rabbit anti-inducible nitric oxide synthase (iNOS) and rabbit anti-iNOS (ab15323) antibodies from Abcam Biologicals (Cambridge, MA, USA); rabbit anti-TFEB (MBS9125929) from MyBioSource Biologicals (San Diego, CA, USA); and rabbit anti-Cytochrome c oxidase (COX) IV (3E11) from cell signaling Biologicals (Danvers, MA, USA). 	Cytochrome c	6149	6161	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:3	Cytochrome c showed a significant response to Bombyx Mori Nucleopolyhedrovirus infection in our previous transcriptome study. 	Cytochrome c	207	219	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC7308462_OgerInput.txtOger_out.csv:203	In addition, the blood circulation time of Mycophenolic Acid also increased by QC through inhibition of Mycophenolic Acid metabolism mediated by cytochrome P450 enzyme as discussed blow in pharmacokinetic analysis. 	cytochrome P450 enzyme	31511	31533	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:81	Importantly, common functional polymorphisms in CYP2B6 alter enzyme activity in a substratedependent manner,,  and thus it is important to evaluate these enzyme variants for any CYP2B6 substrate. 	CYP2B6	14964	14970	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:81	Importantly, common functional polymorphisms in CYP2B6 alter enzyme activity in a substratedependent manner,,  and thus it is important to evaluate these enzyme variants for any CYP2B6 substrate. 	CYP2B6	14964	14970	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:81	Importantly, common functional polymorphisms in CYP2B6 alter enzyme activity in a substratedependent manner,,  and thus it is important to evaluate these enzyme variants for any CYP2B6 substrate. 	CYP2B6	15094	15100	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:81	Importantly, common functional polymorphisms in CYP2B6 alter enzyme activity in a substratedependent manner,,  and thus it is important to evaluate these enzyme variants for any CYP2B6 substrate. 	CYP2B6	15094	15100	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:83	The differences we report, both for (S)nicotine and (R)nicotine, confirm the expectation of altered activities for common variants including CYP2B6.6 and CYP2B6.9, relative to the reference allele enzyme, CYP2B6.1. 	CYP2B6	15342	15348	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:83	The differences we report, both for (S)nicotine and (R)nicotine, confirm the expectation of altered activities for common variants including CYP2B6.6 and CYP2B6.9, relative to the reference allele enzyme, CYP2B6.1. 	CYP2B6	15342	15348	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:83	The differences we report, both for (S)nicotine and (R)nicotine, confirm the expectation of altered activities for common variants including CYP2B6.6 and CYP2B6.9, relative to the reference allele enzyme, CYP2B6.1. 	CYP2B6	15355	15361	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:83	The differences we report, both for (S)nicotine and (R)nicotine, confirm the expectation of altered activities for common variants including CYP2B6.6 and CYP2B6.9, relative to the reference allele enzyme, CYP2B6.1. 	CYP2B6	15355	15361	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:83	The differences we report, both for (S)nicotine and (R)nicotine, confirm the expectation of altered activities for common variants including CYP2B6.6 and CYP2B6.9, relative to the reference allele enzyme, CYP2B6.1. 	CYP2B6	15406	15412	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:83	The differences we report, both for (S)nicotine and (R)nicotine, confirm the expectation of altered activities for common variants including CYP2B6.6 and CYP2B6.9, relative to the reference allele enzyme, CYP2B6.1. 	CYP2B6	15406	15412	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:87	Of particular interest are the differences in activity related to the two amino acid changes, Q172H and K262R, which individually define the CYP2B6*9 and CYP2B6*4 variants respectively, and together define the very common CYP2B6*6 haplotype. 	CYP2B6	16199	16205	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:87	Of particular interest are the differences in activity related to the two amino acid changes, Q172H and K262R, which individually define the CYP2B6*9 and CYP2B6*4 variants respectively, and together define the very common CYP2B6*6 haplotype. 	CYP2B6	16199	16205	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:87	Of particular interest are the differences in activity related to the two amino acid changes, Q172H and K262R, which individually define the CYP2B6*9 and CYP2B6*4 variants respectively, and together define the very common CYP2B6*6 haplotype. 	CYP2B6	16212	16218	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:87	Of particular interest are the differences in activity related to the two amino acid changes, Q172H and K262R, which individually define the CYP2B6*9 and CYP2B6*4 variants respectively, and together define the very common CYP2B6*6 haplotype. 	CYP2B6	16212	16218	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:87	Of particular interest are the differences in activity related to the two amino acid changes, Q172H and K262R, which individually define the CYP2B6*9 and CYP2B6*4 variants respectively, and together define the very common CYP2B6*6 haplotype. 	CYP2B6	16280	16286	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:87	Of particular interest are the differences in activity related to the two amino acid changes, Q172H and K262R, which individually define the CYP2B6*9 and CYP2B6*4 variants respectively, and together define the very common CYP2B6*6 haplotype. 	CYP2B6	16280	16286	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16337	16343	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16337	16343	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16392	16398	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16392	16398	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16488	16494	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16488	16494	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16510	16516	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16510	16516	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16523	16529	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:88	For most substrates, activity of the CYP2B6.9 variant is exceptionally low, activity of the CYP2B6.4 variant is similar or greater than that of the reference allele, while the activity of CYP2B6.6 lies between CYP2B6.4 and CYP2B6.9, depending on substrate.,  This demonstrates that the K262R amino acid change can partially compensate for the Q172H lossoffunction, depending on substrate, and we find this to be the case for nicotine as well. 	CYP2B6	16523	16529	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:89	CYP2B6*6 is the most commonly studied variant haplotype because of its high population frequency and has been associated with low activity in vivo.,  However, it is also important to note that part of this loss of activity may be due to differences in mRNA or protein expression or splicing, and not strictly related to catalytic activity.,  CYP2B6*6 (and CYP2B6*9) have also been reportedly associated with more rapid in vivo nicotine metabolism. 	CYP2B6	16743	16749	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:89	CYP2B6*6 is the most commonly studied variant haplotype because of its high population frequency and has been associated with low activity in vivo.,  However, it is also important to note that part of this loss of activity may be due to differences in mRNA or protein expression or splicing, and not strictly related to catalytic activity.,  CYP2B6*6 (and CYP2B6*9) have also been reportedly associated with more rapid in vivo nicotine metabolism. 	CYP2B6	16743	16749	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_505', 'CUI-less')
PMC6411694_OgerInput.txtOger_out.csv:89	CYP2B6*6 is the most commonly studied variant haplotype because of its high population frequency and has been associated with low activity in vivo.,  However, it is also important to note that part of this loss of activity may be due to differences in mRNA or protein expression or splicing, and not strictly related to catalytic activity.,  CYP2B6*6 (and CYP2B6*9) have also been reportedly associated with more rapid in vivo nicotine metabolism. 	CYP2B6	17085	17091	('Cytochromes', 'Cytochrome P-450 CYP2B6', 'NCCS', 'NCCS_395', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:39	P450 Oxidoreductase contains a flavin adenine dinucleotide and a flavin mononucleotide allowing the enzyme to oxidize NADPH and reduce the Cytochrome P450 enzyme in a stepwise manner. 	Cytochrome P450 enzyme	6525	6547	('Cytochromes', 'Cytochrome P-450 Enzyme System', 'NCCS', 'NCCS_345', 'CUI-less')
PMC6214003_OgerInput.txtOger_out.csv:134	The genes that are overexpressed in Theca cells (cluster 4) are particularly involved in cholesterol import (SCARB1, STARD5), bile acid metabolism (CH25H), HDL-mediated lipid transport (APOA1, PLTP, SCARB1), lipid degradation (LPL, PLIN5), and steroidogenesis (CYP27A, CYP7B1, TM7SF2). 	CYP7	25478	25482	('Cytochromes', 'Cholesterol 7-alpha-Hydroxylase', 'NCCS', 'NCCS_714', 'CUI-less')
PMC6646835_OgerInput.txtOger_out.csv:135	Numerous oxidative metabolic functions were identified in these bins, including oxygen respiration, thiosulfate oxidation through the Sox pathway and metal oxidation via multiheme cytochrome C. A strong metabolic potential for degradation of various organic compounds, including urea, hydrocarbons and aromatic compounds was also identified. 	cytochrome C	23902	23914	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6646835_OgerInput.txtOger_out.csv:135	Numerous oxidative metabolic functions were identified in these bins, including oxygen respiration, thiosulfate oxidation through the Sox pathway and metal oxidation via multiheme cytochrome C. A strong metabolic potential for degradation of various organic compounds, including urea, hydrocarbons and aromatic compounds was also identified. 	cytochrome C	23902	23914	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6850936_OgerInput.txtOger_out.csv:7	Apoptosis rate, cytochrome C and cleaved caspase3 increased, and cell viability decreased following bubble contact for 10, 20 or 30 minutes, but not for 1 or 5 minutes. 	cytochrome C	769	781	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6850936_OgerInput.txtOger_out.csv:7	Apoptosis rate, cytochrome C and cleaved caspase3 increased, and cell viability decreased following bubble contact for 10, 20 or 30 minutes, but not for 1 or 5 minutes. 	cytochrome C	769	781	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6850936_OgerInput.txtOger_out.csv:29	Cell viability, apoptosis rate and expressions of cytochrome C and cleaved caspase3 were determined prior to the experiment for assessing endothelial function at 12 hours following bubble contact. 	cytochrome C	4222	4234	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC5546780_OgerInput.txtOger_out.csv:255	We showed an effective targeting and Cytochrome P450 3a4 inhibition following intravenous injection of PLGA-Ga Bergamottin nanoparticles. 	Cytochrome P450 3a	38899	38917	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:96	The most abundant in the plasma is sorafenib N-oxide (M2), which is produced by Cytochrome P450 3a4 and exhibits an in vitro potency similar to the parental drug. 	Cytochrome P450 3a	18034	18052	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:98	Given the key role of Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 in sorafenib metabolism, inducers or inhibitors of these enzymes, such as some foods and co-administered drugs (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, rifabutin, St. 	Cytochrome P450 3a	18347	18365	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_608', 'CUI-less')
PMC5546780_OgerInput.txtOger_out.csv:255	We showed an effective targeting and Cytochrome P450 3a4 inhibition following intravenous injection of PLGA-Ga Bergamottin nanoparticles. 	Cytochrome P450 3a4	38899	38918	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:96	The most abundant in the plasma is sorafenib N-oxide (M2), which is produced by Cytochrome P450 3a4 and exhibits an in vitro potency similar to the parental drug. 	Cytochrome P450 3a4	18034	18053	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC6689804_OgerInput.txtOger_out.csv:98	Given the key role of Cytochrome P450 3a4 and Udp Glucuronosyltransferase 1a9 in sorafenib metabolism, inducers or inhibitors of these enzymes, such as some foods and co-administered drugs (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, rifabutin, St. 	Cytochrome P450 3a4	18347	18366	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_609', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:13	The results demonstrate that cytochrome b 5 plays a dual role in the CYP3A4-catalyzed oxidation of ellipticine: (1) cytochrome b 5 mediates CYP3A4 catalytic activities by donating the first and second electron to this enzyme in its catalytic cycle, indicating that NADH:cytochrome b 5 reductase can substitute NADPH-dependent POR in this enzymatic reaction and (2) cytochrome b 5 can act as an allosteric modifier of the CYP3A4 oxygenase. 	cytochrome b 5	2026	2040	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:67	Our results demonstrated that the function of cytochrome b _5 in this reaction is complex. 	cytochrome b _5	13940	13955	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b _5	14140	14155	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b _5	14140	14155	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b _5	14170	14185	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b _5	14170	14185	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b _5	14216	14231	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:68	We found that oxidation of ellipticine by human CYP3A4 in the natural microsomal system of human liver or in Supersomes, where the reductases POR and NADH:cytochrome b _5 reductase and cytochrome b _5 are expressed, is enhanced by cytochrome b _5. 	cytochrome b _5	14216	14231	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:69	Ellipticine oxidation does not only occur in the presence of the coenzymes of POR, NADPH, but also in the presence of NADH, which is the exclusive coenzyme of another microsomal reductase, NADH:cytochrome b _5 reductase. 	cytochrome b _5	14427	14442	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:69	Ellipticine oxidation does not only occur in the presence of the coenzymes of POR, NADPH, but also in the presence of NADH, which is the exclusive coenzyme of another microsomal reductase, NADH:cytochrome b _5 reductase. 	cytochrome b _5	14427	14442	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b _5	14487	14502	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b _5	14487	14502	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b _5	14631	14646	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_321', 'CUI-less')
PMC5653753_OgerInput.txtOger_out.csv:70	These findings demonstrated that cytochrome b _5 is included in the reduction of CYP3A4 catalyzed both by the NADPH/POR system and a system consisting exclusively of NADH, NADH:cytochrome b _5 reductase and cytochrome b _5, and thus also without any participation of NADPH and POR. 	cytochrome b _5	14631	14646	('Cytochromes', 'Cytochromes b5', 'NCCS', 'NCCS_322', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:211	Cyp1a2 Knockout mice liver cDNA microarray analysis showed that Cyp1a2 deficiency affected insulin function, lipogenesis, fatty acid biosynthesis and cholesterol biosynthesis. 	Cyp1a2	28044	28050	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_375', 'CUI-less')
PMC6984740_OgerInput.txtOger_out.csv:211	Cyp1a2 Knockout mice liver cDNA microarray analysis showed that Cyp1a2 deficiency affected insulin function, lipogenesis, fatty acid biosynthesis and cholesterol biosynthesis. 	Cyp1a2	28044	28050	('Cytochromes', 'Cytochrome P-450 CYP1A2', 'NCCS', 'NCCS_374', 'CUI-less')
PMC7566554_OgerInput.txtOger_out.csv:87	A higher expression of Cyp3a11 in female mice than males was reported earlier (;. 	Cyp3a	12199	12204	('Cytochromes', 'Cytochrome P-450 CYP3A', 'NCCS', 'NCCS_602', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:163	Sort=Bait  CYP11B2 complex formation was a new and unexpected result, since CYP11B2 was not identified as a protein partner of Https://Thebiogrid.org/112778/Summary/Homo-Sapiens/Tbxas1.Html? 	CYP11B2	22812	22819	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:165	These data are quite comparable, they are not due to the false-negative results of molecular fishing, and can be explained in terms of the tissue-specific CYP11B2 expression profile (preferential expression in the adrenal tissue), which appears from the information in the open Internet resources Proteinatlas (http://www.proteinatlas.org) and Genecards (http://www.genecards.org) and publications [38]. 	CYP11B2	23173	23180	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:165	These data are quite comparable, they are not due to the false-negative results of molecular fishing, and can be explained in terms of the tissue-specific CYP11B2 expression profile (preferential expression in the adrenal tissue), which appears from the information in the open Internet resources Proteinatlas (http://www.proteinatlas.org) and Genecards (http://www.genecards.org) and publications [38]. 	CYP11B2	23173	23180	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:165	These data are quite comparable, they are not due to the false-negative results of molecular fishing, and can be explained in terms of the tissue-specific CYP11B2 expression profile (preferential expression in the adrenal tissue), which appears from the information in the open Internet resources Proteinatlas (http://www.proteinatlas.org) and Genecards (http://www.genecards.org) and publications [38]. 	CYP11B2	23173	23180	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_437', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:165	These data are quite comparable, they are not due to the false-negative results of molecular fishing, and can be explained in terms of the tissue-specific CYP11B2 expression profile (preferential expression in the adrenal tissue), which appears from the information in the open Internet resources Proteinatlas (http://www.proteinatlas.org) and Genecards (http://www.genecards.org) and publications [38]. 	CYP11B2	23173	23180	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_685', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:167	Sort=Bait and CYP11B2. 	CYP11B2	23713	23720	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_684', 'CUI-less')
PMC5762833_OgerInput.txtOger_out.csv:167	Sort=Bait and CYP11B2. 	CYP11B2	23713	23720	('Cytochromes', 'Cytochrome P-450 CYP11B2', 'NCCS', 'NCCS_438', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:112	CYP11A1 performs the 22R-C hydroxylation of cholesterol, followed by 20R-C hydroxylation (B). 	CYP11A1	16200	16207	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:115	CYP11A1 displays a cavity, called a sterol-binding pocket, which interacts with the 3BETA-hydroxyl group of cholesterol. 	CYP11A1	16449	16456	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:115	CYP11A1 displays a cavity, called a sterol-binding pocket, which interacts with the 3BETA-hydroxyl group of cholesterol. 	CYP11A1	16449	16456	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:115	CYP11A1 displays a cavity, called a sterol-binding pocket, which interacts with the 3BETA-hydroxyl group of cholesterol. 	CYP11A1	16449	16456	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_426', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:115	CYP11A1 displays a cavity, called a sterol-binding pocket, which interacts with the 3BETA-hydroxyl group of cholesterol. 	CYP11A1	16449	16456	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_427', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:120	A major difference between CYP11A1 and CYP90B1 is the stereo specificity. 	CYP11A1	17210	17217	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_722', 'CUI-less')
PMC7570361_OgerInput.txtOger_out.csv:120	A major difference between CYP11A1 and CYP90B1 is the stereo specificity. 	CYP11A1	17210	17217	('Cytochromes', 'Cholesterol Side-Chain Cleavage Enzyme', 'NCCS', 'NCCS_723', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:72	Finally, CYP11B1, located in the mitochondria of the zona fasciculata cells, facilitates the final step in glucocorticoid biosynthesis by catalyzing the conversion of 11-deoxycortisol to cortisol. 	CYP11B1	12119	12126	('Cytochromes', 'Steroid 11-beta-Hydroxylase', 'NCCS', 'NCCS_780', 'CUI-less')
PMC7077309_OgerInput.txtOger_out.csv:162	Treatment of resveratrol (p-value < 0.0001, n =3), ellipticine (p-value < 0.0001, n =3), or tryptamine (p-value < 0.0001, n =3) significantly reduced the viral load in CCS-EVs exposed U1 cells, suggesting the role of CYP 1A1 and 2A6, and oxidative stress on viral load increase in U1 cells (A,B). 	CYP 1A1	28317	28324	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_367', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:90	These results indicated allele A and H of mitochondrial cytochrome B gene may be predominant in animals with the high or low replicative pattern of WHV infection, respectively. 	cytochrome B	13968	13980	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:99	All of the animals belong to the same subspecies M. himalayana robusta identified by the analysis of mitochondrial cytochrome B sequences. 	cytochrome B	15621	15633	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6006932_OgerInput.txtOger_out.csv:100	Based on the profiles of the nucleotide substitutions, eight different alleles of mitochondrial cytochrome B gene were identified in the animals used in this study. 	cytochrome B	15741	15753	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7531579_OgerInput.txtOger_out.csv:154	Estrogen deficiency in men with mutations in the gene codifying for aromatase (CYP19A1, the enzyme converting testosterone in estrogen) show impaired glucose and lipid liver metabolism (,. 	CYP19	43041	43046	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_694', 'CUI-less')
PMC7531579_OgerInput.txtOger_out.csv:154	Estrogen deficiency in men with mutations in the gene codifying for aromatase (CYP19A1, the enzyme converting testosterone in estrogen) show impaired glucose and lipid liver metabolism (,. 	CYP19	43041	43046	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_695', 'CUI-less')
PMC7531579_OgerInput.txtOger_out.csv:154	Estrogen deficiency in men with mutations in the gene codifying for aromatase (CYP19A1, the enzyme converting testosterone in estrogen) show impaired glucose and lipid liver metabolism (,. 	CYP19	43041	43046	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_480', 'CUI-less')
PMC7531579_OgerInput.txtOger_out.csv:154	Estrogen deficiency in men with mutations in the gene codifying for aromatase (CYP19A1, the enzyme converting testosterone in estrogen) show impaired glucose and lipid liver metabolism (,. 	CYP19	43041	43046	('Cytochromes', 'Aromatase', 'NCCS', 'NCCS_479', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:97	Thus, CYP2B1 and CYP2C11, in cultured rat hepatocytes treated with Autophagic-Lysosomal Degradation inhibitors [3-methyladenine (3MA)/NH_4Cl] or heterologously expressed in a vacuolar (lysosomal) degradation-deficient S. cerevisiae strain, are stabilized relative to those expressed in wild-type or proteasomal-subunit defective strains,. 	CYP2B1	22490	22496	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_389', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:97	Thus, CYP2B1 and CYP2C11, in cultured rat hepatocytes treated with Autophagic-Lysosomal Degradation inhibitors [3-methyladenine (3MA)/NH_4Cl] or heterologously expressed in a vacuolar (lysosomal) degradation-deficient S. cerevisiae strain, are stabilized relative to those expressed in wild-type or proteasomal-subunit defective strains,. 	CYP2B1	22490	22496	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_499', 'CUI-less')
PMC6976991_OgerInput.txtOger_out.csv:97	Thus, CYP2B1 and CYP2C11, in cultured rat hepatocytes treated with Autophagic-Lysosomal Degradation inhibitors [3-methyladenine (3MA)/NH_4Cl] or heterologously expressed in a vacuolar (lysosomal) degradation-deficient S. cerevisiae strain, are stabilized relative to those expressed in wild-type or proteasomal-subunit defective strains,. 	CYP2B1	22490	22496	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_390', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:97	Elevated levels of miRs, including miR-21, can contribute to the post-transcriptional downregulation of ovary CYP1A1 protein expression. 	CYP1A1 protein	13248	13262	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6150360_OgerInput.txtOger_out.csv:98	Although one immunoblot showed a weak to mild elevation in CYP1A1 protein in MCF-7 cells exposed to 10-40 M berberine for 48 h, the statistical significance has not been proven. 	CYP1A1 protein	13334	13348	('Cytochromes', 'Cytochrome P-450 CYP1A1', 'NCCS', 'NCCS_368', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:504	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin and PROD activities were increased by treatment with 3-methylcholanthrene, while PROD and 7-methoxy-4-trifluoromethylcoumarin O-dealkylase activities remained undetected even after treatment with CITCO (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) or rifampicin. 	PROD	77876	77880	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:504	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin and PROD activities were increased by treatment with 3-methylcholanthrene, while PROD and 7-methoxy-4-trifluoromethylcoumarin O-dealkylase activities remained undetected even after treatment with CITCO (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) or rifampicin. 	PROD	77876	77880	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:504	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin and PROD activities were increased by treatment with 3-methylcholanthrene, while PROD and 7-methoxy-4-trifluoromethylcoumarin O-dealkylase activities remained undetected even after treatment with CITCO (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) or rifampicin. 	PROD	77953	77957	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:504	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin and PROD activities were increased by treatment with 3-methylcholanthrene, while PROD and 7-methoxy-4-trifluoromethylcoumarin O-dealkylase activities remained undetected even after treatment with CITCO (6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl)oxime) or rifampicin. 	PROD	77953	77957	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_392', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:506	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD or BROD activities (LOD 1, 4 and 1 pmol/min/mg protein, respectively). 	PROD	78333	78337	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_502', 'CUI-less')
PMC6063329_OgerInput.txtOger_out.csv:506	Reported Cutaneous Dealkylase Activity For 7-Ethoxyresorufin, PROD or BROD activities (LOD 1, 4 and 1 pmol/min/mg protein, respectively). 	BROD	78341	78345	('Cytochromes', 'Cytochrome P-450 CYP2B1', 'NCCS', 'NCCS_497', 'CUI-less')
PMC6487167_OgerInput.txtOger_out.csv:57	Paliperidone is not metabolized by CYP 2D6 cytochrome system. 	CYP 2D6	8822	8829	('Cytochromes', 'Cytochrome P-450 CYP2D6', 'NCCS', 'NCCS_403', 'CUI-less')
PMC8001203_OgerInput.txtOger_out.csv:120	Considering the ability of CYP26B1 to metabolize retinoic acid, there is support for the observed effect of rs62150087 on worse patient survival. 	CYP26B1	17212	17219	('Cytochromes', 'Retinoic Acid 4-Hydroxylase', 'NCCS', 'NCCS_571', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:434	The involvement of D1/D2/Cytochrome B559 in electron transfer reactions of PSII indicates that D1/D2/Cytochrome B559 is a redox active component that can potentially reduce O_2. 	Cytochrome B	63991	64003	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:435	It has been shown that fast, dark reoxidation of the PQ pool in thylakoid membranes is not caused by direct oxidation of PQH_2 by O_2, and it was suggested that the Low Potential form of D1/D2/Cytochrome B559 can transfer an electron to O_2 and thereby act as a PQH_2:O_2 oxidoreductase. 	Cytochrome B	64261	64273	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:436	In isolated PSII membranes, O_2 has been shown to compete with prenylquinones for oxidation of the Low Potential form of D1/D2/Cytochrome B559, suggesting that Low Potential D1/D2/Cytochrome B559 can form O_2^. 	Cytochrome B	64483	64495	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:436	In isolated PSII membranes, O_2 has been shown to compete with prenylquinones for oxidation of the Low Potential form of D1/D2/Cytochrome B559, suggesting that Low Potential D1/D2/Cytochrome B559 can form O_2^. 	Cytochrome B	64536	64548	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:438	This finding was interpreted to indicate that these quinones reduce Low Potential D1/D2/Cytochrome B559, which then undergoes spontaneous autoxidation, resulting in O_2^ formation. 	Cytochrome B	64741	64753	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC7020446_OgerInput.txtOger_out.csv:439	However, the reduction in O_2 by Low Potential D1/D2/Cytochrome B559 is thermodynamically unfavorable, taking into account that the redox potential of the Low Potential form is usually within 20-110 mV in untreated membranes, although sometimes an Low Potential form with a negative potential is observed. 	Cytochrome B	64887	64899	('Cytochromes', 'Cytochromes b', 'NCCS', 'NCCS_319', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:40	The CDS sequence of Bombyx Mori Cytc and those in other species were derived from NCBI, which were used to analyze the evolutionary relationships of Cytochrome C among different species. 	Cytochrome C	7055	7067	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC6770455_OgerInput.txtOger_out.csv:43	The homologous gene sequences of Bombyx Mori Cytc in M. musculus and Arabidopsis shared a low sequence identity with Bombyx Mori Cytc, indicating that Cytochrome C gene in the earlier species might have diverged before the appearance of these orders during evolution. 	Cytochrome C	7523	7535	"('Cytochromes', ""Cytochromes c'"", 'NCCS', 'NCCS_331', 'CUI-less')"
PMC6770455_OgerInput.txtOger_out.csv:43	The homologous gene sequences of Bombyx Mori Cytc in M. musculus and Arabidopsis shared a low sequence identity with Bombyx Mori Cytc, indicating that Cytochrome C gene in the earlier species might have diverged before the appearance of these orders during evolution. 	Cytochrome C	7523	7535	('Cytochromes', 'Cytochromes c', 'NCCS', 'NCCS_328', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:95	The most active compound, 12n, fitted the active sites of CYP17A1 (6CIZ) well. 	CYP17	15833	15838	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:95	The most active compound, 12n, fitted the active sites of CYP17A1 (6CIZ) well. 	CYP17	15833	15838	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:200	The X-ray structures and data of protein targets were obtained from the protein data bank (www.rcsb.org): CYP17A1 (17a-hydroxylase/C17,20-lyase, Protein Data Bank ID: 6CIZ, 6CHI, 6CIR, 5UYS, 4NKZ, 4NKX, 4NKV, 4NKW, and 3RUK) and CYP19A1 (aromatase, Protein Data Bank ID: 3S7S). 	CYP17	33665	33670	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_768', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:200	The X-ray structures and data of protein targets were obtained from the protein data bank (www.rcsb.org): CYP17A1 (17a-hydroxylase/C17,20-lyase, Protein Data Bank ID: 6CIZ, 6CHI, 6CIR, 5UYS, 4NKZ, 4NKX, 4NKV, 4NKW, and 3RUK) and CYP19A1 (aromatase, Protein Data Bank ID: 3S7S). 	CYP17	33665	33670	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_465', 'CUI-less')
PMC6857441_OgerInput.txtOger_out.csv:267	Interestingly, enzymes with 20BETA-HSD and 17,20-lyase activity have been recently identified in a microbial inhabitant of the urinary tract. 	17,20-lyase	43860	43871	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_464', 'CUI-less')
PMC7084598_OgerInput.txtOger_out.csv:200	The X-ray structures and data of protein targets were obtained from the protein data bank (www.rcsb.org): CYP17A1 (17a-hydroxylase/C17,20-lyase, Protein Data Bank ID: 6CIZ, 6CHI, 6CIR, 5UYS, 4NKZ, 4NKX, 4NKV, 4NKW, and 3RUK) and CYP19A1 (aromatase, Protein Data Bank ID: 3S7S). 	17,20-lyase	33691	33702	('Cytochromes', 'Steroid 17-alpha-Hydroxylase', 'NCCS', 'NCCS_767', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:123	Only three enzymes (CYP27A1, CYP46A1, and SOAT1) metabolize intracellular (unesterified) cholesterol in the retina with retinal cholesterol content being almost doubled in Cyp27a1^/Cyp46a1^/ mice and normal in Soat1^/ mice. 	CYP46A1	21069	21076	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:126	Similarly, by generating Cyp27a1^/Cyp46a1^/Apoe^/ mice, we expected an additive genotype effect due to simultaneous blockage of the two major pathways of retinal cholesterol output - cholesterol removal via metabolism (CYP27A1 and CYP46A1) and Lipoprotein Particles containing Apolipoprotein E which accepts cholesterol effluxed from cells. 	CYP46A1	21877	21884	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:126	Similarly, by generating Cyp27a1^/Cyp46a1^/Apoe^/ mice, we expected an additive genotype effect due to simultaneous blockage of the two major pathways of retinal cholesterol output - cholesterol removal via metabolism (CYP27A1 and CYP46A1) and Lipoprotein Particles containing Apolipoprotein E which accepts cholesterol effluxed from cells. 	Cyp46	21680	21685	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:127	However, the Cyp27a1^/Cyp46a1^/Apoe^/ retina had lower, not higher, total cholesterol levels than the Apoe^/ retina (B), also an indication of the compensatory responses. 	Cyp46	22009	22014	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46	22374	22379	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46	22434	22439	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46	22500	22505	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:130	These decreases suggested that the retinal cholesterol biosynthesis is decreased in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, and represents a compensatory response to the triple gene ablations. 	Cyp46	22656	22661	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:130	These decreases suggested that the retinal cholesterol biosynthesis is decreased in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, and represents a compensatory response to the triple gene ablations. 	Cyp46	22686	22691	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:131	Next, we assessed the apolipoprotein-mediated retinal cholesterol traffic by measuring the mRNA for different apolipoproteins and conducting retinal proteomics on Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type mice (;. 	Cyp46	22949	22954	('Cytochromes', 'Cytochrome P450 Family 46', 'NCCS', 'NCCS_630', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:126	Similarly, by generating Cyp27a1^/Cyp46a1^/Apoe^/ mice, we expected an additive genotype effect due to simultaneous blockage of the two major pathways of retinal cholesterol output - cholesterol removal via metabolism (CYP27A1 and CYP46A1) and Lipoprotein Particles containing Apolipoprotein E which accepts cholesterol effluxed from cells. 	Cyp46a1	21680	21687	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:126	Similarly, by generating Cyp27a1^/Cyp46a1^/Apoe^/ mice, we expected an additive genotype effect due to simultaneous blockage of the two major pathways of retinal cholesterol output - cholesterol removal via metabolism (CYP27A1 and CYP46A1) and Lipoprotein Particles containing Apolipoprotein E which accepts cholesterol effluxed from cells. 	Cyp46a1	21680	21687	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:127	However, the Cyp27a1^/Cyp46a1^/Apoe^/ retina had lower, not higher, total cholesterol levels than the Apoe^/ retina (B), also an indication of the compensatory responses. 	Cyp46a1	22009	22016	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:127	However, the Cyp27a1^/Cyp46a1^/Apoe^/ retina had lower, not higher, total cholesterol levels than the Apoe^/ retina (B), also an indication of the compensatory responses. 	Cyp46a1	22009	22016	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46a1	22374	22381	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46a1	22374	22381	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46a1	22434	22441	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46a1	22434	22441	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46a1	22500	22507	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:129	The levels of lathosterol were decreased in the Cyp27a1^/Cyp46a1^/Soat1^/ retina as compared to Soat1^/ and Cyp27a1^/Cyp46a1^/ retina, and both sterols were decreased in the Cyp27a1^/Cyp46a1^/Apoe^/ retina as compared to the Apoe^/ retina (C,D). 	Cyp46a1	22500	22507	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:130	These decreases suggested that the retinal cholesterol biosynthesis is decreased in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, and represents a compensatory response to the triple gene ablations. 	Cyp46a1	22656	22663	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:130	These decreases suggested that the retinal cholesterol biosynthesis is decreased in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, and represents a compensatory response to the triple gene ablations. 	Cyp46a1	22656	22663	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:130	These decreases suggested that the retinal cholesterol biosynthesis is decreased in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, and represents a compensatory response to the triple gene ablations. 	Cyp46a1	22686	22693	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:130	These decreases suggested that the retinal cholesterol biosynthesis is decreased in Cyp27a1^/Cyp46a1^/Soat1^/ and Cyp27a1^/Cyp46a1^/Apoe^/ mice, and represents a compensatory response to the triple gene ablations. 	Cyp46a1	22686	22693	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:131	Next, we assessed the apolipoprotein-mediated retinal cholesterol traffic by measuring the mRNA for different apolipoproteins and conducting retinal proteomics on Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type mice (;. 	Cyp46a1	22949	22956	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:131	Next, we assessed the apolipoprotein-mediated retinal cholesterol traffic by measuring the mRNA for different apolipoproteins and conducting retinal proteomics on Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type mice (;. 	Cyp46a1	22949	22956	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_678', 'CUI-less')
PMC6995521_OgerInput.txtOger_out.csv:133	Rather, retinal proteomics pointed to enhanced vesicle formation in the Cyp27a1^/Cyp46a1^/Soat1^/ versus Wild Type retina as an expression of 7 proteins from the endosomal, secretory, and protrusion formation pathways (CHGA, HDAC6, PAFAH1B, SEPT6, SRP19, TAGLN2, and TAGLN3, ) was increased in the former. 	Cyp46a1	23293	23300	('Cytochromes', 'Cholesterol 24-Hydroxylase', 'NCCS', 'NCCS_636', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:113	Membrane-associated rapid response steroid-binding proteins, such as GRP58, ERp57, ERp60, and Pdia3^, could be involved in calcium absorption in the small intestine, and it is presumed that the remarkable difference in the plasma calcium concentration between Vdr (R270L) rats and Cyp27b1-KO rats was based on the Vdr-independent effects of 1,25(OH)_2D_3. 	Cyp27b1	19382	19389	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:114	As with Vdr (R270L) rats, administration of 25(OH)D_3 exerted pronounced effects on Cyp27b1-KO rats, resulting in normalization of plasma calcium and Parathyroid Hormone levels, osteogenesis, and infertility in females. 	Cyp27b1	19541	19548	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:114	As with Vdr (R270L) rats, administration of 25(OH)D_3 exerted pronounced effects on Cyp27b1-KO rats, resulting in normalization of plasma calcium and Parathyroid Hormone levels, osteogenesis, and infertility in females. 	Cyp27b1	19541	19548	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:115	However, 1,25(OH)_2D_3 was detected in the blood of Cyp27b1-KO rats at the same levels as in wild-type rats. 	Cyp27b1	19729	19736	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:115	However, 1,25(OH)_2D_3 was detected in the blood of Cyp27b1-KO rats at the same levels as in wild-type rats. 	Cyp27b1	19729	19736	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:116	As described in our previous study, the generation of 1,25(OH)_2D_3 following 25(OH)D_3 administration was also observed in Cyp27b1-KO mice^. 	Cyp27b1	19910	19917	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:116	As described in our previous study, the generation of 1,25(OH)_2D_3 following 25(OH)D_3 administration was also observed in Cyp27b1-KO mice^. 	Cyp27b1	19910	19917	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:117	1ALPHA-Hydroxylase activity toward 25(OH)D_3 in a liver mitochondrial fraction prepared from Cyp27b1-KO rats suggested that Cyp27a1, a 1ALPHA-hydroxylase abundant in the liver, is most likely responsible for the generation of 1,25(OH)_2D_3. 	Cyp27b1	20021	20028	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:117	1ALPHA-Hydroxylase activity toward 25(OH)D_3 in a liver mitochondrial fraction prepared from Cyp27b1-KO rats suggested that Cyp27a1, a 1ALPHA-hydroxylase abundant in the liver, is most likely responsible for the generation of 1,25(OH)_2D_3. 	Cyp27b1	20021	20028	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:118	It should be noted that 25(OH)D_3 administration is highly effective in type I rickets models, such as Cyp27b1-KO rats. 	Cyp27b1	20272	20279	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:118	It should be noted that 25(OH)D_3 administration is highly effective in type I rickets models, such as Cyp27b1-KO rats. 	Cyp27b1	20272	20279	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:155	By contrast, the Cyp27b1-KO rats for analysis were continuously fed the CE-2 diet because most male Cyp27b1-Knockout rats were not able to survive more than 10 weeks when fed the F-2 diet (data not shown). 	Cyp27b1	25143	25150	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_736', 'CUI-less')
PMC7105495_OgerInput.txtOger_out.csv:155	By contrast, the Cyp27b1-KO rats for analysis were continuously fed the CE-2 diet because most male Cyp27b1-Knockout rats were not able to survive more than 10 weeks when fed the F-2 diet (data not shown). 	Cyp27b1	25143	25150	('Cytochromes', '25-Hydroxyvitamin D3 1-alpha-Hydroxylase', 'NCCS', 'NCCS_588', 'CUI-less')
